

=> file biosis caba caplus embase japio lifesci medline scisearch uspatfull
FILE 'BIOSIS' ENTERED AT 16:32:18 ON 27 JUL 2005
Copyright (c) 2005 The Thomson Corporation

FILE 'CABA' ENTERED AT 16:32:18 ON 27 JUL 2005
COPYRIGHT (C) 2005 CAB INTERNATIONAL (CABI)

FILE 'CAPLUS' ENTERED AT 16:32:18 ON 27 JUL 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'EMBASE' ENTERED AT 16:32:18 ON 27 JUL 2005
COPYRIGHT (C) 2005 Elsevier Inc. All rights reserved.

FILE 'JAPIO' ENTERED AT 16:32:18 ON 27 JUL 2005
COPYRIGHT (C) 2005 Japanese Patent Office (JPO)- JAPIO

FILE 'LIFESCI' ENTERED AT 16:32:18 ON 27 JUL 2005
COPYRIGHT (C) 2005 Cambridge Scientific Abstracts (CSA)

FILE 'MEDLINE' ENTERED AT 16:32:18 ON 27 JUL 2005

FILE 'SCISEARCH' ENTERED AT 16:32:18 ON 27 JUL 2005
Copyright (c) 2005 The Thomson Corporation

FILE 'USPATFULL' ENTERED AT 16:32:18 ON 27 JUL 2005
CA INDEXING COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

=> e cai kang/au

| | | |
|-----|--------|------------------|
| E1 | 25 | CAI KAIYONG/AU |
| E2 | 4 | CAI KAIZHEN/AU |
| E3 | 32 --> | CAI KANG/AU |
| E4 | 13 | CAI KANG RONG/AU |
| E5 | 2 | CAI KANGMEI/AU |
| E6 | 16 | CAI KANGRONG/AU |
| E7 | 1 | CAI KANGWEI/AU |
| E8 | 2 | CAI KANGXU/AU |
| E9 | 1 | CAI KANGYU/AU |
| E10 | 1 | CAI KANGYUAN/AU |
| E11 | 1 | CAI KAOYUAN/AU |
| E12 | 1 | CAI KATHY Q I/AU |

=> s e3-e4 and prion?

L1 17 ("CAI KANG"/AU OR "CAI KANG RONG"/AU) AND PRION?

=> dup rem l1

PROCESSING COMPLETED FOR L1

L2 8 DUP REM L1 (9 DUPLICATES REMOVED)

=> d bib ab 1-

YOU HAVE REQUESTED DATA FROM 8 ANSWERS - CONTINUE? Y/(N):y

L2 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2005 ACS on STN DUPLICATE 1
AN 2005:369084 CAPLUS
DN 142:426439
TI Rapid method of determining clearance of **prion** protein
IN **Cai, Kang**; Stenland, Christopher J.
PA USA
SO U.S. Pat. Appl. Publ., 16 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|----|---------------|------|----------|-----------------|----------|
| | ----- | ---- | ---- | ----- | ----- |
| PI | US 2005089943 | A1 | 20050428 | US 2003-693734 | 20031023 |

WO 2005040832 A1 20050506 WO 2004-US35288 20041022

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
SN, TD, TG

PRAI US 2003-693734 A 20031023

AB The invention provides a rapid, sensitive immunoassay capable of detecting and quantitating pathogenic protein to a level of 3 to 5 logs. The preferred immunoassay utilized is a chemiluminescent endpoint for a Western blot immunoassay. The invention has been successfully applied to track the clearance of pathogenic protein during production of proteins derived from plasma. It is particularly applicable and has been confirmed by bioassay to relate TSE infectivity to quant. results on **prion** protein.

L2 ANSWER 2 OF 8 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
DUPLICATE 2

AN 2005:269087 BIOSIS

DN PREV200510060071

TI An improved Western blot assay to assess the clearance of **prion** protein from plasma-derived therapeutic proteins.

AU Hartwell, Randal C.; Nelson, Mark S.; Kislan, Michele M.; Stenland, Christopher J.; Miller, Jeanette L. C.; Pifat, Dominique Y.; Petteway, Stephen R. Jr; **Cai, Kang** [Reprint Author]

CS Bayer HealthCare, Dept Pre Clin Res and Pathogen Safety, Div Biol Prod, 85 TW Alexander Dr, Res Triangle Pk, NC 27709 USA
kang.cai.b@bayer.com

SO Journal of Virological Methods, (MAY 05) Vol. 125, No. 2, pp. 187-193.
CODEN: JVMEDE. ISSN: 0166-0934.

DT Article

LA English

ED Entered STN: 21 Jul 2005

Last Updated on STN: 21 Jul 2005

AB Specific detection of the pathogenic **prion** protein, PrPSc, is essential for determining the **prion** clearance capacity of purification processes for therapeutic proteins. Use of a previously described indirect (two-antibody) Western blot assay sometimes resulted in the appearance of non-specific protein bands that interfered with the detection of small amounts of PrPSc-specific signal, limiting the amount of clearance that could be determined for steps so affected. It is shown that these non-specific signals are due to the interaction between immunoglobulin fragments in the sample and the secondary antibody used in the assay. To circumvent this problem, a direct Western blot assay using a **prion**-specific primary antibody conjugated to the reporter enzyme alkaline phosphatase was developed. Application of the direct Western blot assay resulted in a significant reduction of non-specific signal while retaining the detection sensitivity for PrPSc-specific signal. Therefore, the direct Western blot assay format is an improved tool for determining **prion** clearance capacity, particularly for immunoglobulin-rich samples. (c) 2005 Elsevier B.V. All rights reserved.

L2 ANSWER 3 OF 8 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
DUPLICATE 3

AN 2005:253571 BIOSIS

DN PREV200510035449

TI Ensuring the biologic safety of plasma-derived therapeutic proteins - Detection, inactivation, and removal of pathogens.

AU **Cai, Kang** [Reprint Author]; Gierman, Todd M.; Hotta, JoAnn; Stenland, Christopher J.; Lee, Douglas C.; Pifat, Dominique Y.; Petteway, Steve R. Jr.

CS Bayer HealthCare LLC, Dept Preclin Res and Pathogen Safety, 85 TW

Alexander Dr, Res Triangle Pk, NC 27709 USA

kang.cai.b@bayer.com

SO BioDrugs, (05) Vol. 19, No. 2, pp. 79-96.

ISSN: 1173-8804.

DT Article

LA English

ED Entered STN: 8 Jul 2005

Last Updated on STN: 8 Jul 2005

AB Human plasma-derived proteins, such as immunoglobulins, coagulation factors, alpha(1)-antitrypsin, fibrin sealants, and albumin, are widely used as therapeutics for many serious and life-threatening medical conditions. The human origin of these proteins ensures excellent efficacy and compatibility but may also introduce the risk of unintentional disease transmission. Historically, only viruses, particularly hepatitis and HIV, have posed serious threats to the safety of these therapeutics. Fortunately, between 1970 and 1990, the molecular biology of each of the major viruses was elucidated. These advances led to the development and implementation of effective donor screening tests, mainly based on immunoassays and nucleic acid testing, which resulted in a significant reduction of disease transmission risk. In addition, viral inactivation and removal steps were implemented and validated by manufacturers, further reducing the risk associated with known, as well as unidentified, viruses. Since the late 1990s, a different class of transmissible agent, referred to as **prions**, has been identified as a new risk for disease transmission. However, **prion** diseases are very rare, and **prion** transmission through plasma-derived proteins has not been reported to date. The **prion**-related risk is minimized by deferring donors with certain key risk factors, and by the manufacturing processes that are capable of removing **prions**. Advances in science and pathogen safety-related technology, compliance with good manufacturing practices by manufacturers, and increasingly stringent regulatory oversight, has meant that plasma-derived proteins have been developed into today's highly effective therapeutics with very low risk of disease transmission.

L2 ANSWER 4 OF 8 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
DUPLICATE 4

AN 2002:361924 BIOSIS

DN PREV200200361924

TI Solvent-dependent precipitation of **prion** protein.

AU **Cai, Kang** [Reprint author]; Miller, Jeanette L. C.; Stenland, Christopher J.; Gilligan, Kevin J.; Hartwell, Randal C.; Terry, Jarrett C.; Evans-Storms, Rosemary B.; Rubenstein, Richard; Petteway, Stephen R., Jr.; Lee, Douglas C.

CS Department of Pathogen Safety and Research/Biological Products, Bayer Corporation, 85 T.W. Alexander Dr., Research Triangle Park, NC, 27709, USA
kang.cai.b@bayer.com

SO Biochimica et Biophysica Acta, (20 May, 2002) Vol. 1597, No. 1, pp. 28-35.
print.

CODEN: BBACAQ. ISSN: 0006-3002.

DT Article

LA English

ED Entered STN: 26 Jun 2002

Last Updated on STN: 26 Jun 2002

AB The misfolded isoform of the **prion** protein (PrPSc) possesses many unusual physiochemical properties. Previously, we and others reported on the differential partitioning of PrPSc from plasma derived therapeutic proteins during their purification processes. To understand the driving force behind these partitioning differences, we investigated the effects of various solvent conditions on the precipitation of PrPSc. In a physiological buffer, PrPSc remained in the supernatant after low speed centrifugation. At pH 5, PrPSc precipitation was nearly complete regardless of the salt content. PrPSc could also be precipitated at pH 8 by adding ethanol, but this precipitation was salt dependent. Based on these observations, an empirical mathematical model was constructed in which the PrPSc precipitation trends were fully described as a function of solvent pH, salt, and ethanol concentration. This model consistently predicted PrPSc partitioning during cold ethanol precipitation steps used

in plasma protein purification processes, as shown by experimentally determined distributions of PrPSc and transmissible spongiform encephalopathy (TSE) infectivity. These results indicate that pH, salt, and ethanol content are the major solvent factors determining the precipitation of the infectious PrPSc in these processes and may provide a useful tool for assessing the differential partitioning of PrPSc in a given solvent environment.

L2 ANSWER 5 OF 8 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
AN 2003:356933 BIOSIS
DN PREV200300356933
TI TSE Clearance during the IGIV-C Filtration Process.
AU Stenland, Chris [Reprint Author]; Terry, Jarrett [Reprint Author];
Cai, Kang [Reprint Author]; Nelson, Mark [Reprint Author];
Hartwell, Randal [Reprint Author]; Rubenstein, Richard [Reprint Author];
Fournel, Michael [Reprint Author]; Petteway, Stephen Jr. [Reprint Author];
Research, Department of Pathogen Safety [Reprint Author]
CS Bayer Corporation, Research Triangle Park, NC, USA
SO Blood, (November 16 2002) Vol. 100, No. 11, pp. Abstract No. 2799. print.
Meeting Info.: 44th Annual Meeting of the American Society of Hematology.
Philadelphia, PA, USA. December 06-10, 2002. American Society of
Hematology.
CODEN: BLOOAW. ISSN: 0006-4971.
DT Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
Conference; (Meeting Poster)
LA English
ED Entered STN: 6 Aug 2003
Last Updated on STN: 6 Aug 2003
AB Recent work with animal models (Rohwer et al., Houston et al.)
demonstrated the presence of transmissible spongiform encephalopathy (TSE)
infectivity in rodent and ovine blood. Transmission of TSE infectivity by
human blood or blood components has not been established, but remains a
theoretical risk. TSE agents are resistant to standard methods of
pathogen inactivation. Current methods that can reduce TSE infectivity
titers (e.g., treatment with strong base or autoclaving) destroy the
biological activity of therapeutic proteins. Thus, increasing the margin
of safety for biologicals regarding TSE transmission relies heavily on
clearance methods. The initial filtration steps employed in the
manufacture of a new intravenous immune globulin produced by caprylate
virus inactivation and column chromatography, IGIV-C, were evaluated for
their ability to remove spiked TSE infectivity and the pathogenic
prion protein. The bench scale model was characterized by
biochemical analysis found to operate similarly to the larger scale
process. Resuspended II + III paste, the starting material for the
production of IGIV-C, was spiked with 1% final concentration hamster
scrapie brain homogenate and the filtration steps were performed. The
input and output fractions were evaluated for PrPSc content by Western
blot and TSE infectivity by animal bioassay. More than 10 logs of TSE
infectivity removal was demonstrated during the filtration steps.

L2 ANSWER 6 OF 8 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
DUPLICATE 5
AN 2001:304345 BIOSIS
DN PREV200100304345
TI A direct relationship between the partitioning of the pathogenic
prion protein and transmissible spongiform encephalopathy
infectivity during the purification of plasma proteins.
AU Lee, Douglas C. [Reprint author]; Stenland, Christopher J.; Miller,
Jeanette L. C.; **Cai, Kang**; Ford, Elizabeth K.; Gilligan, Kevin
J.; Hartwell, Randal C.; Terry, Jarrett C.; Rubenstein, Richard; Fournel,
Michael; Petteway, Stephen R., Jr.
CS Bayer Corporation, 85 TW Alexander Drive, Research Triangle Park, NC,
27709, USA
doug.lee.b@bayer.com
SO Transfusion (Bethesda), (April, 2001) Vol. 41, No. 4, pp. 449-455. print.
CODEN: TRANAT. ISSN: 0041-1132.
DT Article

LA English
ED Entered STN: 27 Jun 2001
Last Updated on STN: 19 Feb 2002
AB BACKGROUND: Experimental evidence from rodent models indicates that blood can contain transmissible spongiform encephalopathy (TSE) infectivity, which suggests a potential risk for TSE transmission via proteins isolated from human plasma. Because methods that can reduce TSE infectivity typically are detrimental to protein function, infectivity must be removed to ensure the safety of these therapeutic proteins. Animal bioassays are conventionally used to detect infectivity, but the pathogenic form of the **prion** protein (PrPSc) can serve as a marker for TSE infectivity. STUDY DESIGN AND METHODS: Seven plasma protein-purification steps were performed after the plasma intermediates were spiked with TSE-infected material. Resulting fractions were analyzed for PrPSc by using a Western blot assay and for TSE infectivity by using an animal bioassay. Western blots were quantitated by an endpoint dilution analysis, and infectivity titers were calculated by the Spearman-Kärber method. RESULTS: PrPSc partitioning paralleled TSE infectivity partitioning, regardless of the nature of the protein-purification step. The detection ranges for PrPSc and infectivity were 0 to 5.3 log and 1.1 to 8.9 log median infectious dose per unit, respectively. Clearance of PrPSc and infectivity ranged from 1.0 to 6.0 log. CONCLUSION: Purification steps for isolating therapeutic proteins from human plasma showed the removal of both PrPSc and TSE infectivity. PrPSc partitioning coincided with infectivity partitioning, which showed a close relationship between PrPSc and TSE infectivity. By exploiting this association, the in vitro Western blot assay for PrPSc was valuable for estimating the partitioning of TSE infectivity during plasma protein purification.

L2 ANSWER 7 OF 8 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
DUPLICATE 6
AN 2000:91700 BIOSIS
DN PREV200000091700
TI Monitoring plasma processing steps with a sensitive Western blot assay for the detection of the **prion** protein.
AU Lee, Douglas C. [Reprint author]; Stenland, Christopher J.; Hartwell, Randal C.; Ford, Elizabeth K.; **Cai, Kang**; Miller, Jeanette L. C.; Gilligan, Kevin J.; Rubenstein, Richard; Fournel, Michael; Petteway, Stephen R., Jr.
CS Department of Pathogen Safety Research/Biological Products, Bayer Corp., 85 TW Alexander Drive, Research Triangle Park, NC, 27709, USA
SO Journal of Virological Methods, (Jan., 2000) Vol. 84, No. 1, pp. 77-89. print.
CODEN: JVMEDH. ISSN: 0166-0934.

DT Article
LA English
ED Entered STN: 10 Mar 2000
Last Updated on STN: 3 Jan 2002
AB Determining the risk of transmissible spongiform encephalopathy (TSE) transmission by blood or plasma-derived products requires sensitive and specific assays for the detection of either infectivity or a reliable marker for infectivity. To this end, a Western blot assay that is both sensitive and reproducible for the detection of PrPRES, a marker for TSE infectivity, was developed. Using the 263K strain of TSE as a model system, the Western blot assay proved to be sensitive, specific and quantitative over a 3-4 log dynamic range. Compared to the rodent bioassay, the assay was shown to detect PrPRES down to approx 103.4 IU/ml, which is approx 5-10 pg of PrP or approx 10-20 ng brain equivalents. The Western blot was applied to monitor the partitioning of spiked PrPSc through three plasma fractionation steps, cryoprecipitation, fraction I and fraction III, that are common to the purification of several human plasma-derived therapeutic products including albumin and immunoglobulins. The results from these studies demonstrated 1 log, 1 log and 4 logs of PrPSc partitioning away from the effluent fraction for the cryoprecipitation, fraction I and fraction III steps, respectively.

L2 ANSWER 8 OF 8 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
AN 2001:311745 BIOSIS

DN PREV200100311745

TI Exploiting the pathogenic **prion** protein as a marker for tracking the clearance of transmissible spongiform encephalopathy infectivity during the purification of plasma proteins.

AU Miller, Jeanette L. C. [Reprint author]; Cai, Kang [Reprint author]; Evans-Storms, Rose [Reprint author]; Ford, Elizabeth K. [Reprint author]; Fournel, Michael [Reprint author]; Gilligan, Kevin J. [Reprint author]; Hartwell, Randal C. [Reprint author]; Petteway, Stephen R., Jr. [Reprint author]; Steriland, Christopher J. [Reprint author]; Terry, Jarrett C. [Reprint author]; Lee, Douglas C. [Reprint author]

CS Department of Pathogen Safety Research, Bayer Corporation, Research Triangle Park, NC, USA

SO Blood, (November 16, 2000) Vol. 96, No. 11 Part 1, pp. 60a. print.
Meeting Info.: 42nd Annual Meeting of the American Society of Hematology. San Francisco, California, USA. December 01-05, 2000. American Society of Hematology.
CODEN: BLOOAW. ISSN: 0006-4971.

DT Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
Conference; (Meeting Poster)

LA English

ED Entered STN: 27 Jun 2001
Last Updated on STN: 19 Feb 2002

AB Experimental evidence from rodent models indicates that blood can contain transmissible spongiform encephalopathy (TSE) infectivity (Brown et al. Transfusion 1998, 38:810-816), suggesting a potential risk for TSE transmission via proteins isolated from human plasma. Since methods that can reduce TSE infectivity are typically detrimental to protein function, infectivity must be removed to ensure the safety of these therapeutic proteins. Conventionally, the animal bioassay is used to detect infectivity; however, 7-12 months are required to complete a bioassay and it is not conducive to performing experimental replicates. The pathogenic form of the **prion** protein (PrPSc) can serve as a marker for TSE infectivity; therefore, we exploited this relationship and used a sensitive and robust Western blot assay to track PrPSc, and therefore infectivity, during the purification of plasma proteins. Several plasma protein purification steps used during the manufacture of factor VIII, immunoglobulins, alpha1-proteinase inhibitor, anti-thrombin, and albumin were performed on a miniaturized scale after spiking the appropriate, starting materials with a TSE-infected reagent. Resulting fractions were analyzed for PrPSc using a Western blot assay and for TSE infectivity using an animal bioassay. The detection ranges for PrPSc and infectivity were 0-5.3 logs and 1.1-8.9 log ID50 units, respectively. Clearance of PrPSc and infectivity ranged from 1.0 to 6.0 logs depending on the particular purification step. PrPSc partitioning paralleled TSE infectivity regardless of the nature of the protein purification step, demonstrating the close relationship between PrPSc and TSE infectivity. By exploiting this association, the in vitro Western blot assay for PrPSc was valuable for estimating partitioning of TSE infectivity during plasma protein purification and for demonstrating the ability of these processes to reduce the risk of TSE transmission through blood protein products.

=> e stenland christopher j/au

| | | |
|-----|----|--------------------------------|
| E1 | 9 | STENLAND CHRIS J/AU |
| E2 | 5 | STENLAND CHRISTOPHER/AU |
| E3 | 30 | ---> STENLAND CHRISTOPHER J/AU |
| E4 | 1 | STENLAND CHRISTOPHER JOHN/AU |
| E5 | 1 | STENLAND M/AU |
| E6 | 2 | STENLANDER C/AU |
| E7 | 1 | STENLANDER CLAES/AU |
| E8 | 1 | STENLE P/AU |
| E9 | 4 | STENLEY/AU |
| E10 | 5 | STENLI G/AU |
| E11 | 2 | STENLI S A/AU |
| E12 | 49 | STENLID G/AU |

=> s e1-e4 and prion?

L3 32 ("STENLAND CHRIS J"/AU OR "STENLAND CHRISTOPHER"/AU OR "STENLAND CHRISTOPHER J"/AU OR "STENLAND CHRISTOPHER JOHN"/AU) AND PRION?

=> dup rem l3

PROCESSING COMPLETED FOR L3

L4 17 DUP REM L3 (15 DUPLICATES REMOVED)

=> d bib ab 1-

YOU HAVE REQUESTED DATA FROM 17 ANSWERS - CONTINUE? Y/(N):y

L4 ANSWER 1 OF 17 CAPLUS COPYRIGHT 2005 ACS on STN DUPLICATE 1

AN 2005:369084 CAPLUS

DN 142:426439

TI Rapid method of determining clearance of **prion** protein

IN Cai, Kang; **Stenland, Christopher J.**

PA USA

SO U.S. Pat. Appl. Publ., 16 pp.

CODEN: USXXCO

DT Patent

LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|----|---|------|----------|-----------------|----------|
| PI | US 2005089943 | A1 | 20050428 | US 2003-693734 | 20031023 |
| | WO 2005040832 | A1 | 20050506 | WO 2004-US35288 | 20041022 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| | RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |

PRAI US 2003-693734 A 20031023

AB The invention provides a rapid, sensitive immunoassay capable of detecting and quantitating pathogenic protein to a level of 3 to 5 logs. The preferred immunoassay utilized is a chemiluminescent endpoint for a Western blot immunoassay. The invention has been successfully applied to track the clearance of pathogenic protein during production of proteins derived from plasma. It is particularly applicable and has been confirmed by bioassay to relate TSE infectivity to quant. results on **prion** protein.

L4 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2005 ACS on STN DUPLICATE 2

AN 2005:219997 CAPLUS

DN 142:285329

TI **Prion** clearance from biological materials using particulate metal oxides

IN **Stenland, Christopher J.**; Terry, Jarrett C.; Yuziuk, Jeffrey A.

PA USA

SO U.S. Pat. Appl. Publ., 14 pp.

CODEN: USXXCO

DT Patent

LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|----|--|------|----------|-----------------|----------|
| PI | US 2005054003 | A1 | 20050310 | US 2003-659789 | 20030910 |
| | WO 2005026197 | A1 | 20050324 | WO 2004-US29024 | 20040907 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, | | | | |

TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
 AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
 EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
 SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
 SN, TD, TG

PRAI US 2003-659789 A 20030910

AB A method of preparing a solution containing biol. material by adding a fumed metal oxide and/or particulate silicon dioxide to biol. material to obtain a mixture of fumed metal oxide and/or particulate silicon dioxide and the biol. material; and separating the fumed metal oxide and/or particulate silicon dioxide from the mixture to form a resulting solution, wherein any pathogenic **prion** proteins possibly contaminating the biol. material are substantially reduced in the resulting solution PrPSc was removed during a plasminogen purification process using CAB-O-SIL M-5P silica. Following three hours of mixing, the material was filtered and the filtrate was analyzed by Western blot for PrP content. The CAB-O-SIL removed **prion** protein with minimal effect on the desired protein components.

L4 ANSWER 3 OF 17 CAPLUS COPYRIGHT 2005 ACS on STN DUPLICATE 3

AN 2005:34290 CAPLUS

DN 142:110054

TI Sanitization of chromatographic media

IN Jones, Nathan C.; Korneyeva, Marina N.; Rebbear, James F.; Rosenthal, Richard Scott; **Stenland, Christopher J.**

PA Bayer Healthcare LLC, USA

SO U.S. Pat. Appl. Publ., 8 pp.

CODEN: USXXCO

DT Patent

LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|-----|--|------|----------|-----------------|----------|
| PI | US 2005006307 | A1 | 20050113 | US 2003-614904 | 20030708 |
| | US 6913695 | B2 | 20050705 | | |
| | WO 2005007204 | A1 | 20050127 | WO 2004-US20891 | 20040630 |
| W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: | BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |

PRAI US 2003-614904 A 20030708

AB A method of sanitizing chromatog. media is provided. The method includes contacting the media with an acidic chaotropic agent, at low temperature and low pH. The method provides pathogen removal and/or inactivation, including viral inactivation in particular embodiments.

RE.CNT 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 17 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN DUPLICATE 4

AN 2005:269087 BIOSIS

DN PREV200510060071

TI An improved Western blot assay to assess the clearance of **prion** protein from plasma-derived therapeutic proteins.

AU Hartwell, Randal C.; Nelson, Mark S.; Kislan, Michele M.; **Stenland, Christopher J.**; Miller, Jeanette L. C.; Pifat, Dominique Y.; Petteway, Stephen R. Jr; Cai, Kang [Reprint Author]

CS Bayer HealthCare, Dept Pre Clin Res and Pathogen Safety, Div Biol Prod, 85 TW Alexander Dr, Res Triangle Pk, NC 27709 USA
 kang.cai.b@bayer.com

SO Journal of Virological Methods, (MAY 05) Vol. 125, No. 2, pp. 187-193.

DT Article
LA English
ED Entered STN: 21 Jul 2005
Last Updated on STN: 21 Jul 2005
AB Specific detection of the pathogenic **prion** protein, PrPSc, is essential for determining the **prion** clearance capacity of purification processes for therapeutic proteins. Use of a previously described indirect (two-antibody) Western blot assay sometimes resulted in the appearance of non-specific protein bands that interfered with the detection of small amounts of PrPSc-specific signal, limiting the amount of clearance that could be determined for steps so affected. It is shown that these non-specific signals are due to the interaction between immunoglobulin fragments in the sample and the secondary antibody used in the assay. To circumvent this problem, a direct Western blot assay using a **prion**-specific primary antibody conjugated to the reporter enzyme alkaline phosphatase was developed. Application of the direct Western blot assay resulted in a significant reduction of non-specific signal while retaining the detection sensitivity for PrPSc-specific signal. Therefore, the direct Western blot assay format is an improved tool for determining **prion** clearance capacity, particularly for immunoglobulin-rich samples. (c) 2005 Elsevier B.V. All rights reserved.

L4 ANSWER 5 OF 17 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
DUPLICATE 5

AN 2005:253571 BIOSIS

DN PREV200510035449

TI Ensuring the biologic safety of plasma-derived therapeutic proteins - Detection, inactivation, and removal of pathogens.

AU Cai, Kang [Reprint Author]; Gierman, Todd M.; Hotta, JoAnn; **Stenland, Christopher J.**; Lee, Douglas C.; Pifat, Dominique Y.; Petteway, Steve R. Jr.

CS Bayer HealthCare LLC, Dept Preclin Res and Pathogen Safety, 85 TW Alexander Dr, Res Triangle Pk, NC 27709 USA
kang.cai.b@bayer.com

SO BioDrugs, (05) Vol. 19, No. 2, pp. 79-96.
ISSN: 1173-8804.

DT Article

LA English

ED Entered STN: 8 Jul 2005

Last Updated on STN: 8 Jul 2005

AB Human plasma-derived proteins, such as immunoglobulins, coagulation factors, alpha(1)-antitrypsin, fibrin sealants, and albumin, are widely used as therapeutics for many serious and life-threatening medical conditions. The human origin of these proteins ensures excellent efficacy and compatibility but may also introduce the risk of unintentional disease transmission. Historically, only viruses, particularly hepatitis and HIV, have posed serious threats to the safety of these therapeutics. Fortunately, between 1970 and 1990, the molecular biology of each of the major viruses was elucidated. These advances led to the development and implementation of effective donor screening tests, mainly based on immunoassays and nucleic acid testing, which resulted in a significant reduction of disease transmission risk. In addition, viral inactivation and removal steps were implemented and validated by manufacturers, further reducing the risk associated with known, as well as unidentified, viruses. Since the late 1990s, a different class of transmissible agent, referred to as **prions**, has been identified as a new risk for disease transmission. However, **prion** diseases are very rare, and **prion** transmission through plasma-derived proteins has not been reported to date. The **prion**-related risk is minimized by deferring donors with certain key risk factors, and by the manufacturing processes that are capable of removing **prions**. Advances in science and pathogen safety-related technology, compliance with good manufacturing practices by manufacturers, and increasingly stringent regulatory oversight, has meant that plasma-derived proteins have been developed into today's highly effective therapeutics with very low risk of disease transmission.

L4 ANSWER 6 OF 17 USPATFULL on STN
 AN 2004:221334 USPATFULL
 TI Process for the production of a reversibly inactive acidified plasmin composition
 IN Bradley, Rita T., Cary, NC, UNITED STATES
 Cook, Scott A., Garner, NC, UNITED STATES
 Dadd, Christopher A., Holly Springs, NC, UNITED STATES
 Kent, Jonathan D., Holly Springs, NC, UNITED STATES
 Korneyeva, Marina N., Raleigh, NC, UNITED STATES
 Novokhatny, Valery V., Raleigh, NC, UNITED STATES
 Rebbeor, James F., Garner, NC, UNITED STATES
 Stenland, Christopher J., Cary, NC, UNITED STATES
 Strauss, Jonathan S., Walnut Creek, CA, UNITED STATES
 Terry, Jarrett C., Raleigh, NC, UNITED STATES
 Yuziuk, Jeffrey A., Garner, NC, UNITED STATES
 PI US 2004171103 A1 20040902
 AI US 2003-692105 A1 20031023 (10)
 RLI Continuation-in-part of Ser. No. US 2002-143156, filed on 10 May 2002,
 PENDING Continuation of Ser. No. WO 2000-US42143, filed on 13 Nov 2000,
 PENDING Continuation-in-part of Ser. No. US 1999-438331, filed on 13 Nov
 1999, GRANTED, Pat. No. US 6355243
 DT Utility
 FS APPLICATION
 LREP WOMBLE CARLYLE SANDRIDGE & RICE, PLLC, P.O. BOX 7037, ATLANTA, GA,
 30357-0037
 CLMN Number of Claims: 53
 ECL Exemplary Claim: 1
 DRWN 12 Drawing Page(s)
 LN.CNT 1312
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB Disclosed is both a process for producing a reversibly inactive
 acidified plasmin by activating plasminogen and a process for producing
 a purified plasminogen. The produced plasmin is isolated and stored with
 a low pH-buffering capacity agent to provide a substantially stable
 formulation. The purified plasminogen is typically purified from a
 fraction obtained in the separation of immunoglobulin from Fraction
 II+III chromatographic process and eluted at a low pH. The reversibly
 inactive acidified plasmin may be used in the administration of a
 thrombolytic therapy.

L4 ANSWER 7 OF 17 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
 DUPLICATE 6
 AN 2002:523392 BIOSIS
 DN PREV200200523392
 TI Method of separating **prions** from biological materials.
 AU Lee, Douglas C. [Inventor]; Petteway, Steve R. [Inventor, Reprint author];
 Stenland, Christopher J. [Inventor]
 CS Cary, NC, USA
 ASSIGNEE: Bayer Corporation
 PI US 6437102 20020820
 SO Official Gazette of the United States Patent and Trademark Office Patents,
 (Aug. 20, 2002) Vol. 1261, No. 3. <http://www.uspto.gov/web/menu/patdata.ht>
 ml. e-file.
 CODEN: OGUPE7. ISSN: 0098-1133.
 DT Patent
 LA English
 ED Entered STN: 9 Oct 2002
 Last Updated on STN: 9 Oct 2002
 AB Disclosed is a method for separating **prions** from biological
 materials. The method includes adding a polyalkylene glycol, such as
 polyethylene glycol, to a solution of the biological material such that a
 precipitate containing the **prion** is formed. This precipitate is
 then separated from the solution of biological material, thereby removing
prions. Biological materials include biologically derived fluids,
 such as cerebrospinal fluid, biological samples, such as brain
 homogenates, blood plasma fractions, and aqueous solutions of
 recombinantly produced products. The disclosed method provides an
 effective process for the removal of these infectious materials from the

biological materials, which may be further processed to provide the therapeutic compositions.

L4 ANSWER 8 OF 17 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
DUPLICATE 7
AN 2003:26373 BIOSIS
DN PREV200300026373
TI Partitioning of human and sheep forms of the pathogenic **prion**
protein during the purification of therapeutic proteins from human plasma.
AU **Stenland, Christopher J.** [Reprint Author]; Lee, Douglas C.;
Brown, Paul; Petteway, Stephen R. Jr.; Rubenstein, Richard
CS Department of Pathogen Safety Research, Bayer Corporation, 85 T. W.
Alexander Drive, PO Box 13887, Research Triangle Park, NC, 27709, USA
chris.stenland.b@bayer.com
SO Transfusion (Bethesda), (November 2002) Vol. 42, No. 11, pp. 1497-1500.
print.
ISSN: 0041-1132 (ISSN print).
DT Article
LA English
ED Entered STN: 1 Jan 2003
Last Updated on STN: 1 Jan 2003
AB BACKGROUND: Therapeutic proteins derived from human plasma and other
biologic sources have demonstrated an excellent safety record relative to
the potential threat of transmissible spongiform encephalopathy (TSE)
transmission. Previously, hamster-adapted scrapie was used as a model
agent to assess TSE clearance in purification steps leading to the
isolation of biopharmaceutical proteins. The current study investigated
the validity of hamster scrapie as a model for human TSE clearance
studies. The partitioning of the pathogenic forms of the **prion**
protein associated with human variant CJD (PrPvCJD), human sporadic CJD
(PrPsCJD) and Gerstmann-Straussler-Scheinker (PrPGSS) syndrome was
compared to the partitioning of hamster scrapie (PrPSc) in three plasma
protein purification steps. Sheep scrapie (PrPSc) was similarly
evaluated. STUDY DESIGN AND METHODS: The starting materials for three
plasma protein purification steps, cryoseparation, 3 percent PEG
separation, and 11.5 percent PEG separation, were spiked with brain
homogenates containing human PrPvCJD, human PrPsCJD, human PrPGSS, sheep
PrPSc, and hamster 263K PrPSc. The partitioning of the pathogenic form of
the PrP was analyzed. RESULTS: Clearance of the pathogenic form of the
PrP was measured relative to the effluent fraction. Regardless of the
source of the pathogenic **prion**, clearance was similar to hamster
PrPSc. A nominal amount of clearance (approx., 1 log), an intermediate
amount of clearance (approx., 2 log), and a substantial amount of
clearance (gtoreq3 log) were observed for the cryoseparation, 3 percent
PEG separation, and 11.5 percent PEG separation steps, respectively. In
the latter step, no PrP was detected in the effluents. CONCLUSIONS: These
data demonstrate that human **prions**, including vCJD
prions, can be removed during the purification of human
therapeutic proteins and indicate that partitioning of human
prions is similar to that observed in the hamster scrapie model.

L4 ANSWER 9 OF 17 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
AN 2002:301526 BIOSIS
DN PREV200200301526
TI A new chromatography-based process for IGIV incorporates pathogen safety
into the overall manufacturing strategy.
AU Remington, Kathryn [Reprint author]; Trejo, Samuel [Reprint author];
Hotta, JoAnn [Reprint author]; Lebing, Wytold [Reprint author];
Stenland, Christopher [Reprint author]; Lee, Douglas [Reprint
author]; Pifat, Dominique [Reprint author]; Petteway, Steve [Reprint
author]
CS Bayer Corporation, Research Triangle Park, NC, USA
SO Journal of Allergy and Clinical Immunology, (January, 2002) Vol. 109, No.
1 Supplement, pp. S198. print.
Meeting Info.: 58th Annual Meeting of the American Academy of Allergy,
Asthma and Immunology. New York, NY, USA. March 01-06, 2002. American
Academy of Allergy, Asthma, and Immunology.
CODEN: JACIBY. ISSN: 0091-6749.

DT Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
LA English
ED Entered STN: 22 May 2002
Last Updated on STN: 22 May 2002

L4 ANSWER 10 OF 17 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on
STN DUPLICATE 8
AN 2002:361924 BIOSIS
DN PREV200200361924
TI Solvent-dependent precipitation of **prion** protein.
AU Cai, Kang [Reprint author]; Miller, Jeanette L. C.; **Stenland, Christopher J.**; Gilligan, Kevin J.; Hartwell, Randal C.; Terry, Jarrett C.; Evans-Storms, Rosemary B.; Rubenstein, Richard; Petteway, Stephen R., Jr.; Lee, Douglas C.
CS Department of Pathogen Safety and Research/Biological Products, Bayer Corporation, 85 T.W. Alexander Dr., Research Triangle Park, NC, 27709, USA kang.cai.b@bayer.com
SO Biochimica et Biophysica Acta, (20 May, 2002) Vol. 1597, No. 1, pp. 28-35. print.
CODEN: BBACAQ. ISSN: 0006-3002.

DT Article
LA English
ED Entered STN: 26 Jun 2002
Last Updated on STN: 26 Jun 2002

AB The misfolded isoform of the **prion** protein (PrPSc) possesses many unusual physiochemical properties. Previously, we and others reported on the differential partitioning of PrPSc from plasma derived therapeutic proteins during their purification processes. To understand the driving force behind these partitioning differences, we investigated the effects of various solvent conditions on the precipitation of PrPSc. In a physiological buffer, PrPSc remained in the supernatant after low speed centrifugation. At pH 5, PrPSc precipitation was nearly complete regardless of the salt content. PrPSc could also be precipitated at pH 8 by adding ethanol, but this precipitation was salt dependent. Based on these observations, an empirical mathematical model was constructed in which the PrPSc precipitation trends were fully described as a function of solvent pH, salt, and ethanol concentration. This model consistently predicted PrPSc partitioning during cold ethanol precipitation steps used in plasma protein purification processes, as shown by experimentally determined distributions of PrPSc and transmissible spongiform encephalopathy (TSE) infectivity. These results indicate that pH, salt, and ethanol content are the major solvent factors determining the precipitation of the infectious PrPSc in these processes and may provide a useful tool for assessing the differential partitioning of PrPSc in a given solvent environment.

L4 ANSWER 11 OF 17 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2001:396890 CAPLUS
DN 135:9971
TI Method of separating **prions** from biological materials
IN Lee, Douglas; Petteway, Steve R.; **Stenland, Christopher J.**
PA Bayer Corporation, USA
SO PCT Int. Appl., 20 pp.
CODEN: PIXXD2

DT Patent
LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|----|---------------|--|----------|-----------------|----------|
| PI | WO 2001038354 | A1 | 20010531 | WO 2000-US32052 | 20001122 |
| | W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | |
| | RW: | GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, | | | |

DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

| | | | | |
|--|----|----------|-----------------|----------|
| US 6437102 | B1 | 20020820 | US 2000-638275 | 20000814 |
| CA 2392015 | AA | 20010531 | CA 2000-2392015 | 20001122 |
| EP 1235854 | A1 | 20020904 | EP 2000-979220 | 20001122 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR | | | | |
| JP 2003514916 | T2 | 20030422 | JP 2001-540117 | 20001122 |
| AU 781814 | B2 | 20050616 | AU 2001-16622 | 20001122 |
| PRAI US 1999-448771 | A | 19991124 | | |
| US 2000-638275 | A | 20000814 | | |
| WO 2000-US32052 | W | 20001122 | | |

AB Disclosed is a method for separating **prions** from biol. materials.
The method includes adding a polyalkylene glycol, such as polyethylene glycol, to a solution of the biol. material such that a precipitate containing the **prion** is formed. This precipitate is then separated from the solution of biol. material, thereby removing **prions**. Biol. materials include biol. derived fluids, such as cerebrospinal fluid, biol. samples, such as brain homogenates, blood plasma fractions, and aqueous solns. of recombinantly produced products. The disclosed method provides an effective process for the removal of these infectious materials from the biol. materials, which may be further processed to provide the therapeutic compns.

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 12 OF 17 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2001:380752 CAPLUS
DN 134:363346
TI Production and purification of a reversibly inactivated acidified plasmin for thrombolytic therapy
IN Dadd, Christopher; **Stenland, Christopher J.**; Kent, Jonathan D.; Korneyeva, Marina N.; Baumbach, George A.; Cook, Scott A.; Bradley, Rita T.; Novokhatny, Valery; Villines, Tanette B.
PA Bayer Corporation, USA
SO PCT Int. Appl., 50 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 5

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | WO 2001036611 | A1 | 20010525 | WO 2000-US42143 | 20001113 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL | | | | |
| | RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | | |
| | US 6355243 | B1 | 20020312 | US 1999-438331 | 19991113 |
| | CA 2389487 | AA | 20010525 | CA 2000-2389487 | 20001113 |
| | AU 2001036436 | A5 | 20010530 | AU 2001-36436 | 20001113 |
| | EP 1232254 | A1 | 20020821 | EP 2000-991956 | 20001113 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR | | | | |
| | JP 2003535574 | T2 | 20031202 | JP 2001-538490 | 20001113 |
| | US 2002192794 | A1 | 20021219 | US 2002-143156 | 20020510 |
| | US 2004171103 | A1 | 20040902 | US 2003-692105 | 20031023 |
| PRAI | US 1999-438331 | A | 19991113 | | |
| | WO 2000-US42143 | W | 20001113 | | |
| | US 2002-143156 | A2 | 20020510 | | |

AB Disclosed is both a process for producing a reversibly inactivated acidified plasmin by activating plasminogen and a process for producing a purified plasminogen. The produced plasmin is isolated and stored with a low pH-buffering capacity agent to provide a substantially stable formulation. The purified plasminogen is typically purified from a fraction obtained in the separation of Ig from Fraction II + III chromatog.

process and eluted at a low pH. The reversibly inactivated acidified plasmin may be used in the administration of a thrombolytic therapy.

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

- L4 ANSWER 13 OF 17 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on
STN DUPLICATE 9
- AN 2001:304345 BIOSIS
- DN PREV200100304345
- TI A direct relationship between the partitioning of the pathogenic
prion protein and transmissible spongiform encephalopathy
infectivity during the purification of plasma proteins.
- AU Lee, Douglas C. [Reprint author]; **Stenland, Christopher J.**;
Miller, Jeanette L. C.; Cai, Kang; Ford, Elizabeth K.; Gilligan, Kevin J.;
Hartwell, Randal C.; Terry, Jarrett C.; Rubenstein, Richard; Fournel,
Michael; Petteway, Stephen R., Jr.
- CS Bayer Corporation, 85 TW Alexander Drive, Research Triangle Park, NC,
27709, USA
doug.lee.b@bayer.com
- SO Transfusion (Bethesda), (April, 2001) Vol. 41, No. 4, pp. 449-455. print.
CODEN: TRANAT. ISSN: 0041-1132.
- DT Article
- LA English
- ED Entered STN: 27 Jun 2001
Last Updated on STN: 19 Feb 2002
- AB BACKGROUND: Experimental evidence from rodent models indicates that blood
can contain transmissible spongiform encephalopathy (TSE) infectivity,
which suggests a potential risk for TSE transmission via proteins isolated
from human plasma. Because methods that can reduce TSE infectivity
typically are detrimental to protein function, infectivity must be removed
to ensure the safety of these therapeutic proteins. Animal bioassays are
conventionally used to detect infectivity, but the pathogenic form of the
prion protein (PrPSc) can serve as a marker for TSE infectivity.
STUDY DESIGN AND METHODS: Seven plasma protein-purification steps were
performed after the plasma intermediates were spiked with TSE-infected
material. Resulting fractions were analyzed for PrPSc by using a Western
blot assay and for TSE infectivity by using an animal bioassay. Western
blots were quantitated by an endpoint dilution analysis, and infectivity
titers were calculated by the Spearman-Kärber method. RESULTS: PrPSc
partitioning paralleled TSE infectivity partitioning, regardless of the
nature of the protein-purification step. The detection ranges for PrPSc
and infectivity were 0 to 5.3 log and 1.1 to 8.9 log median infectious
dose per unit, respectively. Clearance of PrPSc and infectivity ranged
from 1.0 to 6.0 log. CONCLUSION: Purification steps for isolating
therapeutic proteins from human plasma showed the removal of both PrPSc
and TSE infectivity. PrPSc partitioning coincided with infectivity
partitioning, which showed a close relationship between PrPSc and TSE
infectivity. By exploiting this association, the in vitro Western blot
assay for PrPSc was valuable for estimating the partitioning of TSE
infectivity during plasma protein purification.
- L4 ANSWER 14 OF 17 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on
STN DUPLICATE 10
- AN 2000:91700 BIOSIS
- DN PREV200000091700
- TI Monitoring plasma processing steps with a sensitive Western blot assay for
the detection of the **prion** protein.
- AU Lee, Douglas C. [Reprint author]; **Stenland, Christopher J.**;
Hartwell, Randal C.; Ford, Elizabeth K.; Cai, Kang; Miller, Jeanette L.
C.; Gilligan, Kevin J.; Rubenstein, Richard; Fournel, Michael; Petteway,
Stephen R., Jr.
- CS Department of Pathogen Safety Research/Biological Products, Bayer Corp.,
85 TW Alexander Drive, Research Triangle Park, NC, 27709, USA
- SO Journal of Virological Methods, (Jan., 2000) Vol. 84, No. 1, pp. 77-89.
print.
CODEN: JVMEDH. ISSN: 0166-0934.
- DT Article
- LA English

ED Entered STN: 10 Mar 2000
 Last Updated on STN: 3 Jan 2002

AB Determining the risk of transmissible spongiform encephalopathy (TSE) transmission by blood or plasma-derived products requires sensitive and specific assays for the detection of either infectivity or a reliable marker for infectivity. To this end, a Western blot assay that is both sensitive and reproducible for the detection of PrPRES, a marker for TSE infectivity, was developed. Using the 263K strain of TSE as a model system, the Western blot assay proved to be sensitive, specific and quantitative over a 3-4 log dynamic range. Compared to the rodent bioassay, the assay was shown to detect PrPRES down to approx 103.4 IU/ml, which is approx 5-10 pg of PrP or approx 10-20 ng brain equivalents. The Western blot was applied to monitor the partitioning of spiked PrPSc through three plasma fractionation steps, cryoprecipitation, fraction I and fraction III, that are common to the purification of several human plasma-derived therapeutic products including albumin and immunoglobulins. The results from these studies demonstrated 1 log, 1 log and 4 logs of PrPSc partitioning away from the effluent fraction for the cryoprecipitation, fraction I and fraction III steps, respectively.

L4 ANSWER 15 OF 17 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN

AN 2001:311745 BIOSIS

DN PREV200100311745

TI Exploiting the pathogenic **prion** protein as a marker for tracking the clearance of transmissible spongiform encephalopathy infectivity during the purification of plasma proteins.

AU Miller, Jeanette L. C. [Reprint author]; Cai, Kang [Reprint author]; Evans-Storms, Rose [Reprint author]; Ford, Elizabeth K. [Reprint author]; Fournel, Michael [Reprint author]; Gilligan, Kevin J. [Reprint author]; Hartwell, Randal C. [Reprint author]; Petteway, Stephen R., Jr. [Reprint author]; **Stenland, Christopher J.** [Reprint author]; Terry, Jarrett C. [Reprint author]; Lee, Douglas C. [Reprint author]

CS Department of Pathogen Safety Research, Bayer Corporation, Research Triangle Park, NC, USA

SO Blood, (November 16, 2000) Vol. 96, No. 11 Part 1, pp. 60a. print.
 Meeting Info.: 42nd Annual Meeting of the American Society of Hematology. San Francisco, California, USA. December 01-05, 2000. American Society of Hematology.
 CODEN: BLOOAW. ISSN: 0006-4971.

DT Conference; (Meeting)
 Conference; Abstract; (Meeting Abstract)
 Conference; (Meeting Poster)

LA English

ED Entered STN: 27 Jun 2001
 Last Updated on STN: 19 Feb 2002

AB Experimental evidence from rodent models indicates that blood can contain transmissible spongiform encephalopathy (TSE) infectivity (Brown et al. Transfusion 1998, 38:810-816), suggesting a potential risk for TSE transmission via proteins isolated from human plasma. Since methods that can reduce TSE infectivity are typically detrimental to protein function, infectivity must be removed to ensure the safety of these therapeutic proteins. Conventionally, the animal bioassay is used to detect infectivity; however, 7-12 months are required to complete a bioassay and it is not conducive to performing experimental replicates. The pathogenic form of the **prion** protein (PrPSc) can serve as a marker for TSE infectivity; therefore, we exploited this relationship and used a sensitive and robust Western blot assay to track PrPSc, and therefore infectivity, during the purification of plasma proteins. Several plasma protein purification steps used during the manufacture of factor VIII, immunoglobulins, alpha1-proteinase inhibitor, anti-thrombin, and albumin were performed on a miniaturized scale after spiking the appropriate, starting materials with a TSE-infected reagent. Resulting fractions were analyzed for PrPSc using a Western blot assay and for TSE infectivity using an animal bioassay. The detection ranges for PrPSc and infectivity were 0-5.3 logs and 1.1-8.9 log ID50 units, respectively. Clearance of PrPSc and infectivity ranged from 1.0 to 6.0 logs depending on the particular purification step. PrPSc partitioning paralleled TSE

infectivity regardless of the nature of the protein purification step, demonstrating the close relationship between PrPSc and TSE infectivity. By exploiting this association, the in vitro Western blot assay for PrPSc was valuable for estimating partitioning of TSE infectivity during plasma protein purification and for demonstrating the ability of these processes to reduce the risk of TSE transmission through blood protein products.

L4 ANSWER 16 OF 17 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on
STN DUPLICATE 11

AN 1997:344655 BIOSIS
DN PREV199799643858
TI Kinetics and mechanism of amyloid formation by the **prion** protein
H1 peptide as determined by time-dependent ESR.

AU Lundberg, Karen M.; **Stenland, Chris J.**; Cohen, Fred E.;
Prusiner, Stanley B.; Millhauser, Glenn L. [Reprint author]
CS Dep. Chem. and Biochem., Univ. Calif., Santa Cruz, CA 95064, USA
SO Chemistry and Biology (London), (1997) Vol. 4, No. 5, pp. 345-355.
ISSN: 1074-5521.

DT Article
LA English
ED Entered STN: 11 Aug 1997
Last Updated on STN: 11 Aug 1997

AB Background: Peptides derived from three of four putative α -helical regions of the **prion** protein (PrP) form amyloid in solution. These peptides serve as models for amyloidogenesis and for understanding the α helix to β strand conformational change that is responsible for the development of disease. Kinetic studies of amyloid formation usually rely on the detection of fibrils. No study has yet explored the rate of monomer peptide uptake or the presence of nonfibrillar, intermediate species. We present a new electron spin resonance (ESR) method for probing the kinetics of amyloid formation. A spin label was covalently attached to a highly amyloidogenic peptide and kinetic trials were monitored by ESR. Results: Electron microscopy shows that the spin-labeled peptide forms amyloid, and ESR reveals the kinetic decay of free peptide monomer during amyloid formation. The combination of electron microscopy and ESR suggests that there are three kinetically relevant species: monomer peptide, amyloid and amorphous aggregate (peptide aggregates devoid of fibrils or other structures with long-range order). A rather surprising result is that amyloid formation requires the presence of this amorphous aggregate. This is particularly interesting because PrP-Sc, the form of PrP associated with scrapie, is often found as an aggregate and amyloid formation is not a necessary component of **prion** replication or pathogenesis. Conclusions: Kinetic analysis of the time-dependent data suggests a model whereby the amorphous aggregate has a previously unsuspected dual role: it releases monomer into solution and also provides initiation sites for fibril growth. These findings suggest that the β -sheet-rich PrP-Sc may be stabilized by aggregation.

L4 ANSWER 17 OF 17 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on
STN

AN 1995:139398 BIOSIS
DN PREV199598153698
TI Exploring **prion** kinetics and replication with a spin-labeled **prion** peptide fragment.

AU Lundberg, Karen M. [Reprint author]; **Stenland, Chris J.**;
Millhauser, Glenn L.; Cohen, Fred E.
CS Univ. California, Dep. Chem. Biochem., Santa Cruz, CA 95064, USA
SO Biophysical Journal, (1995) Vol. 68, No. 2 PART 2, pp. A342.
Meeting Info.: 39th Annual Meeting of the Biophysical Society. San Francisco, California, USA. February 12-16, 1995.
CODEN: BIOJAU. ISSN: 0006-3495.

DT Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
Conference; (Meeting Poster)

LA English
ED Entered STN: 3 Apr 1995
Last Updated on STN: 4 Apr 1995

=> s (prion? or TSE?)and immunoassay?
L5 2667 (PRION? OR TSE?) AND IMMUNOASSAY?

=> s 15 and (western blot?)
L6 1232 L5 AND (WESTERN BLOT?)

=> s 16 and label?
L7 1122 L6 AND LABEL?

=> s 17 and enzyme?
4 FILES SEARCHED...
L8 1098 L7 AND ENZYME?

=> s 18 and (proteinase K)
L9 124 L8 AND (PROTEINASE K)

=> s 19 and monoclonal
L10 111 L9 AND MONOCLONAL

=> d 110 and 3F4

'AND' IS NOT A VALID FORMAT

'3F4' IS NOT A VALID FORMAT

In a multifile environment, a format can only be used if it is valid in at least one of the files. Refer to file specific help messages or the STNGUIDE file for information on formats available in individual files.

REENTER DISPLAY FORMAT FOR ALL FILES (FILEDEFAULT):bib

L10 ANSWER 1 OF 111 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2004:266686 CAPLUS

DN 140:268921

TI Comparative molecular analysis of the abnormal **prion** protein in field scrapie cases and experimental bovine spongiform encephalopathy in sheep by use of **western blotting** and immunohistochemical methods

AU Lezmi, Stephane; Martin, Stuart; Simon, Stephanie; Comoy, Emmanuel; Bencsik, Anna; Deslys, Jean-Philippe; Grassi, Jacques; Jeffrey, Martin; Baron, Thierry

CS Unite Virologie-ATNC, Agence Francaise de Securite Sanitaire des Aliments, Lyon, 69364, Fr.

SO Journal of Virology (2004), 78(7), 3654-3662

CODEN: JOVIAM; ISSN: 0022-538X

PB American Society for Microbiology

DT Journal

LA English

RE.CNT 50 THERE ARE 50 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> s 110 and 3F4
L11 22 L10 AND 3F4

=> d bib ab 1-

YOU HAVE REQUESTED DATA FROM 22 ANSWERS - CONTINUE? Y/(N):y

L11 ANSWER 1 OF 22 USPATFULL on STN

AN 2005:105007 USPATFULL

TI Rapid method of determining clearance of **prion** protein

IN Cai, Kang, Chapel Hill, NC, UNITED STATES

Stenland, Christopher J., Cary, NC, UNITED STATES

PI US 2005089943 A1 20050428

AI US 2003-693734 A1 20031023 (10)

DT Utility

FS APPLICATION

LREP WOMBLE CARLYLE SANDRIDGE & RICE, PLLC, P.O. BOX 7037, ATLANTA, GA, 30357-0037, US

CLMN Number of Claims: 22

ECL Exemplary Claim: 1

DRWN 7 Drawing Page(s)

LN.CNT 800

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides a rapid, sensitive **immunoassay** capable of detecting and quantitating pathogenic protein to a level of 3 to 5 logs. The preferred **immunoassay** utilized is a chemiluminescent endpoint for a **Western blot immunoassay**.
The invention has been successfully applied to track the clearance of pathogenic protein during production of proteins derived from plasma. It is particularly applicable and has been confirmed by bioassay to relate **TSE** infectivity to quantitative results on **prion** protein.

L11 ANSWER 2 OF 22 USPATFULL on STN

AN 2005:63014 USPATFULL

TI Albumin fusion proteins

IN Rosen, Craig A., Laytonsville, MD, UNITED STATES

Haseltine, William A., Washington, DC, UNITED STATES

PA Human Genome Sciences, Inc. (U.S. corporation)

PI US 2005054051 A1 20050310

AI US 2004-922142 A1 20040820 (10)

RLI Division of Ser. No. US 2001-832929, filed on 12 Apr 2001, PENDING

DT Utility

FS APPLICATION

LREP FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER, LLP, 1300 I STREET, NW, WASHINGTON, DC, 20005

CLMN Number of Claims: 33

ECL Exemplary Claim: 1

DRWN 20 Drawing Page(s)

LN.CNT 17526

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.

L11 ANSWER 3 OF 22 USPATFULL on STN

AN 2005:57477 USPATFULL

TI Models of **prion** disease

IN Prusiner, Stanley B., San Francisco, CA, UNITED STATES

Korth, Carsten, San Francisco, CA, UNITED STATES

PA The Regents of the University of California (U.S. corporation)

PI US 2005049395 A1 20050303

AI US 2004-875821 A1 20040623 (10)

RLI Continuation of Ser. No. US 2001-895963, filed on 28 Jun 2001, GRANTED, Pat. No. US 6767712 Continuation of Ser. No. US 1999-318888, filed on 26 May 1999, ABANDONED

DT Utility

FS APPLICATION

LREP BOZICEVIC, FIELD & FRANCIS LLP, 1900 UNIVERSITY AVE, SUITE 200, EAST PALO ALTO, CA, 94303

CLMN Number of Claims: 16

ECL Exemplary Claim: CLM-01-22

DRWN No Drawings

LN.CNT 1397

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides a novel PrP protein, and nucleic acids encoding this protein, where the PrP protein is characterized in vivo by 1) incomplete glycosylation relative to glycosylation of wild-type PrP.sup.C and 2) proper cellular localization, i.e. an ability to be

transported to the cell surface. This novel, under-glycosylated PrP, unlike its normal cellular counterpart, can easily be converted into a protease-resistant isoform by incubation with infectious **prions**. The invention further provides systems for the study of **prion** disorders and methods of using these systems, e.g. the study of the mechanical processes in progression of **prion**-mediated disease or the identification of new therapeutic agents for treatment of **prion**-mediated disorders. In such systems, protease-resistant under-glycosylated PrP is generated de novo and can be detected by standard immunoblot techniques.

L11 ANSWER 4 OF 22 USPATFULL on STN

AN 2005:16795 USPATFULL

TI **Prion** protein binding materials and methods of use

IN Carbonell, Ruben G., Raleigh, NC, UNITED STATES

Shen, Honglue, Raleigh, NC, UNITED STATES

Gurgel, Patrick V., Cary, NC, UNITED STATES

Wiltshire-Lyerly, Viterose, Raleigh, NC, UNITED STATES

Hammond, David J., Laytonsville, MD, UNITED STATES

Burton, Steven J., Little Eversden, UNITED KINGDOM

PI US 2005014196 A1 20050120

AI US 2004-817117 A1 20040402 (10)

PRAI US 2003-460474P 20030404 (60)

DT Utility

FS APPLICATION

LREP JOHN S. PRATT, ESQ, KILPATRICK STOCKTON, LLP, 1100 PEACHTREE STREET, ATLANTA, GA, 30309

CLMN Number of Claims: 49

ECL Exemplary Claim: 1

DRWN 4 Drawing Page(s)

LN.CNT 1929

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB **Prion** protein binding materials and methods for using the binding materials to detect or remove a **prion** protein from a sample, such as a biological fluid or an environmental sample. The binding materials are capable of binding to one or more forms of **prion** protein including cellular **prion** protein (PrPc), infectious **prion** protein (PrPsc), recombinant **prion** protein (PrPr), and proteinase resistant **prion** protein (PrPres). **Prions** from various species, including humans and hamsters, are bound by the binding materials.

L11 ANSWER 5 OF 22 USPATFULL on STN

AN 2004:292196 USPATFULL

TI **Prion** protein ligands and methods of use

IN Hammond, David J., Laytonsville, MD, UNITED STATES

Lathrop, Julia T., Falls Church, VA, UNITED STATES

Cervenakova, Larisa, Rockville, MD, UNITED STATES

Carbonell, Ruben G., Raleigh, NC, UNITED STATES

PI US 2004229280 A1 20041118

AI US 2003-727335 A1 20031203 (10)

PRAI US 2002-430423P 20021203 (60)

DT Utility

FS APPLICATION

LREP JOHN S. PRATT, ESQ, KILPATRICK STOCKTON, LLP, 1100 PEACHTREE STREET, ATLANTA, GA, 30309

CLMN Number of Claims: 37

ECL Exemplary Claim: 1

DRWN 6 Drawing Page(s)

LN.CNT 2859

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Ligands that bind to **prion** proteins and methods for using the ligands for detecting or removing a **prion** protein from a sample, such as a biological fluid or an environmental sample. The ligands are capable of binding to one or more forms of **prion** protein including cellular **prion** protein (PrPc), infectious **prion** protein (PrPsc), and recombinant **prion** protein (PrPr). **Prions** from various species, including humans and

hamsters, are bound by the ligands. Also provided is a method of treating or retarding the development of a **prion**-associated pathology in a subject

L11 ANSWER 6 OF 22 USPATFULL on STN

AN 2004:233296 USPATFULL

TI Antibodies For discrimination of **prions**

IN Zheng, Jian, Raritan, NJ, UNITED STATES

Alexander, Steve Stanley, Flemington, NJ, UNITED STATES

PI US 2004180367 A1 20040916

AI US 2003-740025 A1 20031218 (10)

PRAI US 2002-434627P 20021219 (60)

US 2003-446217P 20030210 (60)

DT Utility

FS APPLICATION

LREP PHILIP S. JOHNSON, JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK, NJ, 08933-7003

CLMN Number of Claims: 9

ECL Exemplary Claim: 1

DRWN 10 Drawing Page(s)

LN.CNT 1247

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB In the present invention, we described the use of anti-DNA antibody for the detection of **prions** and diagnosis of Transmissible Spongiform Encephalopathies (**TSE**) diseases in animals and humans.

L11 ANSWER 7 OF 22 USPATFULL on STN

AN 2004:221354 USPATFULL

TI ALBUMIN FUSION PROTEINS

IN Rosen, Craig A., Laytonsville, MD, UNITED STATES

Haseltine, William A., Washington, DC, UNITED STATES

PI US 2004171123 A1 20040902

AI US 2001-832929 A1 20010412 (9)

DT Utility

FS APPLICATION

LREP FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER, LLP, 1300 I STREET, NW, WASHINGTON, DC, 20005

CLMN Number of Claims: 29

ECL Exemplary Claim: 1

DRWN 18 Drawing Page(s)

LN.CNT 17424

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.

L11 ANSWER 8 OF 22 USPATFULL on STN

AN 2004:178363 USPATFULL

TI Method of preparing cow brain homogenate

IN Prusiner, Stanley B., San Francisco, CA, UNITED STATES

Safar, Jiri G., Walnut Creek, CA, UNITED STATES

PA The Regents of the University of California (U.S. corporation)

PI US 2004137529 A1 20040715

US 6875577 B2 20050405

AI US 2003-742241 A1 20031218 (10)

RLI Continuation of Ser. No. US 2002-47431, filed on 14 Jan 2002, GRANTED, Pat. No. US 6677125 Continuation of Ser. No. US 2001-754443, filed on 3 Jan 2001, GRANTED, Pat. No. US 6406864 Continuation of Ser. No. US 1998-169574, filed on 9 Oct 1998, GRANTED, Pat. No. US 6214565 Continuation-in-part of Ser. No. US 1998-26967, filed on 20 Feb 1998,

GRANTED, Pat. No. US 5977324

DT Utility
FS APPLICATION
LREP BOZICEVIC, FIELD & FRANCIS LLP, 200 MIDDLEFIELD RD, SUITE 200, MENLO
PARK, CA, 94025
CLMN Number of Claims: 27
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1645

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB An assay method is disclosed which isolates and detects the presence of a disease related conformation of a protein (e.g., PrP.sup.Sc) present in a sample also containing the non-disease related conformation of the protein (e.g., PrP.sup.C). The sample is treated (e.g., contacted with protease) in a manner which hydrolyzes the disease related conformation and not the non-disease related conformation. The treated sample is contacted with a binding partner (e.g., a **labeled** antibody which binds PrP.sup.Sc) and the occurrence of binding provides and indication that PrP.sup.Sc is present. Alternatively the PrP.sup.Sc of the treated sample is denatured (e.g., contacted with guanadine) or unfolded. The unfolded PrP.sup.Sc is contacted with a binding partner and the occurrence of binding indicates the presence of PrP.sup.Sc in the sample. In another embodiment, PrP.sup.Sc and PrP.sup.C are reacted with a **labeled** antibody that binds both conformations and a conformation that binds only the disease related conformation, and the presence of the disease related conformation is determined by comparing the two.

L11 ANSWER 9 OF 22 USPATFULL on STN

AN 2003:251654 USPATFULL
TI Pyridylpyrimidine derivatives as effective compounds against
prion diseases
IN Stein-Gerlach, Matthias, Munich, GERMANY, FEDERAL REPUBLIC OF
Salassidis, Konstadinos, Ehcing, GERMANY, FEDERAL REPUBLIC OF
Bacher, Gerald, Germering, GERMANY, FEDERAL REPUBLIC OF
Muller, Stefan, Munich, GERMANY, FEDERAL REPUBLIC OF
PI US 2003176443 A1 20030918
AI US 2002-204041 A1 20020816 (10)
WO 2002-EP5420 20020516
PRAI EP 2001-111858 20010516
EP 2001-117113 20010713

DT Utility
FS APPLICATION
LREP Leon R Yankwich, Yankwich & Associates, 201 Broadway, Cambridge, MA,
02139

CLMN Number of Claims: 48
ECL Exemplary Claim: 1
DRWN 3 Drawing Page(s)
LN.CNT 3218

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to pyridylpyrimidine derivatives of the general formula (I): ##STR1##

wherein R represents hydrogen or methyl and Z represents nitrogen containing functional groups, the use of the pyridylpyrimidine derivatives as pharmaceutically active agents, especially for the prophylaxis and/or treatment of **prion** infections and **prion** diseases, as well as compositions containing at least one pyridylpyrimidine derivative and/or pharmaceutically acceptable salt thereof. Furthermore, the present invention is directed to methods for preventing and/or treating **prion** infections and **prion** diseases using said pyridylpyrimidine derivatives. Human cellular protein kinases, phosphatases and cellular signal transduction molecules are disclosed as targets for detecting, preventing and/or treating **prion** infections and diseases, especially BSE, vCJD, or CJD which can be inhibited by the inventive pyridylpyrimidine derivatives.

L11 ANSWER 10 OF 22 USPATFULL on STN

AN 2003:194529 USPATFULL
TI Method for detecting pathogenic **prion** proteins by means of
mass spectroscopy
IN Lengsfeld, Thomas, Marburg, GERMANY, FEDERAL REPUBLIC OF
PI US 2003134340 A1 20030717
AI US 2003-345148 A1 20030116 (10)
PRAI DE 2002-10201777 20020117
DT Utility
FS APPLICATION
LREP Finnegan, Henderson, Farabow,, Garrett & Dunner, L.L.P., 1300 I Street,
N.W., Washington, DC, 20005-3315
CLMN Number of Claims: 24
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 433

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method for detecting one or more pathogenic **prion** proteins
in a sample, which can be of a body fluid of human or animal origin, and
which contains a PrP protein that assumes a natural, nonpathogenic
conformation, PrP.sup.C, and a pathogenic conformation, termed
PrP.sup.Sc, is described. The method can comprise: providing a sample
suspected of containing the pathogenic form of at least one
prion protein; exposing the sample to a chemical agent under
conditions where the chemical agent and the **prion** protein or
proteins react to form at least one covalent bond involving the
prion protein or proteins; and mass-spectroscopically analyzing
the resulting **prion** protein or proteins to detect the presence
of the pathogenic form of the **prion** protein or proteins;
wherein at least one additional peak is observed in the mass spectrum
when the pathogenic form of a **prion** protein is present.

L11 ANSWER 11 OF 22 USPATFULL on STN

AN 2003:134009 USPATFULL
TI Antibodies for specifically detecting pathogenic **prions** of
human origin, and detection methods carried out using these antibodies
IN Vey, Martin, Marburg, GERMANY, FEDERAL REPUBLIC OF
Lang, Wiegand, Coelbe, GERMANY, FEDERAL REPUBLIC OF
Groener, Albrecht, Marburg, GERMANY, FEDERAL REPUBLIC OF
Bellon, Anne, Marburg, GERMANY, FEDERAL REPUBLIC OF
PI US 2003092094 A1 20030515
AI US 2002-273282 A1 20021018 (10)
PRAI DE 2001-152677 20011019
DT Utility
FS APPLICATION
LREP Finnegan, Henderson, Farabow,, Garrett & Dunner, L.L.P., 1300 I Street,
N.W., Washington, DC, 20005-3315
CLMN Number of Claims: 22
ECL Exemplary Claim: 1
DRWN 3 Drawing Page(s)
LN.CNT 708

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Antibodies for specifically detecting pathogenic **prions** of
human origin, and methods for detecting pathogenic **prions**, are
described. In particular, a conformation-dependent **immunoassay**
method for detecting pathogenic **prion** proteins in a sample of
a body fluid, containing a PrP protein, which contains a first, natural,
non-pathological conformation, i.e. PrP.sup.c, and a second,
pathological conformation, i.e. PrP.sup.Sc, is described, in which
method the **prion** proteins differ in their binding affinity for
monoclonal antibodies which bind specifically to **prion**
proteins of human origin, with the detection method comprising the
following steps:

a) adding one of the abovementioned **monoclonal** antibodies,
which is fixed to a solid support and which exhibits a higher affinity
for the first **prion** protein conformation, to the first portion
of the sample, and determining this first concentration;

b) treating the second portion of the sample in order to increase the binding affinity of the second conformation of the **prion** protein for the **monoclonal** antibody;

c) adding the **monoclonal** antibody to the treated second portion of the sample to be investigated, in order to determine the second concentration;

d) comparing the first **prion** protein concentration with the second **prion** protein concentration in order to ascertain the presence of the pathogenic **prion** protein conformation.

L11 ANSWER 12 OF 22 USPATFULL on STN

AN 2003:33306 USPATFULL

TI Methods for detection of **prion** protein as an indication of transmissible spongiform encephalopathies

IN O'Rourke, Katherine I., Pullman, WA, United States

Knowles, Donald P., Pullman, WA, United States

Baszler, Timothy V., Moscow, ID, United States

Parish, Steven M., Pullman, WA, United States

PA The United States of America as represented by the Secretary of

Agriculture, Washington, DC, United States (U.S. government)

Washington State University Research Foundation, Pullman, WA, United

States (U.S. corporation)

PI US 6514707 B1 20030204

AI US 2000-687672 20001012 (9)

RLI Division of Ser. No. US 1997-950271, filed on 14 Oct 1997, now patented, Pat. No. US 6165784

DT Utility

FS GRANTED

EXNAM Primary Examiner: Navarro, Mark

LREP Connor, Margaret A., Silverstein, M. Howard, Fado, John D.

CLMN Number of Claims: 12

ECL Exemplary Claim: 1

DRWN 0 Drawing Figure(s); 0 Drawing Page(s)

LN.CNT 883

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods to detect **prion** or PrP-Sc protein as an indication of transmissible spongiform encephalopathies (**TSEs**), including preclinical detection of infected live animals, and postmortem detection methods, are described. In one aspect, the invention is directed to a non-invasive diagnostic assay using third eyelid-associated lymphoid tissue. In another aspect, the invention is directed to **monoclonal** antibodies that specifically bind a conserved epitope of PrP-Sc protein in fixed or frozen treated tissue.

L11 ANSWER 13 OF 22 USPATFULL on STN

AN 2002:227919 USPATFULL

TI Assay for disease related conformation of a protein and isolating same

IN Prusiner, Stanley B., San Francisco, CA, UNITED STATES

Safar, Jiri G., Walnut Creek, CA, UNITED STATES

PI US 2002123072 A1 20020905

US 6677125 B2 20040113

AI US 2002-47431 A1 20020114 (10)

RLI Continuation of Ser. No. US 2001-754443, filed on 3 Jan 2001, PENDING

Continuation of Ser. No. US 1998-169574, filed on 9 Oct 1998, GRANTED,

Pat. No. US 6214565 Continuation of Ser. No. US 1998-26967, filed on 20

Feb 1998, GRANTED, Pat. No. US 5977324

DT Utility

FS APPLICATION

LREP BOZICEVIC, FIELD & FRANCIS LLP, 200 MIDDLEFIELD RD, SUITE 200, MENLO

PARK, CA, 94025

CLMN Number of Claims: 27

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 1643

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB An assay method is disclosed which isolates and detects the presence of

a disease related conformation of a protein (e.g., PrP.sup.Sc) present in a sample also containing the non-disease related conformation of the protein (e.g., PrP.sup.C). The sample is treated (e.g., contacted with protease) in a manner which hydrolyzes the disease related conformation and not the non-disease related conformation. The treated sample is contacted with a binding partner (e.g., a **labeled** antibody which binds PrP.sup.Sc) and the occurrence of binding provides and indication that PrP.sup.Sc is present. Alternatively the PrP.sup.Sc of the treated sample is denatured (e.g., contacted with guanadine) or unfolded. The unfolded PrP.sup.Sc is contacted with a binding partner and the occurrence of binding indicates the presence of PrP.sup.Sc in the sample. In another embodiment, PrP.sup.Sc and PrP.sup.C are reacted with a **labeled** antibody that binds both conformations and a conformation that binds only the disease related conformation, and the presence of the disease related conformation is determined by comparing the two.

L11 ANSWER 14 OF 22 USPATFULL on STN

AN 2002:8938 USPATFULL

TI Models of **prion** disease

IN Prusiner, Stanley B., San Francisco, CA, UNITED STATES

Korth, Carsten, San Francisco, CA, UNITED STATES

PI US 2002004938 A1 20020110

US 6767712 B2 20040727

AI US 2001-895963 A1 20010628 (9)

RLI Continuation of Ser. No. US 1999-318888, filed on 26 May 1999, PENDING

DT Utility

FS APPLICATION

LREP Karl Bozicevic, BOZICEVIC, FIELD & FRANCIS, LLP, Suite 200, 200

Middlefield Road, Menlo Park, CA, 94025

CLMN Number of Claims: 22

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 1413

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides a novel PrP protein, and nucleic acids encoding this protein, where the PrP protein is characterized in vivo by 1) incomplete glycosylation relative to glycosylation of wild-type PrP.sup.C and 2) proper cellular localization, i.e. an ability to be transported to the cell surface. This novel, under-glycosylated PrP, unlike its normal cellular counterpart, can easily be converted into a protease-resistant isoform by incubation with infectious **prions**. The invention further provides systems for the study of **prion** disorders and methods of using these systems, e.g. the study of the mechanical processes in progression of **prion**-mediated disease or the identification of new therapeutic agents for treatment of **prion**-mediated disorders. In such systems, protease-resistant under-glycosylated PrP is generated de novo and can be detected by standard immunoblot techniques.

L11 ANSWER 15 OF 22 USPATFULL on STN

AN 2002:3842 USPATFULL

TI Assay for specific strains of multiple disease related conformations of a protein

IN Prusiner, Stanley B., San Francisco, CA, UNITED STATES

Safar, Jiri G., Concord, CA, UNITED STATES

Cohen, Fred E., San Francisco, CA, UNITED STATES

PI US 2002001817 A1 20020103

US 6617119 B2 20030909

AI US 2001-901865 A1 20010709 (9)

RLI Continuation of Ser. No. US 1998-151057, filed on 10 Sep 1998, PENDING

Continuation-in-part of Ser. No. US 1998-26957, filed on 20 Feb 1998,

ABANDONED Continuation-in-part of Ser. No. US 1997-804536, filed on 21 Feb 1997, GRANTED, Pat. No. US 5891641

DT Utility

FS APPLICATION

LREP Karl Bozicevic, Bozicevic, Field and Francis LLP, Suite 200, 200

Middlefield Road, Menlo Park, CA, 94025

CLMN Number of Claims: 20

ECL Exemplary Claim: 1

DRWN 19 Drawing Page(s)

LN.CNT 2676

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Assay methodology of the invention allows for: (1) determining if a sample contains a conformation of a protein which is associated with disease and the concentration and amount of such if present; (2) determining the amount of protease resistant disease related protein in a sample and by subtracting that amount from the total amount of disease related protein present determining the amount of protease sensitive disease protein in the sample; and (3) determining the strain and incubation time of a disease related protein by (i) relating the relative amounts of protease resistant and protease sensitive protein to known strains to thereby determine the strain; and (ii) plotting the concentration of protease sensitive protein on a graph of incubation time versus concentration of protease sensitive protein for known strains to predict the incubation time of an unknown strain of pathogenic protein in a sample.

L11 ANSWER 16 OF 22 USPATFULL on STN

AN 2001:134006 USPATFULL

TI Assay for disease related conformation of a protein and isolating same

IN Prusiner, Stanley B., San Francisco, CA, United States

Safar, Jiri G., Concord, CA, United States

PI US 2001014455 A1 20010816

US 6406864 B2 20020618

AI US 2001-754443 A1 20010103 (9)

RLI Continuation of Ser. No. US 1998-169574, filed on 9 Oct 1998, GRANTED, Pat. No. US 6214565

DT Utility

FS APPLICATION

LREP Karl Bozicevic, BOZICEVIC, FIELD & FRANCIS LLP, Suite 200, 200

Middlefield Road, Menlo Park, CA, 94025

CLMN Number of Claims: 27

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 1618

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB An assay method is disclosed which isolates and detects the presence of a disease related conformation of a protein (e.g., PrP.sup.Sc) present in a sample also containing the non-disease related conformation of the protein (e.g., PrP.sup.C). The sample is treated (e.g., contacted with protease) in a manner which hydrolyzes the disease related conformation and not the non-disease related conformation. The treated sample is contacted with a binding partner (e.g., a **labeled** antibody which binds PrP.sup.Sc) and the occurrence of binding provides and indication that PrP.sup.Sc is present. Alternatively the PrP.sup.Sc of the treated sample is denatured (e.g., contacted with guanadine) or unfolded. The unfolded PrP.sup.SC is contacted with a binding partner and the occurrence of binding indicates the presence of PrP.sup.Sc in the sample. In another embodiment, PrP.sup.Sc and PrP.sup.C are reacted with a **labeled** antibody that binds both conformations and a conformation that binds only the disease related conformation, and the presence of the disease related conformation is determined by comparing the two.

L11 ANSWER 17 OF 22 USPATFULL on STN

AN 2001:112058 USPATFULL

TI **Monoclonal** antibodies and antibody cocktail for detection of **prion** protein as an indication of transmissible spongiform encephalopathies

IN O'Rourke, Katherine I., Albion, WA, United States

PA The United States of America as represented by the Secretary of Agriculture, Washington, DC, United States (U.S. corporation)

PI US 6261790 B1 20010717

AI US 1999-353348 19990715 (9)

DT Utility

FS GRANTED
EXNAM Primary Examiner: Swartz, Rodney P
LREP Connor, Margaret A., Silverstein, M. Howard, Fado, John D.
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 954

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods to detect **prion** or PrP-Sc protein as an indication of transmissible spongiform encephalopathies (**TSEs**) are described. In one aspect, the invention is directed to **monoclonal** antibodies that specifically bind a conserved epitope of **prion** proteins and use of the antibodies in **immunoassays** to detect PrP-Sc, in fixed or unfixed tissue, as an indication of the presence of **TSE** infection. In another aspect, the invention is directed to a **monoclonal** antibody cocktail having the **monoclonal** antibody in combination with a second **monoclonal** antibody which specifically binds to a second conserved epitope of **prion** proteins. One or both **monoclonal** antibodies of the cocktail can recognize epitopes found in all mammalian species in which a natural **TSE** has been reported and in a number of closely related species. Thus, the antibody cocktail provides high sensitivity, defined specificity, and broad reactivity to PrP proteins in spite of interspecies and intraspecies variation of species such as ruminant livestock, cats, mink, humans, and non-human primates.

L11 ANSWER 18 OF 22 USPATFULL on STN

AN 2001:88925 USPATFULL

TI Assay for disease related conformation of a protein

IN Prusiner, Stanley B., San Francisco, CA, United States

Safar, Jiri G., Concord, CA, United States

PI US 2001001061 A1 20010510

AI US 2000-731419 A1 20001205 (9)

RLI Continuation of Ser. No. US 1998-26957, filed on 20 Feb 1998, PENDING
Continuation-in-part of Ser. No. US 1997-804536, filed on 21 Feb 1997,
GRANTED, Pat. No. US 5891641

DT Utility

FS APPLICATION

LREP Karl Bozicevic, BOZICEVIC, FIELD & FRANCIS LLP, Suite 200, 200

Middlefield Road, Menlo Park, CA, 94025

CLMN Number of Claims: 20

ECL Exemplary Claim: 1

DRWN 14 Drawing Page(s)

LN.CNT 2288

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB An assay method is disclosed which makes it possible to determine the presence of a diseased related conformation of a protein (e.g., PrP.sup.Sc or the β -sheet form of β A4) in a sample. A sample is divided into two portions and the first portion is cross-linked to a first solid support and then contacted with a **labeled** antibody which binds to a non-disease form of the protein with a higher degree of affinity (e.g., 4 to 30 fold higher) than to the disease form of the protein. The second portion is treated in a manner which causes any disease form of the protein to change conformation to a form with a higher binding affinity for the **labeled** antibody. The treated second portion is then bound to a second solid support and contacted with **labeled** antibody. The level of **labeled** antibody binding to a protein in the first and second portions is determined and the amounts measured in each are compared. The difference between the two measurements is an indication of whether the disease related conformation of the protein was present in the sample. The method can also determine the concentration of the disease related conformation and the particular strain present.

L11 ANSWER 19 OF 22 USPATFULL on STN

AN 2001:51789 USPATFULL

TI Assay for disease related conformation of a protein and isolating same

IN Prusiner, Stanley B., San Francisco, CA, United States
Safar, Jiri G., Concord, CA, United States
PA The Regents of the University of California, Oakland, CA, United States
(U.S. corporation)
PI US 6214565 B1 20010410
AI US 1998-169574 19981009 (9)
DT Utility
FS Granted
EXNAM Primary Examiner: Swartz, Rodney P.
LREP Bozicevic, Karl, DeVore, Dianna L.Bozicevic, Field & Francis LLP
CLMN Number of Claims: 25
ECL Exemplary Claim: 1
DRWN No Drawings

LN.CNT 1675

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB An assay method is disclosed which isolates and detects the presence of a disease related conformation of a protein (e.g., PrP.sup.Sc) present in a sample also containing the non-disease related conformation of the protein (e.g., PrP.sup.C). The sample is treated (e.g., contacted with protease) in a manner which hydrolyzes the disease related conformation and not the non-disease related conformation. The treated sample is contacted with a binding partner (e.g., a **labeled** antibody which binds PrP.sup.Sc) and the occurrence of binding provides and indication that PrP.sup.Sc is present. Alternatively the PrP.sup.Sc of the treated sample is denatured (e.g., contacted with guanadine) or unfolded. The unfolded PrP.sup.Sc is contacted with a binding partner and the occurrence of binding indicates the presence of PrP.sup.Sc in the sample. In another embodiment, PrP.sup.Sc and PrP.sup.C are reacted with a **labeled** antibody that binds both conformations and a conformation that binds only the disease related conformation, and the presence of the disease related conformation is determined by comparing the two.

L11 ANSWER 20 OF 22 USPATFULL on STN

AN 2000:174412 USPATFULL

TI Antibodies for the detection of **prion** protein as an indication of transmissible spongiform encephalopathies

IN O'Rourke, Katherine I., Albion, WA, United States

Knowles, Donald P., Pullman, WA, United States

Baszler, Timothy V., Moscow, ID, United States

Parish, Steven M., Pullman, WA, United States

PA The United States of America as represented by the Secretary of Agriculture, Washington, DC, United States (U.S. government)
Washington State University Research Foundation, Pullman, WA, United States (U.S. corporation)

PI US 6165784 20001226

AI US 1997-950271 19971014 (8)

DT Utility

FS Granted

EXNAM Primary Examiner: Navarro, Albert

LREP Silverstein, M. Howard, Fado, John D., Connor, Margaret A.

CLMN Number of Claims: 3

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 843

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods to detect **prion** or PrP-Sc protein as an indication of transmissible spongiform encephalopathies (**TSEs**), including preclinical detection of infected live animals, and postmortem detection methods, are described. In one aspect, the invention is directed to a non-invasive diagnostic assay using third eyelid-associated lymphoid tissue. In another aspect, the invention is directed to **monoclonal** antibodies that specifically bind a conserved epitope of PrP-Sc protein in fixed or frozen treated tissue.

L11 ANSWER 21 OF 22 USPATFULL on STN

AN 2000:13000 USPATFULL

TI **Prion** protein standard and method of making same

IN Prusiner, Stanley B., San Francisco, CA, United States
PA The Regents of the University of California, Oakland, CA, United States
(U.S. corporation)
PI US 6020537 20000201
AI US 1998-199523 19981125 (9)
RLI Continuation-in-part of Ser. No. US 1997-935363, filed on 22 Sep 1997
which is a continuation-in-part of Ser. No. US 1996-692892, filed on 30
Jul 1996, now patented, Pat. No. US 5792901 which is a
continuation-in-part of Ser. No. US 1995-521992, filed on 31 Aug 1995,
now patented, Pat. No. US 5908969 which is a continuation-in-part of
Ser. No. US 1995-509261, filed on 31 Jul 1995, now patented, Pat. No. US
5763740 which is a continuation-in-part of Ser. No. US 1994-242188,
filed on 13 May 1994, now patented, Pat. No. US 5565186
DT Utility
FS Granted
EXNAM Primary Examiner: Campell, Bruce R.; Assistant Examiner: Baker,
Anne-Marie
LREP DeVore, Dianna L.Bozicevic, Field & Francis LLP
CLMN Number of Claims: 31
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1796

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides **prion** protein standards for use as
reference materials for **prion** detection. The standard may be
species specific, i.e. the standard is comprised of a preparation for
detection of a single strain **prion** or it may be prepared to
allow detection of multiple **prion** strains simultaneously. The
invention also provides methods of preparing the **prion** protein
standards using a group of non-human host mammals which have their
genome manipulated with respect to genetic material related to a PrP
gene such that the mammals are susceptible to infection with a
prion which generally only infects an animal which is
genetically diverse from the host.

L11 ANSWER 22 OF 22 USPATFULL on STN

AN 1999:43389 USPATFULL
TI Assay for disease related conformation of a protein
IN Prusiner, Stanley B., San Francisco, CA, United States
Safar, Jiri G., Concord, CA, United States
PA The Regents of the University of California, Oakland, CA, United States
(U.S. corporation)
PI US 5891641 19990406
AI US 1997-804536 19970221 (8)
DT Utility
FS Granted
EXNAM Primary Examiner: Woodward, Michael P.; Assistant Examiner: Zeman, Mary
K.
LREP Bozicevic, KarlBozicevic & Reed LLP
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN 11 Drawing Figure(s); 6 Drawing Page(s)
LN.CNT 1990

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB An assay method is disclosed which makes it possible to determine the
presence of a diseased related conformation of a protein (e.g.,
PrP.sup.Sc) in a sample. A sample is divided into two portions and the
first portion is cross-linked to a first solid support and then
contacted with a **labelled** antibody which binds to a
non-disease form of the protein with a higher degree of affinity (e.g, 4
to 30 fold higher) than to the disease form of the protein. The second
portion is treated in a manner which causes any disease form of the
protein to change conformation to a form with a higher binding affinity
for the **labelled** antibody. The treated second portion is then
bound to a second solid support and contacted with **labelled**
antibody. The level of **labelled** antibody binding to a protein
in the first and second portions is determined and the amounts measured
in each are compared. The difference between the two measurements is an

indication of whether the diseased related conformation of the protein was present in the sample.

=> d bib ab 110 1-

YOU HAVE REQUESTED DATA FROM 111 ANSWERS - CONTINUE? Y/(N):y

L10 ANSWER 1 OF 111 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2004:266686 CAPLUS

DN 140:268921

TI Comparative molecular analysis of the abnormal **prion** protein in field scrapie cases and experimental bovine spongiform encephalopathy in sheep by use of **western blotting** and immunohistochemical methods

AU Lezmi, Stephane; Martin, Stuart; Simon, Stephanie; Comoy, Emmanuel; Bencsik, Anna; Deslys, Jean-Philippe; Grassi, Jacques; Jeffrey, Martin; Baron, Thierry

CS Unite Virologie-ATNC, Agence Francaise de Securite Sanitaire des Aliments, Lyon, 69364, Fr.

SO Journal of Virology (2004), 78(7), 3654-3662

CODEN: JOVIAM; ISSN: 0022-538X

PB American Society for Microbiology

DT Journal

LA English

AB Since the appearance of bovine spongiform encephalopathy (BSE) in cattle and its linkage with the human variant of Creutzfeldt-Jakob disease, the possible spread of this agent to sheep flocks has been of concern as a potential new source of contamination. Mol. anal. of the protease cleavage of the abnormal **prion** protein (PrP), by **Western blotting** (PrPres) or by immunohistochem. methods (PrPd), has shown some potential to distinguish BSE and scrapie in sheep. Using a newly developed ELISA, the authors identified 18 infected sheep in which PrPres showed an increased sensitivity to **proteinase K** digestion. When analyzed by **Western blotting**, two of them showed a low mol. mass of unglycosylated PrPres as found in BSE-infected sheep, in contrast to other naturally infected sheep. A decrease of the **labeling** by P4 **monoclonal** antibody, which recognizes an epitope close to the protease cleavage site, was also found by **Western blotting** in the former two samples, but this was less marked than in BSE-infected sheep. These two samples, and all of the other natural scrapie cases studied, were clearly distinguishable from those from sheep inoculated with the BSE agent from either French or British cattle by immunohistochem. anal. of PrPd **labeling** in the brain and lymphoid tissues. Final characterization of the strain involved in these samples will require anal. of the features of the disease following infection of mice, but the authors' data already emphasize the need to use the different available methods to define the mol. properties of abnormal PrP and its possible similarities with the BSE agent.

RE.CNT 50 THERE ARE 50 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 2 OF 111 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2003:872319 CAPLUS

DN 139:347738

TI Preparation of avian antibodies to mammalian **prions**, **immunoassay** and test kit for the diagnosis of transmissible spongiform encephalopathy

IN Lusky, Klaus; Doberschuetz, Klaus-Dieter; Henklein, Peter; Schade, Ruediger; Fischer, Lothar; Sasse, Mirko

PA Universitaetsklinikum Charite Medizinische Fakultaet der Humboldt-Universitaet Akademische Verwaltung - Forschung, Germany; Institut fuer Veterinaer-Pharmakologie und Toxikologie GmbH

SO Ger. Offen., 6 pp.

CODEN: GWXXBX

DT Patent

LA German

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|--------|---|------|---------------|------------------|----------|
| PI | DE 10219298 | A1 | 20031106 | DE 2002-10219298 | 20020425 |
| PRAI | DE 2002-10219298 | | 20020425 | | |
| AB | <p>The invention concerns chicken antibodies, preferably monoclonal vitelline antibodies against mammalian prions or their fragments in physiol. and pathogenic stage, as well as against their relevant peptide sequences; further the invention concerns an ELISA test and test kit. Chicken are immunized with one of three peptides or their combination; monoclonal antibodies are isolated from egg yolk or blood. Lymphocytes can be immortalized by fusion with B-cells; monoclonal antibodies are then produced in hybridoma cell cultures. A test kit contains the avian monoclonal antibodies, buffers for homogenization, cytolysis reagent, proteinase K for prion protein digestion, digestion buffer, enzyme-labeled anti-chicken secondary antibodies, color reagent, stop reagent and sample buffer. The test kit can be used in conjunction with Western blot and immunochromatog.</p> | | | | |
| L10 | ANSWER 3 OF 111 USPATFULL on STN | | | | |
| AN | 2005:167671 USPATFULL | | | | |
| TI | Neisserial antigens | | | | |
| IN | Scarlato, Vincenzo, Siena, ITALY Massignani, Vega, Siena, ITALY Rappuoli, Rino, Siena, ITALY Pizza, Mariagrazia, Siena, ITALY Grandi, Guido, Siena, ITALY | | | | |
| PA | Chiron S.r.l., Siena, ITALY (non-U.S. corporation) | | | | |
| PI | US 6914131 | B1 | 20050705 | | |
| AI | US 1999-303518 | | 19990430 (9) | | |
| RLI | Continuation-in-part of Ser. No. WO 1998-IB1665, filed on 9 Oct 1998, PENDING | | | | |
| DT | Utility | | | | |
| FS | GRANTED | | | | |
| EXNAM | Primary Examiner: Marschel, Ardin H.; Assistant Examiner: Zhou, Shubo (Joe) | | | | |
| LREP | Robins, Roberta L., Harbin, Alisa A., Blackburn, Robert P. | | | | |
| CLMN | Number of Claims: 12 | | | | |
| ECL | Exemplary Claim: 1 | | | | |
| DRWN | 61 Drawing Figure(s); 24 Drawing Page(s) | | | | |
| LN.CNT | 31243 | | | | |
| CAS | INDEXING IS AVAILABLE FOR THIS PATENT. | | | | |
| AB | <p>The invention provides proteins from Neisseria meningitidis (strains A & B) and from Neisseria gonorrhoeae, including amino acid sequences, the corresponding nucleotide sequences, expression data, and serological data. The proteins are useful antigens for vaccines, immunogenic compositions, and/or diagnostics.</p> | | | | |
| L10 | ANSWER 4 OF 111 USPATFULL on STN | | | | |
| AN | 2005:144275 USPATFULL | | | | |
| TI | Whole cell engineering by mutagenizing a substantial portion of a starting genome combining mutations and optionally repeating | | | | |
| IN | Short, Jay M, Rancho Santa Fe, CA, UNITED STATES Fu, Pengcheng, Lowrey Avenue, HI, UNITED STATES Wei, Jing, San Diego, CA, UNITED STATES Levin, Michael, San Diego, CA, UNITED STATES Latterich, Martin, Montellano Terrace, San Diego, CA, UNITED STATES | | | | |
| PI | US 2005124010 | A1 | 20050609 | | |
| AI | US 2003-398271 | A1 | 20011001 (10) | | |
| | WO 2001-US31004 | | 20011001 | | |
| PRAI | US 2003-9677584 | | 20000930 | | |
| | US 2003-279702P | | 20010328 (60) | | |
| DT | Utility | | | | |
| FS | APPLICATION | | | | |
| LREP | FISH & RICHARDSON, PC, 12390 EL CAMINO REAL, SAN DIEGO, CA, 92130-2081, US | | | | |
| CLMN | Number of Claims: 179 | | | | |
| ECL | Exemplary Claim: 1 | | | | |

DRWN 31 Drawing Page(s)

LN.CNT 31291

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention relates to the field of cellular and whole organism engineering. Specifically, this invention relates to a cellular transformation, directed evolution, and screening method for creating novel transgenic organisms having desirable properties. Thus in one aspect, this invention relates to a method of generating a transgenic organism, such as a microbe or a plant, having a plurality of traits that are differentially activatable.

L10 ANSWER 5 OF 111 USPATFULL on STN

AN 2005:137996 USPATFULL

TI **Prion**-specific peptide reagents

IN Michelitsch, Melissa D., Oakland, CA, UNITED STATES

Hu, Celine Y-H., Tiburon, CA, UNITED STATES

PI US 2005118645 A1 20050602

AI US 2004-917646 A1 20040813 (10)

PRAI US 2003-494962P 20030813 (60)

US 2004-570368P 20040512 (60)

US 2004-586509P 20040709 (60)

DT Utility

FS APPLICATION

LREP Chiron Corporation, Intellectual Property - R440, P.O. Box 8097,
Emeryville, CA, 94662-8097, US

CLMN Number of Claims: 55

ECL Exemplary Claim: 1

DRWN 5 Drawing Page(s)

LN.CNT 4670

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Peptide reagents that interact preferentially with the PrP^{sup.sc} form of the **prion** protein are described. Methods of using the reagents or antibodies to the reagents for detection, diagnosis, purification, therapy and prophylaxis for **prions** and **prion**-associated diseases are also described.

L10 ANSWER 6 OF 111 USPATFULL on STN

AN 2005:133947 USPATFULL

TI Induction of apoptic or cytotoxic gene expression by adenoviral mediated gene codelivery

IN McDonnell, Timothy J., Houston, TX, UNITED STATES

Swisher, Stephen G., Fresno, TX, UNITED STATES

Fang, Bingliang, Houston, TX, UNITED STATES

Bruckheimer, Elizabeth M., Houston, TX, UNITED STATES

Sarkiss, Mona G., Houston, TX, UNITED STATES

Ji, Lin, SugarLand, TX, UNITED STATES

Roth, Jack A., Houston, TX, UNITED STATES

PA Board of Regents, The University of Texas System, Austin, TX, UNITED STATES (U.S. corporation)

PI US 6899870 B1 20050531

AI US 1999-266465 19990311 (9)

PRAI US 1998-77541P 19980311 (60)

DT Utility

FS GRANTED

EXNAM Primary Examiner: Guzo, David

LREP Fulbright & Jaworski

CLMN Number of Claims: 49

ECL Exemplary Claim: 1

DRWN 19 Drawing Figure(s); 16 Drawing Page(s)

LN.CNT 3999

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention generally relates to viral vectors and their use as expression vectors for transforming human cells, both in vitro and in vivo. More particularly, the present invention relates to adenoviral vectors containing propapoptotic genes and their use in cancer therapy.

L10 ANSWER 7 OF 111 USPATFULL on STN

AN 2005:117724 USPATFULL

TI Albumin fusion proteins
IN Rosen, Craig A., Laytonsville, MD, UNITED STATES
Haseltine, William A., Washington, DC, UNITED STATES
PA Human Genome Sciences, Inc. (U.S. corporation)
PI US 2005100991 A1 20050512
AI US 2004-932104 A1 20040902 (10)
RLI Division of Ser. No. US 2001-833118, filed on 12 Apr 2001, PENDING
DT Utility
FS APPLICATION
LREP FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER, LLP, 901 NEW YORK
AVENUE, NW, WASHINGTON, DC, 20001-4413, US
CLMN Number of Claims: 33
ECL Exemplary Claim: 1
DRWN 20 Drawing Page(s)
LN.CNT 15444

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.

L10 ANSWER 8 OF 111 USPATFULL on STN
AN 2005:112372 USPATFULL
TI Full-length human cDNAs encoding potentially secreted proteins
IN Dumas Milne Edwards, Jean-Baptiste, Paris, FRANCE
Bougueleret, Lydie, Petit Lancy, SWITZERLAND
Jobert, Severin, Paris, FRANCE
PI US 2005096458 A1 20050505
AI US 2003-643836 A1 20030819 (10)
RLI Division of Ser. No. US 2000-731872, filed on 7 Dec 2000, ABANDONED
PRAI US 1999-169629P 19991208 (60)
US 2000-187470P 20000306 (60)
DT Utility
FS APPLICATION
LREP SALIWANCHIK LLOYD & SALIWANCHIK, A PROFESSIONAL ASSOCIATION, PO BOX
142950, GAINESVILLE, FL, 32614-2950, US
CLMN Number of Claims: 16
ECL Exemplary Claim: 1
DRWN 5 Drawing Page(s)
LN.CNT 28075

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention concerns GENSET polynucleotides and polypeptides. Such GENSET products may be used as reagents in forensic analyses, as chromosome markers, as tissue/cell/organelle-specific markers, in the production of expression vectors. In addition, they may be used in screening and diagnosis assays for abnormal GENSET expression and/or biological activity and for screening compounds that may be used in the treatment of GENSET-related disorders.

L10 ANSWER 9 OF 111 USPATFULL on STN
AN 2005:105007 USPATFULL
TI Rapid method of determining clearance of prion protein
IN Cai, Kang, Chapel Hill, NC, UNITED STATES
Stenland, Christopher J., Cary, NC, UNITED STATES
PI US 2005089943 A1 20050428
AI US 2003-693734 A1 20031023 (10)
DT Utility
FS APPLICATION
LREP WOMBLE CARLYLE SANDRIDGE & RICE, PLLC, P.O. BOX 7037, ATLANTA, GA,
30357-0037, US
CLMN Number of Claims: 22
ECL Exemplary Claim: 1

DRWN 7 Drawing Page(s)

LN.CNT 800

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides a rapid, sensitive **immunoassay** capable of detecting and quantitating pathogenic protein to a level of 3 to 5 logs. The preferred **immunoassay** utilized is a chemiluminescent endpoint for a **Western blot immunoassay**.
The invention has been successfully applied to track the clearance of pathogenic protein during production of proteins derived from plasma. It is particularly applicable and has been confirmed by bioassay to relate **TSE** infectivity to quantitative results on **prion** protein.

L10 ANSWER 10 OF 111 USPATFULL on STN

AN 2005:87328 USPATFULL

TI Methods for using chemokine teck

IN Wang, Wei, Palo Alto, CA, UNITED STATES

Gish, Kurt C., Sunnyvale, CA, UNITED STATES

Schall, Thomas J., Menlo Park, CA, UNITED STATES

Vicari, Alain, Mountain View, CA, UNITED STATES

Zlotnik, Albert, Palo Alto, CA, UNITED STATES

PI US 2005074790 A1 20050407

AI US 2004-759860 A1 20040116 (10)

RLI Division of Ser. No. US 2002-39659, filed on 3 Jan 2002, GRANTED, Pat.
No. US 6723520 Division of Ser. No. US 1997-887977, filed on 3 Jul 1997,
ABANDONED

PRAI US 1996-21664P 19960705 (60)

US 1996-28329P 19961011 (60)

US 1997-48593P 19970604 (60)

DT Utility

FS APPLICATION

LREP SCHERING-PLOUGH CORPORATION, PATENT DEPARTMENT (K-6-1, 1990), 2000
GALLOPING HILL ROAD, KENILWORTH, NJ, 07033-0530

CLMN Number of Claims: 31

ECL Exemplary Claim: 1

DRWN 1 Drawing Page(s)

LN.CNT 4111

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Novel chemokines from mammals, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding said chemokines. Chemokine receptors are also provided. Methods of using said reagents and diagnostic kits are also provided.

L10 ANSWER 11 OF 111 USPATFULL on STN

AN 2005:87301 USPATFULL

TI Denaturat stable and/or protease resistant, chaperone-like oligomeric proteins, polynucleotides encoding same and their uses

IN Wang, Wangxia, Rehovot, ISRAEL

Pelah, Dan, Rehovot, ISRAEL

Alegrand, Tal, Gedera, ISRAEL

Shoseyov, Oded, Yossef, ISRAEL

Altman, Arie, Rehovot, ISRAEL

PI US 2005074763 A1 20050407

AI US 2003-468841 A1 20030903 (10)

WO 2002-IL174 20020305

PRAI US 2001-272771P 20010305 (60)

DT Utility

FS APPLICATION

LREP Anthony Castorina, G E Ehrlich, Suite 207, 2001Jefferson Davis Highway,
Arlington, VA, 22202

CLMN Number of Claims: 113

ECL Exemplary Claim: 1

DRWN 18 Drawing Page(s)

LN.CNT 3299

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Novel denaturant-stable, protease resistant, homo-oligomeric proteins, also referred to herein as stable proteins (SPs), having chaperone-like activity; methods of production and purification of SPs; nucleic acids

encoding SPs; methods of isolating nucleic acids encoding SPs; antibodies recognizing SPs; the use of SPs for stabilizing, refolding, repairing, preventing aggregation and de-aggregating macromolecules such as proteins; fusion proteins including SPs; nucleic acid constructs encoding the fusion proteins; and their uses in a variety of methods and applications.

L10 ANSWER 12 OF 111 USPATFULL on STN

AN 2005:82246 USPATFULL

TI Antagonistic anti-htnfsf13b human antibodies

IN Gelfanova, Valentina Pavlovna, Indianapolis, IN, UNITED STATES

Hale, John Edward, Fishers, IN, UNITED STATES

Kikly, Kristine Kay, Fortville, IN, UNITED STATES

Rathnachalam, Rahakrishnan, Carmel, IN, UNITED STATES

Witcher, Derrick Ryan, Fishers, IN, UNITED STATES

PI US 2005070694 A1 20050331

AI US 2004-484790 A1 20040122 (10)

WO 2002-US21842 20020815

PRAI US 2001-60312808 20010816

DT Utility

FS APPLICATION

LREP ELI LILLY AND COMPANY, PATENT DIVISION, P.O. BOX 6288, INDIANAPOLIS, IN, 46206-6288

CLMN Number of Claims: 35

ECL Exemplary Claim: 1

DRWN 2 Drawing Page(s)

LN.CNT 1781

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Human **monoclonal** antibodies that specifically bind to TNFSF13b polypeptides are disclosed. These antibodies have high affinity for hTNFSF13b (e.g., $K_{sub.D}=10^{sup.-8}$ M or less), a slow off rate for TNFSF13b dissociation (e.g., $K_{sub.off}=10^{sup.-3}$ sec.sub.-1 or less) and neutralize TNFSF13b activity in vitro and in vivo. The antibodies of the invention are useful in one embodiment for inhibiting TNFSF13b activity in a human subject suffering from a disorder in which hTNFSF13b activity is detrimental. Nucleic acids encoding the antibodies of the present invention, as well as, vectors and host cells for expressing them are also encompassed by the invention.

L10 ANSWER 13 OF 111 USPATFULL on STN

AN 2005:81469 USPATFULL

TI Proteome epitope tags and methods of use thereof in protein modification analysis

IN Lee, Frank D., Chestnut Hill, MA, UNITED STATES

Meng, Kun, Newton, MA, UNITED STATES

Afeyan, Noubar B., Lexington, MA, UNITED STATES

PA engeneOS, Inc., Waltham, MA (U.S. corporation)

PI US 2005069911 A1 20050331

AI US 2004-773032 A1 20040205 (10)

RLI Continuation-in-part of Ser. No. US 2003-712425, filed on 13 Nov 2003, PENDING Continuation-in-part of Ser. No. US 2003-436549, filed on 12 May 2003, PENDING

PRAI US 2002-379626P 20020510 (60)

US 2002-393197P 20020701 (60)

US 2002-393233P 20020701 (60)

US 2002-393235P 20020701 (60)

US 2002-393211P 20020701 (60)

US 2002-393223P 20020701 (60)

US 2002-393280P 20020701 (60)

US 2002-393137P 20020701 (60)

US 2002-430948P 20021204 (60)

US 2002-433319P 20021213 (60)

DT Utility

FS APPLICATION

LREP ROPES & GRAY LLP, ONE INTERNATIONAL PLACE, BOSTON, MA, 02110-2624

CLMN Number of Claims: 41

ECL Exemplary Claim: 1

DRWN 24 Drawing Page(s)

LN.CNT 12020

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed are methods for reliably detecting the presence of proteins, including proteins with various post-translational modifications (phosphorylation, glycosylation, methylation, acetylation, etc.) in a sample by the use of one or more capture agents that recognize and interact with recognition sequences uniquely characteristic of a protein or a set of proteins (Proteome Epitope Tags, or PETs) in the sample. Arrays comprising these capture agents or PETs are also provided.

L10 ANSWER 14 OF 111 USPATFULL on STN

AN 2005:63800 USPATFULL

TI Intraflagellar transport

IN Witman, George B., Grafton, MA, UNITED STATES
Pazour, Gregory J., Framingham, MA, UNITED STATES
Rosenbaum, Joel L., Branford, CT, UNITED STATES
Cole, Douglas G., Pullman, WA, UNITED STATES

PA University of Massachusetts, a Massachusetts corporation (U.S. corporation)

PI US 2005054842 A1 20050310

AI US 2004-839016 A1 20040505 (10)

RLI Continuation of Ser. No. US 2001-866582, filed on 24 May 2001, ABANDONED

PRAI US 2000-206923P 20000524 (60)

DT Utility

FS APPLICATION

LREP FISH & RICHARDSON PC, 225 FRANKLIN ST, BOSTON, MA, 02110

CLMN Number of Claims: 36

ECL Exemplary Claim: 1

DRWN 28 Drawing Page(s)

LN.CNT 7679

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to various intraflagellar transport (IFT) polypeptides and the nucleic acids that encode them. The new IFT particle polypeptides and nucleic acids can be used in a variety of diagnostic, screening, and therapeutic methods.

L10 ANSWER 15 OF 111 USPATFULL on STN

AN 2005:63014 USPATFULL

TI Albumin fusion proteins

IN Rosen, Craig A., Laytonsville, MD, UNITED STATES
Haseltine, William A., Washington, DC, UNITED STATES

PA Human Genome Sciences, Inc. (U.S. corporation)

PI US 2005054051 A1 20050310

AI US 2004-922142 A1 20040820 (10)

RLI Division of Ser. No. US 2001-832929, filed on 12 Apr 2001, PENDING

DT Utility

FS APPLICATION

LREP FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER, LLP, 1300 I STREET, NW, WASHINGTON, DC, 20005

CLMN Number of Claims: 33

ECL Exemplary Claim: 1

DRWN 20 Drawing Page(s)

LN.CNT 17526

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.

L10 ANSWER 16 OF 111 USPATFULL on STN

AN 2005:57477 USPATFULL

TI Models of prion disease

IN Prusiner, Stanley B., San Francisco, CA, UNITED STATES
Korth, Carsten, San Francisco, CA, UNITED STATES
PA The Regents of the University of California (U.S. corporation)
PI US 2005049395 A1 20050303
AI US 2004-875821 A1 20040623 (10)
RLI Continuation of Ser. No. US 2001-895963, filed on 28 Jun 2001, GRANTED,
Pat. No. US 6767712 Continuation of Ser. No. US 1999-318888, filed on 26
May 1999, ABANDONED
DT Utility
FS APPLICATION
LREP BOZICEVIC, FIELD & FRANCIS LLP, 1900 UNIVERSITY AVE, SUITE 200, EAST
PALO ALTO, CA, 94303
CLMN Number of Claims: 16
ECL Exemplary Claim: CLM-01-22
DRWN No Drawings
LN.CNT 1397

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides a novel PrP protein, and nucleic acids
encoding this protein, where the PrP protein is characterized in vivo by
1) incomplete glycosylation relative to glycosylation of wild-type
PrP^{sup.C} and 2) proper cellular localization, i.e. an ability to be
transported to the cell surface. This novel, under-glycosylated PrP,
unlike its normal cellular counterpart, can easily be converted into a
protease-resistant isoform by incubation with infectious **prions**
. The invention further provides systems for the study of **prion**
disorders and methods of using these systems, e.g. the study of the
mechanical processes in progression of **prion**-mediated disease
or the identification of new therapeutic agents for treatment of
prion-mediated disorders. In such systems, protease-resistant
under-glycosylated PrP is generated de novo and can be detected by
standard immunoblot techniques.

L10 ANSWER 17 OF 111 USPATFULL on STN

AN 2005:56667 USPATFULL
TI Method for the detection of **prion** diseases
IN Cornelis Schreuder, Bram Edward, Lelystad, NETHERLANDS
Van Keulen, Lucius Johannes Mattheus, Bunnik, NETHERLANDS
Wilhelmina Vromans, Maria Elisabeth, Lelystad, NETHERLANDS
Maria Langeveld, Johannes Pieter, Harderwijk, NETHERLANDS
Smits, Marinus Adrianus, Harderwijk, NETHERLANDS
PI US 2005048582 A1 20050303
AI US 2004-949880 A1 20040924 (10)
RLI Continuation of Ser. No. US 1999-155794, filed on 20 May 1999, PENDING
PRAI EP 1996-200917 19960403
DT Utility
FS APPLICATION
LREP TRASK BRITT, P.O. BOX 2550, SALT LAKE CITY, UT, 84110
CLMN Number of Claims: 3
ECL Exemplary Claim: 1
DRWN 2 Drawing Page(s)
LN.CNT 919

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides methods for the detection of **prion**
diseases, such as scrapie of sheep, bovine spongiform encephalopathy of
cattle, Creutzfeld-Jacob disease of man, whereby aberrant proteins or
prion proteins are detected in tissues which can be sampled from
live animals.

L10 ANSWER 18 OF 111 USPATFULL on STN

AN 2005:49894 USPATFULL
TI Diagnosis and management of infection caused by chlamydia
IN Mitchell, William M., Nashville, TN, UNITED STATES
Stratton, Charles W., Nashville, TN, UNITED STATES
PI US 2005042690 A1 20050224
AI US 2004-873768 A1 20040622 (10)
RLI Continuation of Ser. No. US 2000-709201, filed on 8 Nov 2000, GRANTED,
Pat. No. US 6838552 Continuation of Ser. No. US 1998-25521, filed on 18
Feb 1998, ABANDONED Continuation-in-part of Ser. No. US 1997-911593,

filed on 14 Aug 1997, ABANDONED
PRAI US 1996-23921P 19960814 (60)
DT Utility
FS APPLICATION
LREP CLARK & ELBING LLP, 101 FEDERAL STREET, BOSTON, MA, 02110
CLMN Number of Claims: 5
ECL Exemplary Claim: CLM-01-67
DRWN 4 Drawing Page(s)
LN.CNT 3160

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides a unique approach for the diagnosis and management of infections by Chlamydia species, particularly C. pneumoniae. The invention is based, in part, upon the discovery that a combination of agents directed toward the various stages of the chlamydial life cycle is effective in substantially reducing infection. Products comprising combination of antichlamydial agents, novel compositions and pharmaceutical packs are also described.

L10 ANSWER 19 OF 111 USPATFULL on STN

AN 2005:43296 USPATFULL
TI Albumin fusion proteins
IN Rosen, Craig A., Laytonsville, MD, UNITED STATES
Haseltine, William A., Washington, DC, UNITED STATES
PI US 2005037022 A1 20050217
AI US 2004-816042 A1 20040402 (10)
RLI Continuation of Ser. No. WO 2002-US31794, filed on 4 Oct 2002, PENDING
PRAI US 2001-327281P 20011005 (60)
DT Utility
FS APPLICATION
LREP HUMAN GENOME SCIENCES INC, INTELLECTUAL PROPERTY DEPT., 14200 SHADY GROVE ROAD, ROCKVILLE, MD, 20850
CLMN Number of Claims: 29
ECL Exemplary Claim: 1
DRWN 18 Drawing Page(s)
LN.CNT 17090

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.

L10 ANSWER 20 OF 111 USPATFULL on STN

AN 2005:32787 USPATFULL
TI Alpha-hemoglobin stabilizing protein transgenic mouse and methods of use thereof
IN Weiss, Mitchell, Wynnewood, PA, UNITED STATES
Blobel, Gerd, Merion, PA, UNITED STATES
Kong, Yi, Philadelphia, PA, UNITED STATES
PI US 2005028229 A1 20050203
AI US 2004-824448 A1 20040414 (10)
PRAI US 2003-462771P 20030414 (60)
US 2003-477991P 20030612 (60)
DT Utility
FS APPLICATION
LREP DANN, DORFMAN, HERRELL & SKILLMAN, 1601 MARKET STREET, SUITE 2400, PHILADELPHIA, PA, 19103-2307
CLMN Number of Claims: 38
ECL Exemplary Claim: 1
DRWN 12 Drawing Page(s)
LN.CNT 2367

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A transgenic non-human animal with alterations in the Alpha Hemoglobin

Stabilizing Protein (AHSP) gene is prepared by introduction of a gene encoding an altered Alpha Hemoglobin Stabilizing Protein (AHSP) protein into a host non-human animal. Methods for using transgenic mice so generated to screen for agents that effect Alpha Hemoglobin Stabilizing Protein (AHSP)'s hemoglobin binding activity are also provided.

L10 ANSWER 21 OF 111 USPATFULL on STN

AN 2005:16795 USPATFULL

TI **Prion** protein binding materials and methods of use

IN Carbonell, Ruben G., Raleigh, NC, UNITED STATES

Shen, Honglue, Raleigh, NC, UNITED STATES

Gurgel, Patrick V., Cary, NC, UNITED STATES

Wiltshire-Lyerly, Viterose, Raleigh, NC, UNITED STATES

Hammond, David J., Laytonsville, MD, UNITED STATES

Burton, Steven J., Little Eversden, UNITED KINGDOM

PI US 2005014196 A1 20050120

AI US 2004-817117 A1 20040402 (10)

PRAI US 2003-460474P 20030404 (60)

DT Utility

FS APPLICATION

LREP JOHN S. PRATT, ESQ, KILPATRICK STOCKTON, LLP, 1100 PEACHTREE STREET,

ATLANTA, GA, 30309

CLMN Number of Claims: 49

ECL Exemplary Claim: 1

DRWN 4 Drawing Page(s)

LN.CNT 1929

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB **Prion** protein binding materials and methods for using the binding materials to detect or remove a **prion** protein from a sample, such as a biological fluid or an environmental sample. The binding materials are capable of binding to one or more forms of **prion** protein including cellular **prion** protein (PrPc), infectious **prion** protein (PrPsc), recombinant **prion** protein (PrPr), and proteinase resistant **prion** protein (PrPres). **Prions** from various species, including humans and hamsters, are bound by the binding materials.

L10 ANSWER 22 OF 111 USPATFULL on STN

AN 2005:10897 USPATFULL

TI Genes and polymorphisms on chromosome 10 associated with Alzheimer's disease and other neurodegenerative diseases

IN Becker, Kenneth David, San Diego, CA, UNITED STATES

Velicelebi, Gonul, San Diego, CA, UNITED STATES

Elliott, Kathryn J., San Diego, CA, UNITED STATES

Wang, Xin, San Diego, CA, UNITED STATES

Tanzi, Rudolph E., Hull, MA, UNITED STATES

Bertram, Lars, Boston, MA, UNITED STATES

Saunders, Aleister J., Philadelphia, PA, UNITED STATES

Mullin, Kristina M., Weymouth, MA, UNITED STATES

Sampson, Andrew Joseph, Oakwood, OH, UNITED STATES

PI US 2005009031 A1 20050113

AI US 2003-600009 A1 20030618 (10)

RLI Continuation-in-part of Ser. No. US 2002-282174, filed on 25 Oct 2002, PENDING Continuation-in-part of Ser. No. WO 2002-US34679, filed on 25 Oct 2002, PENDING

PRAI US 2001-339525P 20011025 (60)

US 2001-338010P 20011108 (60)

US 2001-336929P 20011108 (60)

US 2001-338363P 20011109 (60)

US 2001-337052P 20011204 (60)

US 2002-368919P 20020328 (60)

DT Utility

FS APPLICATION

LREP FISH & RICHARDSON, PC, 12390 EL CAMINO REAL, SAN DIEGO, CA, 92130-2081

CLMN Number of Claims: 242

ECL Exemplary Claim: 1

DRWN 113 Drawing Page(s)

LN.CNT 15528

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Isolated nucleic acid molecules containing polymorphisms in genes involved in neurodegenerative diseases are provided. Probes, primers, kits and methods for detection of polymorphisms in genes involved in neurodegenerative disease are provided. Methods based on detecting such polymorphisms for prognosticating, determining the occurrence, profiling drug response and drug discovery are also provided. Methods of screening for agents that modulate expression and/or activity of genes involved in neurodegenerative diseases, and of screening for agents that modulate a biological event characteristic of a neurodegenerative disease are further provided.

L10 ANSWER 23 OF 111 USPATFULL on STN

AN 2005:534 USPATFULL

TI Diagnosis and management of infection caused by Chlamydia

IN Mitchell, William M., Nashville, TN, United States

Stratton, Charles W., Nashville, TN, United States

PA Vanderbilt University, Nashville, TN, United States (U.S. corporation)

PI US 6838552 B1 20050104

AI US 2000-709201 20001108 (9)

RLI Continuation of Ser. No. US 1998-25521, filed on 18 Feb 1998, now abandoned Continuation-in-part of Ser. No. US 1997-911593, filed on 14 Aug 1997, now abandoned

DT Utility

FS GRANTED

EXNAM Primary Examiner: Duffy, Patricia A.; Assistant Examiner: Hines, Ja-Na

LREP Clark & Elbing LLP

CLMN Number of Claims: 5

ECL Exemplary Claim: 1

DRWN 6 Drawing Figure(s); 4 Drawing Page(s)

LN.CNT 2918

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides a unique approach for the diagnosis and management of infections by Chlamydia species, particularly C. pneumoniae. The invention is based, in part, upon the discovery that a combination of agents directed toward the various stages of the chlamydial life cycle is effective in substantially reducing infection. Products comprising combination of antichlamydial agents, novel compositions and pharmaceutical packs are also described.

L10 ANSWER 24 OF 111 USPATFULL on STN

AN 2004:307835 USPATFULL

TI Method

IN Fisher, Elizabeth Mary Claire, London, UNITED KINGDOM

Lloyd, Sarah Elizabeth, London, UNITED KINGDOM

Collinge, John, Queen Square, UNITED KINGDOM

PI US 2004242511 A1 20041202

AI US 2004-470014 A1 20040122 (10)

WO 2002-GB256 20020122

PRAI GB 2001-1763 20010123

DT Utility

FS APPLICATION

LREP MARSHALL, GERSTEIN & BORUN LLP, 6300 SEARS TOWER, 233 S. WACKER DRIVE, CHICAGO, IL, 60606

CLMN Number of Claims: 31

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 3578

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to a method for the detection of **prions** in a sample comprising the steps of contacting one or more test animals with the sample; incubating the test animals; monitoring the test animals for adverse effects or death; and optionally performing a biopsy on the test animals that display adverse effects or death for evidence of **prions**; wherein the test animals have **prion** incubation times of 196 days or less.

L10 ANSWER 25 OF 111 USPATFULL on STN

AN 2004:292196 USPATFULL
TI **Prion** protein ligands and methods of use
IN Hammond, David J., Laytonsville, MD, UNITED STATES
Lathrop, Julia T., Falls Church, VA, UNITED STATES
Cervenakova, Larisa, Rockville, MD, UNITED STATES
Carbonell, Ruben G., Raleigh, NC, UNITED STATES
PI US 2004229280 A1 20041118
AI US 2003-727335 A1 20031203 (10)
PRAI US 2002-430423P 20021203 (60)
DT Utility
FS APPLICATION
LREP JOHN S. PRATT, ESQ, KILPATRICK STOCKTON, LLP, 1100 PEACHTREE STREET,
ATLANTA, GA, 30309
CLMN Number of Claims: 37
ECL Exemplary Claim: 1
DRWN 6 Drawing Page(s)
LN.CNT 2859
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Ligands that bind to **prion** proteins and methods for using the
ligands for detecting or removing a **prion** protein from a
sample, such as a biological fluid or an environmental sample. The
ligands are capable of binding to one or more forms of **prion**
protein including cellular **prion** protein (PrPc), infectious
prion protein (PrPsc), and recombinant **prion** protein
(PrPr). **Prions** from various species, including humans and
hamsters, are bound by the ligands. Also provided is a method of
treating or retarding the development of a **prion**-associated
pathology in a subject

L10 ANSWER 26 OF 111 USPATFULL on STN

AN 2004:260604 USPATFULL
TI Brain-associated inhibitor of tissue-type plasminogen activator
IN Hastings, Gregg A., Westlake Village, CA, UNITED STATES
Coleman, Timothy A., Derwood, MD, UNITED STATES
Dillon, Patrick J., Carlsbad, CA, UNITED STATES
Lawrence, Daniel A., Derwood, MD, UNITED STATES
Sandkvist, Maria, Derwood, MD, UNITED STATES
Yepes, Manuel, Rockville, MD, UNITED STATES
Wong, Michael K. K., East Amhurst, NY, UNITED STATES
PA Human Genome Sciences, Inc., Rockville, MD (U.S. corporation)
The American Red Cross, Rockville, MD (U.S. corporation)
PI US 2004203101 A1 20041014
AI US 2004-752041 A1 20040107 (10)
RLI Continuation-in-part of Ser. No. US 2001-987021, filed on 13 Nov 2001,
ABANDONED Continuation-in-part of Ser. No. US 2001-957485, filed on 21
Sep 2001, ABANDONED Continuation of Ser. No. US 2000-521664, filed on 8
Mar 2000, ABANDONED Continuation-in-part of Ser. No. US 2000-722292,
filed on 28 Nov 2000, GRANTED, Pat. No. US 6541452 Division of Ser. No.
US 1999-348817, filed on 8 Jul 1999, GRANTED, Pat. No. US 6191260
Division of Ser. No. US 1997-948997, filed on 10 Oct 1997, GRANTED, Pat.
No. US 6008020 Continuation-in-part of Ser. No. US 2003-355208, filed on
31 Jan 2003, PENDING Division of Ser. No. US 2001-957485, filed on 21
Sep 2001, ABANDONED Continuation of Ser. No. US 2000-521664, filed on 8
Mar 2000, ABANDONED
PRAI US 2000-247971P 20001114 (60)
US 1999-123704P 19990310 (60)
US 1996-28117P 19961011 (60)
US 1999-123704P 19990310 (60)
DT Utility
FS APPLICATION
LREP HUMAN GENOME SCIENCES INC, INTELLECTUAL PROPERTY DEPT., 14200 SHADY
GROVE ROAD, ROCKVILLE, MD, 20850
CLMN Number of Claims: 36
ECL Exemplary Claim: 1
DRWN 27 Drawing Page(s)
LN.CNT 10699
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to a novel BAIT protein which is a member

of serpin superfamily which is expressed primarily in brain tissue. In particular, isolated nucleic acid molecules are provided encoding the human and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of BAIT activity. Also provided are diagnostic methods for detecting nervous system-related disorders and therapeutic methods for treating nervous system-related disorders. Additionally, the present invention is related to methods of treating patients with BAIT polynucleotides or polypeptides, wherein said patients have had seizures or epilepsy.

L10 ANSWER 27 OF 111 USPATFULL on STN

AN 2004:254267 USPATFULL

TI Methods and apparatus for biomolecule detection, identification, quantification and/or sequencing

IN Hassibi, Arjang, Palo Alto, CA, UNITED STATES

Hassibi, Babek, San Marino, CA, UNITED STATES

Ghazvini, Siavash, Menlo Park, CA, UNITED STATES

PI US 2004197793 A1 20041007

AI US 2003-627557 A1 20030724 (10)

PRAI US 2002-407412P 20020830 (60)

US 2002-422439P 20021029 (60)

US 2002-435924P 20021220 (60)

US 2002-435934P 20021220 (60)

US 2003-440670P 20030115 (60)

US 2003-451107P 20030227 (60)

US 2003-470347P 20030513 (60)

DT Utility

FS APPLICATION

LREP Blakely, Sokoloff, Taylor & Zafman, Seventh Floor, 12400 Wilshire Boulevard, Los Angeles, CA, 90025-1030

CLMN Number of Claims: 63

ECL Exemplary Claim: 1

DRWN 30 Drawing Page(s)

LN.CNT 3586

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention concerns methods, compositions and apparatus for detecting. Identifying, quantifying and/or sequencing target biomolecules, such as nucleic acids or proteins. Where the target biomolecule is not a nucleic acid, the target or a ligand that binds to the target may be tagged with an oligonucleotide or nucleic acid. The presence of target molecules in samples may be detected by a variety of enzymatic processes that generate a detectable product, such as pyrophosphate (PPi) or ATP. In preferred embodiments of the invention, the product is detected by a bioluminescence regenerative cycle (BRC), utilizing luciferase mediated bioluminescence. In other preferred embodiments, thermostable **enzymes** may be used in either isothermal or cyclic thermal reactions, such as terminal transferase activity or nucleic acid polymerization, to generate PPi. Apparatus and compositions for biomolecule analysis are also disclosed. Methods for analysis of generated data are also disclosed herein.

L10 ANSWER 28 OF 111 USPATFULL on STN

AN 2004:233309 USPATFULL

TI Proteome epitope tags and methods of use thereof in protein modification analysis

IN Lee, Frank D., Chestnut Hill, MA, UNITED STATES

Meng, Xun, Newton, MA, UNITED STATES

Livingston, David, Barrington, RI, UNITED STATES

PA engineOS, Inc., Waltham, MA (U.S. corporation)

PI US 2004180380 A1 20040916

AI US 2003-712425 A1 20031113 (10)

RLI Continuation-in-part of Ser. No. US 2003-436549, filed on 12 May 2003, PENDING

PRAI US 2002-379626P 20020510 (60)

US 2002-393137P 20020701 (60)

US 2002-393233P 20020701 (60)

US 2002-393235P 20020701 (60)

US 2002-393211P 20020701 (60)
US 2002-393223P 20020701 (60)
US 2002-393280P 20020701 (60)
US 2002-393197P 20020701 (60)
US 2002-430948P 20021204 (60)
US 2002-433319P 20021213 (60)
DT Utility
FS APPLICATION
LREP ROPES & GRAY LLP, ONE INTERNATIONAL PLACE, BOSTON, MA, 02110-2624
CLMN Number of Claims: 125
ECL Exemplary Claim: 1
DRWN 24 Drawing Page(s)
LN.CNT 11815
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Disclosed are methods for reliably detecting the presence of proteins, especially proteins with various post-translational modifications (phosphorylation, glycosylation, methylation, acetylation, etc.) in a sample by the use of one or more capture agents that recognize and interact with recognition sequences uniquely characteristic of a set of proteins (Proteome Epitope Tags, or PETs) in the sample. Arrays comprising these capture agents or PETs are also provided.

L10 ANSWER 29 OF 111 USPATFULL on STN
AN 2004:233296 USPATFULL
TI Antibodies For discrimination of **prions**
IN Zheng, Jian, Raritan, NJ, UNITED STATES
Alexander, Steve Stanley, Flemington, NJ, UNITED STATES
PI US 2004180367 A1 20040916
AI US 2003-740025 A1 20031218 (10)
PRAI US 2002-434627P 20021219 (60)
US 2003-446217P 20030210 (60)
DT Utility
FS APPLICATION
LREP PHILIP S. JOHNSON, JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK, NJ, 08933-7003
CLMN Number of Claims: 9
ECL Exemplary Claim: 1
DRWN 10 Drawing Page(s)
LN.CNT 1247
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB In the present invention, we described the use of anti-DNA antibody for the detection of **prions** and diagnosis of Transmissible Spongiform Encephalopathies (**TSE**) diseases in animals and humans.

L10 ANSWER 30 OF 111 USPATFULL on STN
AN 2004:221354 USPATFULL
TI ALBUMIN FUSION PROTEINS
IN Rosen, Craig A., Laytonsville, MD, UNITED STATES
Haseltine, William A., Washington, DC, UNITED STATES
PI US 2004171123 A1 20040902
AI US 2001-832929 A1 20010412 (9)
DT Utility
FS APPLICATION
LREP FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER, LLP, 1300 I STREET, NW, WASHINGTON, DC, 20005
CLMN Number of Claims: 29
ECL Exemplary Claim: 1
DRWN 18 Drawing Page(s)
LN.CNT 17424
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising

albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.

L10 ANSWER 31 OF 111 USPATFULL on STN

AN 2004:205798 USPATFULL

TI Method for diagnosing TSE-induced changes in tissues using infrared spectroscopy

IN Naumann, Dieter, Berlin, GERMANY, FEDERAL REPUBLIC OF
Kneipp, Janina, Berlin, GERMANY, FEDERAL REPUBLIC OF
Baldauf, Elizabeth, Dallgow, GERMANY, FEDERAL REPUBLIC OF
Lasch, Peter, Berlin, GERMANY, FEDERAL REPUBLIC OF
Beekes, Michael, Dallgow, GERMANY, FEDERAL REPUBLIC OF
PA Robert-Koch-Institut, Berlin, GERMANY, FEDERAL REPUBLIC OF (non-U.S. corporation)

PI US 6777241 B1 20040817

WO 2000072007 20001130

AI US 2002-9226 20020306 (10)

WO 2000-DE1404 20000305

PRAI DE 1999-19923811 19990520

DT Utility

FS GRANTED

EXNAM Primary Examiner: Warden, Jill; Assistant Examiner: Gakh, Yelena G.

LREP Webb Ziesenheim Logsdon Orkin & Hanson, P.C.

CLMN Number of Claims: 19

ECL Exemplary Claim: 1

DRWN 5 Drawing Figure(s); 5 Drawing Page(s)

LN.CNT 561

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method for diagnosing TSE-induced pathologic changes in tissues including the steps of: (a) directing infrared radiation to a tissue sample with pathologic changes caused by TSE, recording its spectral characteristics after irradiation and (b) comparing and classifying the infrared spectra thus obtained with a reference database containing infrared spectra of TSE-infected tissues and non-infected tissues.

L10 ANSWER 32 OF 111 USPATFULL on STN

AN 2004:178411 USPATFULL

TI Chemokine TECK polypeptides

IN Wang, Wei, Palo Alto, CA, UNITED STATES
Gish, Kurt C., Sunnyvale, CA, UNITED STATES
Schall, Thomas J., Menlo Park, CA, UNITED STATES
Vicari, Alain, Mountain View, CA, UNITED STATES
Zlotnik, Albert, Palo Alto, CA, UNITED STATES

PI US 2004137578 A1 20040715

AI US 2004-754071 A1 20040109 (10)

RLI Division of Ser. No. US 2002-39659, filed on 3 Jan 2002, GRANTED, Pat. No. US 6723520 Division of Ser. No. US 1997-887977, filed on 3 Jul 1997, ABANDONED

PRAI US 1996-21664P 19960705 (60)

US 1996-28329P 19961011 (60)

US 1997-48593P 19970604 (60)

DT Utility

FS APPLICATION

LREP SCHERING-PLOUGH CORPORATION, PATENT DEPARTMENT (K-6-1, 1990), 2000 GALLOPING HILL ROAD, KENILWORTH, NJ, 07033-0530

CLMN Number of Claims: 12

ECL Exemplary Claim: 1

DRWN 1 Drawing Page(s)

LN.CNT 4080

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Novel chemokines from mammals, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding said chemokines. Chemokine receptors are also provided. Methods of using said reagents and diagnostic kits are also provided.

L10 ANSWER 33 OF 111 USPATFULL on STN

AN 2004:178363 USPATFULL
TI Method of preparing cow brain homogenate
IN Prusiner, Stanley B., San Francisco, CA, UNITED STATES
Safar, Jiri G., Walnut Creek, CA, UNITED STATES
PA The Regents of the University of California (U.S. corporation)
PI US 2004137529 A1 20040715
US 6875577 B2 20050405
AI US 2003-742241 A1 20031218 (10)
RLI Continuation of Ser. No. US 2002-47431, filed on 14 Jan 2002, GRANTED,
Pat. No. US 6677125 Continuation of Ser. No. US 2001-754443, filed on 3
Jan 2001, GRANTED, Pat. No. US 6406864 Continuation of Ser. No. US
1998-169574, filed on 9 Oct 1998, GRANTED, Pat. No. US 6214565
Continuation-in-part of Ser. No. US 1998-26967, filed on 20 Feb 1998,
GRANTED, Pat. No. US 5977324
DT Utility
FS APPLICATION
LREP BOZICEVIC, FIELD & FRANCIS LLP, 200 MIDDLEFIELD RD, SUITE 200, MENLO
PARK, CA, 94025
CLMN Number of Claims: 27
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1645

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB An assay method is disclosed which isolates and detects the presence of
a disease related conformation of a protein (e.g., PrP.sup.Sc) present
in a sample also containing the non-disease related conformation of the
protein (e.g., PrP.sup.C). The sample is treated (e.g., contacted with
protease) in a manner which hydrolyzes the disease related conformation
and not the non-disease related conformation. The treated sample is
contacted with a binding partner (e.g., a **labeled** antibody
which binds PrP.sup.Sc) and the occurrence of binding provides and
indication that PrP.sup.Sc is present. Alternatively the PrP.sup.Sc of
the treated sample is denatured (e.g., contacted with guanadine) or
unfolded. The unfolded PrP.sup.Sc is contacted with a binding partner
and the occurrence of binding indicates the presence of PrP.sup.Sc in
the sample. In another embodiment, PrP.sup.Sc and PrP.sup.C are reacted
with a **labeled** antibody that binds both conformations and a
conformation that binds only the disease related conformation, and the
presence of the disease related conformation is determined by comparing
the two.

L10 ANSWER 34 OF 111 USPATFULL on STN

AN 2004:171948 USPATFULL
TI Method
IN Enari, Masato, Chuo-ku, JAPAN
Flechsigg, Eckhard, Versbacher, GERMANY, FEDERAL REPUBLIC OF
Collinge, John, Queen, UNITED KINGDOM
Weismann, Charles, London, UNITED KINGDOM
PI US 2004132109 A1 20040708
AI US 2004-470022 A1 20040109 (10)
WO 2002-GB257 20020122
PRAI GB 2001-1762 20010123
DT Utility
FS APPLICATION
LREP MARSHALL, GERSTEIN & BORUN LLP, 6300 SEARS TOWER, 233 S. WACKER DRIVE,
CHICAGO, IL, 60606
CLMN Number of Claims: 31
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 3141

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to methods for determining the presence of
prions in a tissue/organ or fluid therefrom; said method
comprising the steps of: contacting the tissue/organ with one or more
devices, wherein said devices are capable of binding **prions**;
removing said devices from contact with said tissue/organ; determining
if said devices are binding **prions** wherein the device is
contacted with the tissue/organ for 120 minutes.

L10 ANSWER 35 OF 111 USPATFULL on STN
AN 2004:165405 USPATFULL
TI Method for detecting **tse**-induced modifications in the human
and animal body
IN Naumann, Dieter, Berlin, GERMANY, FEDERAL REPUBLIC OF
Beekes, Michael, Falkensee, GERMANY, FEDERAL REPUBLIC OF
Schmitt, Jurgen, Gusterath, GERMANY, FEDERAL REPUBLIC OF
Udelhoven, Thomas, Trier, GERMANY, FEDERAL REPUBLIC OF
Brauer, Angelika, Berlin, GERMANY, FEDERAL REPUBLIC OF
PI US 2004126893 A1 20040701
AI US 2004-468012 A1 20040205 (10)
WO 2002-DE210 20020117
PRAI DE 2001-109901 20010222
DT Utility
FS APPLICATION
LREP FOLEY AND LARDNER, SUITE 500, 3000 K STREET NW, WASHINGTON, DC, 20007
CLMN Number of Claims: 16
ECL Exemplary Claim: 1
DRWN 1 Drawing Page(s)
LN.CNT 501
AB The invention relates to a method for detecting transmissible
transmissible spongiform encephalopathies (**TSE**) in the human
and animal body, wherein body fluid is taken in vivo from the individual
to be examined and exposed to infrared radiation. At least one
characteristic spectral pattern is selected from the current infrared
spectrum. Said **TSE**-specific spectral areas are compared to
characteristic spectral patterns of infrared spectrums which are stored
in a reference data bank and which are produced from body fluids of
individuals known to be infected or not infected by **TSE**.

L10 ANSWER 36 OF 111 USPATFULL on STN
AN 2004:158562 USPATFULL
TI Nucleic acid-associated proteins
IN Yang, Junming, US, CHINA
Hafalia, April J.A., US, UNITED STATES
Burford, Neil, United Kingdom, UNITED KINGDOM
Nguyen, Danniel B., US, UNITED STATES
Becha, Shanya D., US, UNITED STATES
Tang, Y. Tom, US, UNITED STATES
Richardson, Thomas W., US, UNITED STATES
Yue, Henry, US, UNITED STATES
Warren, Bridget A., US, UNITED STATES
Emerling, Brooke M., US, UNITED STATES
Baughn, Mariah R., US, UNITED STATES
Griffin, Jennifer A., US, UNITED STATES
Elliott, Vicki S., US, UNITED STATES
Chawla, Narinder K., US, UNITED STATES
Lal, Preeti G., US, UNITED STATES
Azimzai, Yalda, US, UNITED STATES
Mason, Patricia M., US, UNITED STATES
Chinn, Anna M., US, UNITED STATES
Yue, Huibin, US, UNITED STATES
PI US 2004121361 A1 20040624
AI US 2003-473575 A1 20030929 (10)
WO 2002-US10502 20020328
DT Utility
FS APPLICATION
LREP Incyte Corporation, Legal Department, 3160 Porter Drive, Palo Alto, CA,
94304
CLMN Number of Claims: 83
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 8018
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides human nucleic acid-associated proteins (NAAP) and
polynucleotides which identify and encode NAAP. The invention also
provides expression vectors, host cells, antibodies, agonists, and

antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with aberrant expression of NAAP.

L10 ANSWER 37 OF 111 USPATFULL on STN
AN 2004:120069 USPATFULL
TI Degradation and detection of **TSE** infectivity
IN Raven, Neil David Hammond, Salisbury, UNITED KINGDOM
Sutton, John Mark, Salisbury, UNITED KINGDOM
PA Health Protection Agency (non-U.S. corporation)
PI US 2004091474 A1 20040513
AI US 2003-614370 A1 20030708 (10)
RLI Continuation of Ser. No. WO 2002-GB52, filed on 8 Jan 2002, UNKNOWN
PRAI GB 2001-420 20010108
GB 2001-4696 20010226
GB 2002-16146 20020711
DT Utility
FS APPLICATION
LREP STERNE, KESSLER, GOLDSTEIN & FOX PLLC, 1100 NEW YORK AVENUE, N.W.,
WASHINGTON, DC, 20005
CLMN Number of Claims: 35
ECL Exemplary Claim: 1
DRWN 25 Drawing Page(s)
LN.CNT 1838

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A transmissible spongiform encephalopathy (**TSE**) agent is inactivated by exposing the **TSE** agent to a thermostable proteolytic **enzyme** at elevated temperature and at acid or alkaline pH. Following this step, or separately, presence of **TSE** infectivity is detected by detection of dimers of **prion** protein.

L10 ANSWER 38 OF 111 USPATFULL on STN
AN 2004:101228 USPATFULL
TI Whole cell engineering by mutagenizing a substantial portion of a starting genome, combining mutations, and optionally repeating
IN Short, Jay M., Rancho Santa Fe, CA, UNITED STATES
PI US 2004077090 A1 20040422
AI US 2003-383798 A1 20030306 (10)
RLI Continuation of Ser. No. US 2000-677584, filed on 30 Sep 2000, ABANDONED
Continuation-in-part of Ser. No. US 2000-594459, filed on 14 Jun 2000, GRANTED, Pat. No. US 6605449
Continuation-in-part of Ser. No. US 2000-522289, filed on 9 Mar 2000, GRANTED, Pat. No. US 6358709
Continuation-in-part of Ser. No. US 2000-498557, filed on 4 Feb 2000, PENDING
Continuation-in-part of Ser. No. US 2000-495052, filed on 31 Jan 2000, GRANTED, Pat. No. US 6479258
PRAI US 1999-156815P 19990929 (60)
DT Utility
FS APPLICATION
LREP HALE AND DORR LLP, 300 PARK AVENUE, NEW YORK, NY, 10022
CLMN Number of Claims: 22
ECL Exemplary Claim: 1
DRWN 28 Drawing Page(s)
LN.CNT 37121

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB An invention comprising cellular transformation, directed evolution, and screening methods for creating novel transgenic organisms having desirable properties. Thus in one aspect, this invention relates to a method of generating a transgenic organism, such as a microbe or a plant, having a plurality of traits that are differentially activatable. Also, a method of retooling genes and gene pathways by the introduction of regulatory sequences, such as promoters, that are operable in an intended host, thus conferring operability to a novel gene pathway when it is introduced into an intended host. For example a novel man-made gene pathway, generated based on microbially-derived progenitor templates, that is operable in a plant cell. Furthermore, a method of generating novel host organisms having increased expression of desirable traits, recombinant genes, and gene products.

L10 ANSWER 39 OF 111 USPATFULL on STN

AN 2004:88563 USPATFULL

TI Method to reduce false positive outcomes in **prion** tests

IN van Oers, Josephus Wilhelmus, A., M., Zaandam, NETHERLANDS

van der Vorst, Teun Jan, K., Lelystad, NETHERLANDS

Hack, Cornelis Erik, Diemen, NETHERLANDS

Engelenburg, Franciscus Antonius C., Utrecht, NETHERLANDS

PI US 2004067533 A1 20040408

AI US 2003-620082 A1 20030715 (10)

PRAI EP 2002-77909 20020717

DT Utility

FS APPLICATION

LREP HOFFMANN & BARON, LLP, 6900 JERICHO TURNPIKE, SYOSSET, NY, 11791

CLMN Number of Claims: 16

ECL Exemplary Claim: 1

DRWN 4 Drawing Page(s)

LN.CNT 464

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention relates to the field of **prion** diseases. A method is provided to reduce false positive outcomes in a test by monitoring the activity of a proteolytic **enzyme** in a test sample comprising providing the test sample with a substrate and contacting the **enzyme** with said substrate to allow conversion of the substrate by the **enzyme** into a detectable product and detecting said product. Use of a method according to the invention can improve the reliability of **prion** tests.

L10 ANSWER 40 OF 111 USPATFULL on STN

AN 2004:63738 USPATFULL

TI Novel proteins and nucleic acids encoding same

IN Agee, Michele L., Wallingford, CT, UNITED STATES

Alsobrook, John P., II, Madison, CT, UNITED STATES

Anderson, David W., Branford, CT, UNITED STATES

Berghs, Constance, New Haven, CT, UNITED STATES

Boldog, Ferenc L., North Haven, CT, UNITED STATES

Burgess, Catherine E., Wethersfield, CT, UNITED STATES

Casman, Stacie J., North Haven, CT, UNITED STATES

Catterton, Elina, Madison, CT, UNITED STATES

Chant, John S., Branford, CT, UNITED STATES

Chaudhuri, Amitabha, Madison, CT, UNITED STATES

Bokor, Julie, Gainesville, FL, UNITED STATES

DiPippo, Vincent A., East Haven, CT, UNITED STATES

Edinger, Shlomit R., New Haven, CT, UNITED STATES

Eisen, Andrew, Rockville, MD, UNITED STATES

Ellerman, Karen, Branford, CT, UNITED STATES

Gangolli, Esha A., Madison, CT, UNITED STATES

Gerlach, Valerie, Branford, CT, UNITED STATES

Giot, Loic, Madison, CT, UNITED STATES

Gorman, Linda, Branford, CT, UNITED STATES

Guo, Xiaojia (Sasha), Branford, CT, UNITED STATES

Gusev, Vladimir Y., Madison, CT, UNITED STATES

Ji, Weizhen, Branford, CT, UNITED STATES

Kekuda, Ramesh, Norwalk, CT, UNITED STATES

Khramtsov, Nikolai V., Branford, CT, UNITED STATES

Leach, Martin D., Madison, CT, UNITED STATES

Lepley, Denise M., Branford, CT, UNITED STATES

Li, Li, Branford, CT, UNITED STATES

Liu, Xiaohong, Lexington, MA, UNITED STATES

Malyankar, Uriel M., Branford, CT, UNITED STATES

Miller, Charles E., Guilford, CT, UNITED STATES

Ooi, Chean Eng, Branford, CT, UNITED STATES

Ort, Tatiana, Milford, CT, UNITED STATES

Padigar, Muralidhara, Branford, CT, UNITED STATES

Patturajan, Meera, Branford, CT, UNITED STATES

Pena, Carol E. A., Guilford, CT, UNITED STATES

Rieger, Daniel K., Branford, CT, UNITED STATES

Rothenberg, Mark E., Clinton, CT, UNITED STATES

Shenoy, Suresh G., Branford, CT, UNITED STATES
Shimkets, Richard A., Guilford, CT, UNITED STATES
Spaderna, Steven K., Berlin, CT, UNITED STATES
Spytek, Kimberly A., New Haven, CT, UNITED STATES
Taupier, Raymond J., JR., East Haven, CT, UNITED STATES
Twomlow, Nancy, Madison, CT, UNITED STATES
Vernet, Corine A.M., Branford, CT, UNITED STATES
Voss, Edward Z., Wallingford, CT, UNITED STATES
Zerhusen, Bryan D., Branford, CT, UNITED STATES
Zhong, Mei, Branford, CT, UNITED STATES

PI US 2004048256 A1 20040311
AI US 2002-236417 A1 20020906 (10)
PRAI US 2001-318120P 20010907 (60)
US 2001-318430P 20010910 (60)
US 2001-322781P 20010917 (60)
US 2001-318184P 20010907 (60)
US 2002-361663P 20020305 (60)
US 2002-396412P 20020717 (60)
US 2001-322636P 20010917 (60)
US 2001-322817P 20010917 (60)
US 2001-322816P 20010917 (60)
US 2001-323519P 20010919 (60)
US 2001-323631P 20010920 (60)
US 2002-377908P 20020503 (60)
US 2002-381483P 20020517 (60)
US 2001-323636P 20010920 (60)
US 2001-324969P 20010925 (60)
US 2002-383863P 20020529 (60)
US 2001-325091P 20010925 (60)
US 2001-324990P 20010926 (60)
US 2001-341144P 20011214 (60)
US 2002-359599P 20020226 (60)
US 2002-393332P 20020702 (60)
US 2002-403517P 20020813 (60)

DT Utility

FS APPLICATION

LREP MINTZ, LEVIN, COHN, FERRIS, GLOVSKY, AND POPEO, P.C., ONE FINANCIAL
CENTER, BOSTON, MA, 02111

CLMN Number of Claims: 45

ECL Exemplary Claim: 1

DRWN 3 Drawing Page(s)

LN.CNT 23608

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides novel isolated polynucleotides and small molecule target polypeptides encoded by the polynucleotides. Antibodies that immunospecifically bind to a novel small molecule target polypeptide or any derivative, variant, mutant or fragment of that polypeptide, polynucleotide or antibody are disclosed, as are methods in which the small molecule target polypeptide, polynucleotide and antibody are utilized in the detection and treatment of a broad range of pathological states. More specifically, the present invention discloses methods of using recombinantly expressed and/or endogenously expressed proteins in various screening procedures for the purpose of identifying therapeutic antibodies and therapeutic small molecules associated with diseases. The invention further discloses therapeutic, diagnostic and research methods for diagnosis, treatment, and prevention of disorders involving any one of these novel human nucleic acids and proteins.

L10 ANSWER 41 OF 111 USPATFULL on STN

AN 2004:51446 USPATFULL

TI Therapeutic polypeptides, nucleic acids encoding same, and methods of use

IN Alsobrook, John P., II, Madison, CT, UNITED STATES
Anderson, David W., Branford, CT, UNITED STATES
Boldog, Ferenc L., North Haven, CT, UNITED STATES
Burgess, Catherine E., Wethersfield, CT, UNITED STATES
Catterton, Elina, Madison, CT, UNITED STATES
Edinger, Shlomit R., New Haven, CT, UNITED STATES

Ellerman, Karen, Branford, CT, UNITED STATES
Gerlach, Valerie, Branford, CT, UNITED STATES
Gorman, Linda, Branford, CT, UNITED STATES
Guo, Xiaojia (Sasha), Branford, CT, UNITED STATES
Ji, Weizhen, Branford, CT, UNITED STATES
Kekuda, Ramesh, Norwalk, CT, UNITED STATES
Leach, Martin D., Madison, CT, UNITED STATES
Li, Li, Branford, CT, UNITED STATES
Miller, Charles E., Guilford, CT, UNITED STATES
Patturajan, Meera, Branford, CT, UNITED STATES
Rieger, Daniel K., Branford, CT, UNITED STATES
Rothenberg, Mark E., Clinton, CT, UNITED STATES
Shimkets, Richard A., Guilford, CT, UNITED STATES
Smithson, Glennda, Guilford, CT, UNITED STATES
Spytek, Kimberly A., New Haven, CT, UNITED STATES
Taupier, Raymond J., JR., East Haven, CT, UNITED STATES
Vernet, Corine A.M., Branford, CT, UNITED STATES
Voss, Edward Z., Wallingford, CT, UNITED STATES
Zerhusen, Bryan D., Branford, CT, UNITED STATES
Zhong, Mei, Branford, CT, UNITED STATES

PI US 2004038877 A1 20040226
AI US 2002-262839 A1 20021001 (10)
PRAI

US 2001-326483P 20011002 (60)
US 2001-327917P 20011009 (60)
US 2001-328029P 20011009 (60)
US 2001-328056P 20011009 (60)
US 2002-381101P 20020516 (60)
US 2002-371972P 20020412 (60)
US 2001-327342P 20011005 (60)
US 2001-328044P 20011009 (60)
US 2001-328849P 20011012 (60)
US 2002-374738P 20020423 (60)
US 2001-329414P 20011015 (60)
US 2001-330142P 20011017 (60)
US 2002-383830P 20020529 (60)
US 2001-341058P 20011022 (60)
US 2002-373805P 20020419 (60)
US 2002-381635P 20020517 (60)
US 2002-371980P 20020412 (60)
US 2001-343629P 20011024 (60)
US 2001-339266P 20011024 (60)
US 2001-349575P 20011029 (60)
US 2001-346357P 20011101 (60)
US 2002-373261P 20020417 (60)

DT Utility

FS APPLICATION

LREP MINTZ, LEVIN, COHN, FERRIS, GLOVSKY, AND POPEO, P.C., ONE FINANCIAL
CENTER, BOSTON, MA, 02111

CLMN Number of Claims: 45

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 24097

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed herein are nucleic acid sequences that encode novel polypeptides. Also disclosed are polypeptides encoded by these nucleic acid sequences, and antibodies that immunospecifically bind to the polypeptide, as well as derivatives, variants, mutants, or fragments of the novel polypeptide, polynucleotide, or antibody specific to the polypeptide. Vectors, host cells, antibodies and recombinant methods for producing the polypeptides and polynucleotides, as well as methods for using same are also included. The invention further discloses therapeutic, diagnostic and research methods for diagnosis, treatment, and prevention of disorders involving any one of these novel human nucleic acids and proteins.

L10 ANSWER 42 OF 111 USPATFULL on STN

AN 2004:50877 USPATFULL

TI Unique recognition sequences and methods of use thereof in protein

analysis

IN Lee, Frank D., Chestnut Hill, MA, UNITED STATES
Meng, Xun, Newton, MA, UNITED STATES
Chan, John W., Acton, MA, UNITED STATES
Zhang, Shengsheng, Quincy, MA, UNITED STATES
Benkovic, Stephen J., State College, PA, UNITED STATES

PA engeneOS, Inc., Waltham, MA, 02451 (U.S. corporation)

PI US 2004038307 A1 20040226

AI US 2003-436549 A1 20030512 (10)

PRAI US 2002-379626P 20020510 (60)
US 2002-393137P 20020701 (60)
US 2002-393233P 20020701 (60)
US 2002-393235P 20020701 (60)
US 2002-393211P 20020701 (60)
US 2002-393223P 20020701 (60)
US 2002-393280P 20020701 (60)
US 2002-393197P 20020701 (60)
US 2002-430948P 20021204 (60)
US 2002-433319P 20021213 (60)

DT Utility

FS APPLICATION

LREP ROPES & GRAY LLP, ONE INTERNATIONAL PLACE, BOSTON, MA, 02110-2624

CLMN Number of Claims: 115

ECL Exemplary Claim: 1

DRWN 4 Drawing Page(s)

LN.CNT 5402

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed are methods for reliably detecting the presence of proteins in a sample by the use of capture agents that recognize and interact with recognition sequences uniquely characteristic of a set of proteins in the sample. Arrays comprising these capture agents are also provided.

L10 ANSWER 43 OF 111 USPATFULL on STN

AN 2004:18781 USPATFULL

TI Detection of heteroduplex polynucleotides using mutant nucleic acid repair **enzymes** with attenuated catalytic activity

IN Yuan, Chong-Sheng, San Diego, CA, UNITED STATES
Datta, Abhijit, Carlsbad, CA, UNITED STATES

PI US 2004014083 A1 20040122

AI US 2003-373238 A1 20030224 (10)

RLI Continuation-in-part of Ser. No. US 2000-514016, filed on 25 Feb 2000, PENDING

DT Utility

FS APPLICATION

LREP Peng Chen, Morrison & Foerster LLP, Suite 500, 3811 Valley Centre Drive, San Diego, CA, 92130-2332

CLMN Number of Claims: 105

ECL Exemplary Claim: 1

DRWN 2 Drawing Page(s)

LN.CNT 10442

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods for detecting, localizing and removing abnormal base-pairing in a nucleic acid duplex are provided. These methods can be used for prognosis and diagnosis of diseases, disorders, pathogenic infections and nucleic acid polymorphisms. Combinations, kits and articles of manufacture for use in these methods are also provided.

L10 ANSWER 44 OF 111 USPATFULL on STN

AN 2004:13611 USPATFULL

TI Albumin fusion proteins

IN Rosen, Craig A., Laytonsville, MD, UNITED STATES
Haseltine, William A., Washington, DC, UNITED STATES

PI US 2004010134 A1 20040115

AI US 2001-833245 A1 20010412 (9)

PRAI US 2000-256931P 20001221 (60)
US 2000-199384P 20000425 (60)
US 2000-229358P 20000412 (60)

DT Utility

FS APPLICATION
LREP HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850
CLMN Number of Claims: 29
ECL Exemplary Claim: 1
DRWN 18 Drawing Page(s)
LN.CNT 25066

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.

L10 ANSWER 45 OF 111 USPATFULL on STN

AN 2003:318636 USPATFULL

TI Genes and polymorphisms on chromosome 10 associated with Alzheimer's disease and other neurodegenerative diseases

IN Becker, Kenneth David, San Diego, CA, UNITED STATES

Velicelebi, Gonul, San Diego, CA, UNITED STATES

Ellliott, Kathryn J., San Diego, CA, UNITED STATES

Wang, Xin, San Diego, CA, UNITED STATES

Tanzi, Rudolph E., Hull, MA, UNITED STATES

Bertram, Lars, Brighton, MA, UNITED STATES

Saunders, Aleister J., Philadelphia, PA, UNITED STATES

Mullin, Kristina M., south Boston, MA, UNITED STATES

Sampson, Andrew Joseph, Dayton, OH, UNITED STATES

PA The General Hospital Corporation (U.S. corporation)

PI US 2003224380 A1 20031204

AI US 2002-282174 A1 20021025 (10)

PRAI US 2001-339525P 20011025 (60)

US 2001-338010P 20011108 (60)

US 2001-336929P 20011108 (60)

US 2001-338363P 20011109 (60)

US 2001-337052P 20011204 (60)

US 2002-368919P 20020328 (60)

US 2001-348065P 20011025 (60)

US 2001-336983P 20011102 (60)

DT Utility

FS APPLICATION

LREP HELLER EHRMAN WHITE & MCAULIFFE LLP, 4350 LA JOLLA VILLAGE DRIVE, 7TH FLOOR, SAN DIEGO, CA, 92122-1246

CLMN Number of Claims: 173

ECL Exemplary Claim: 1

DRWN 113 Drawing Page(s)

LN.CNT 13662

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Probes, primers and kits for detection of polymorphisms in genes involved in neurodegenerative disease are provided. Methods based on detecting such polymorphisms for prognosticating, determining the occurrence, profiling drug response and drug discovery are also provided.

L10 ANSWER 46 OF 111 USPATFULL on STN

AN 2003:312620 USPATFULL

TI Novel polynucleotides encoding the human citron kinase polypeptide, BMSNKC_0020/0021

IN Davison, Daniel B., Yardley, PA, UNITED STATES

Feder, John N., Belle Mead, NJ, UNITED STATES

Lee, Liana M., Somerset, NJ, UNITED STATES

Ott, Karl-Heinz, Mercer, NJ, UNITED STATES

PI US 2003220224 A1 20031127

AI US 2003-412897 A1 20030411 (10)

PRAI US 2002-372745P 20020412 (60)

DT Utility
FS APPLICATION
LREP STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O
BOX 4000, PRINCETON, NJ, 08543-4000
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN 18 Drawing Page(s)
LN.CNT 7756

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention describes a novel human protein kinase related to citron kinase, and its encoding polynucleotide. Also described are expression vectors, host cells, antisense molecules, and antibodies associated with the protein kinase polynucleotide and/or polypeptide of this invention. In addition, methods for treating, diagnosing, preventing, and screening for disorders or diseases associated with abnormal biological activity of the protein kinase are described, as are methods for screening for modulators, e.g., agonists or antagonists, of the protein kinase activity and/or function.

L10 ANSWER 47 OF 111 USPATFULL on STN

AN 2003:312278 USPATFULL

TI Albumin fusion proteins

IN Rosen, Craig A., Laytonsville, MD, UNITED STATES

Haseltine, William A., Washington, DC, UNITED STATES

PI US 2003219875 A1 20031127

US 6905688 B2 20050614

AI US 2001-833118 A1 20010412 (9)

PRAI US 2000-256931P 20001221 (60)

US 2000-199384P 20000425 (60)

US 2000-229358P 20000412 (60)

DT Utility

FS APPLICATION

LREP HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850

CLMN Number of Claims: 29

ECL Exemplary Claim: 1

DRWN 18 Drawing Page(s)

LN.CNT 15415

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.

L10 ANSWER 48 OF 111 USPATFULL on STN

AN 2003:307939 USPATFULL

TI Transgenic animals expressing heparanase and uses thereof

IN Zcharia, Eyal, Jerusalem, ISRAEL

Vlodavsky, Israel, Mevaseret Zion, ISRAEL

Metzger, Shula, Jerusalem, ISRAEL

Pecker, Iris, Rishon LeZion, ISRAEL

Ilan, Neta, Rehovot, ISRAEL

Chajek-Shaul, Tova, Jerusalem, ISRAEL

Goldshmidt, Orit, Jerusalem, ISRAEL

PI US 2003217375 A1 20031120

AI US 2003-371218 A1 20030224 (10)

RLI Continuation-in-part of Ser. No. US 2001-988113, filed on 19 Nov 2001,
PENDING Continuation of Ser. No. US 2001-776874, filed on 6 Feb 2001,
PENDING Continuation of Ser. No. US 1999-258892, filed on 1 Mar 1999,
ABANDONED Continuation-in-part of Ser. No. WO 1998-US17954, filed on 31
Aug 1998, PENDING

DT Utility

FS APPLICATION

LREP G.E. EHRLICH (1995) LTD., c/o ANTHONY CASTORINA, SUITE 207, 2001
JEFFERSON DAVIS HIGHWAY, ARLINGTON, VA, 22202

CLMN Number of Claims: 28

ECL Exemplary Claim: 1

DRWN 38 Drawing Page(s)

LN.CNT 4467

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A transgenic non-human animal expressing heparanase from a transgene,
methods for its preparation, compositions-of-matter derived therefrom
and uses thereof.

L10 ANSWER 49 OF 111 USPATFULL on STN

AN 2003:306446 USPATFULL

TI Motif-grafted hybrid polypeptides and uses thereof

IN Burton, Dennis R., La Jolla, CA, UNITED STATES

Moroncini, Gianluca, La Jolla, CA, UNITED STATES

Williamson, R. Anthony, San Diego, CA, UNITED STATES

PI US 2003215880 A1 20031120

AI US 2003-410907 A1 20030408 (10)

PRAI US 2002-371610P 20020409 (60)

DT Utility

FS APPLICATION

LREP Stephanie Seidman, Heller Ehrman White & McAuliffe LLP, 7th Floor, 4350
La Jolla Village Dr., San Diego, CA, 92122

CLMN Number of Claims: 108

ECL Exemplary Claim: 1

DRWN 4 Drawing Page(s)

LN.CNT 4132

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Provided herein are hybrid polypeptides that specifically bind to a
disease-associated isoform of a polypeptide involved in diseases of
protein aggregation. The hybrid polypeptides can be used for diagnosis
and treatment of such diseases. In a particular embodiment, a hybrid
protein that specifically binds to the infectious form of a
prion (PrP.sup.Sc) is provided.

L10 ANSWER 50 OF 111 USPATFULL on STN

AN 2003:300243 USPATFULL

TI Methods for identifying functionally related genes and drug targets

IN Keene, Jack D., Durham, NC, UNITED STATES

Tenenbaum, Scott A., Durham, NC, UNITED STATES

Carson, Craig C., Raleigh, NC, UNITED STATES

Phelps, William C., Durham, NC, UNITED STATES

PA Ribonomics, Inc., Durham, NC (U.S. corporation)

PI US 2003211466 A1 20031113

AI US 2002-309788 A1 20021204 (10)

RLI Continuation-in-part of Ser. No. US 2000-750401, filed on 28 Dec 2000,
PENDING

PRAI US 1999-173338P 19991228 (60)

DT Utility

FS APPLICATION

LREP TESTA, HURWITZ & THIBEAULT, LLP, HIGH STREET TOWER, 125 HIGH STREET,
BOSTON, MA, 02110

CLMN Number of Claims: 53

ECL Exemplary Claim: 1

DRWN 16 Drawing Page(s)

LN.CNT 2384

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The identification and evaluation of mRNA and protein targets associated
with mRNP complexes and implicated in the expression of proteins
involved in common physiological pathways is described. Effective
targets are useful for treating a disease, condition or disorder
associated with the physiological pathway.

L10 ANSWER 51 OF 111 USPATFULL on STN

AN 2003:289309 USPATFULL

TI Polynucleotide encoding a novel methionine aminopeptidase, protease-39

IN Chen, Jian, Princeton, NJ, UNITED STATES

Feder, John N., Belle Mead, NJ, UNITED STATES
Nelson, Thomas C., Lawrenceville, NJ, UNITED STATES
Bassolino, Donna A., Hamilton, NJ, UNITED STATES
Krystek, Stanley R., Ringoes, NJ, UNITED STATES
Naglich, Joseph, Yardley, PA, UNITED STATES

PI US 2003204070 A1 20031030
AI US 2003-350516 A1 20030123 (10)
PRAI US 2002-351251P 20020123 (60)
US 2002-362872P 20020308 (60)

DT Utility

FS APPLICATION

LREP STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O
BOX 4000, PRINCETON, NJ, 08543-4000

CLMN Number of Claims: 24

ECL Exemplary Claim: 1

DRWN 16 Drawing Page(s)

LN.CNT 17388

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides novel polynucleotides encoding
Protease-39 polypeptides, fragments and homologues thereof. Also
provided are vectors, host cells, antibodies, and recombinant and
synthetic methods for producing said polypeptides. The invention further
relates to diagnostic and therapeutic methods for applying these novel
Protease-39 polypeptides to the diagnosis, treatment, and/or prevention
of various diseases and/or disorders related to these polypeptides. The
invention further relates to screening methods for identifying agonists
and antagonists of the polynucleotides and polypeptides of the present
invention.

L10 ANSWER 52 OF 111 USPATFULL on STN

AN 2003:282700 USPATFULL

TI Albumin fusion proteins

IN Ballance, David J., Berwyn, PA, UNITED STATES
Sleep, Darrell, West Bridgford, UNITED KINGDOM
Prior, Christopher P., Rosemont, PA, UNITED STATES
Sadeghi, Homayoun, Doylestown, PA, UNITED STATES
Turner, Andrew J., Eagleville, PA, UNITED STATES

PI US 2003199043 A1 20031023
AI US 2001-832501 A1 20010412 (9)
PRAI US 2000-256931P 20001221 (60)
US 2000-199384P 20000425 (60)
US 2000-229358P 20000412 (60)

DT Utility

FS APPLICATION

LREP HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850

CLMN Number of Claims: 60

ECL Exemplary Claim: 1

DRWN 18 Drawing Page(s)

LN.CNT 14339

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention encompasses albumin fusion proteins. Nucleic acid
molecules encoding the albumin fusion proteins of the invention are also
encompassed by the invention, as are vectors containing these nucleic
acids, host cells transformed with these nucleic acids vectors, and
methods of making the albumin fusion proteins of the invention and using
these nucleic acids, vectors, and/or host cells. Additionally the
present invention encompasses pharmaceutical compositions comprising
albumin fusion proteins and methods of treating, preventing, or
ameliorating diseases, disorders or conditions using albumin fusion
proteins of the invention.

L10 ANSWER 53 OF 111 USPATFULL on STN

AN 2003:282670 USPATFULL

TI Fragments of prion proteins

IN Fishleigh, Robert Vincent, Cheshire, UNITED KINGDOM
Robson, Barry, Cheshire, UNITED KINGDOM
Mee, Roger Paul, Manchester, UNITED KINGDOM

PA Proteus Molecular Design Limited (non-U.S. corporation)

PI US 2003199013 A1 20031023
AI US 2002-116061 A1 20020405 (10)
RLI Division of Ser. No. US 1998-76721, filed on 13 May 1998, GRANTED, Pat.
No. US 6379905 Division of Ser. No. US 1994-244701, filed on 2 Jun 1994,
GRANTED, Pat. No. US 5773572 A 371 of International Ser. No. WO
1992-GB2246, filed on 3 Dec 1992, UNKNOWN

PRAI GB 1991-25747 19911203
GB 1992-14663 19920710

DT Utility

FS APPLICATION

LREP PENNIE & EDMONDS LLP, 1667 K STREET NW, SUITE 1000, WASHINGTON, DC,
20006

CLMN Number of Claims: 45

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 2571

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Synthetic polypeptides having at least one antigenic site of a prior
protein, methods for their use and manufacture, antibodies raised
against such polypeptides and diagnostic kits containing these
polypeptides or antibodies.

L10 ANSWER 54 OF 111 USPATFULL on STN

AN 2003:251654 USPATFULL

TI Pyridylpyrimidine derivatives as effective compounds against
prion diseases

IN Stein-Gerlach, Matthias, Munich, GERMANY, FEDERAL REPUBLIC OF
Salassidis, Konstadinos, Ehcing, GERMANY, FEDERAL REPUBLIC OF
Bacher, Gerald, Germering, GERMANY, FEDERAL REPUBLIC OF
Muller, Stefan, Munich, GERMANY, FEDERAL REPUBLIC OF

PI US 2003176443 A1 20030918

AI US 2002-204041 A1 20020816 (10)

WO 2002-EP5420 20020516

PRAI EP 2001-111858 20010516

EP 2001-117113 20010713

DT Utility

FS APPLICATION

LREP Leon R Yankwich, Yankwich & Associates, 201 Broadway, Cambridge, MA,
02139

CLMN Number of Claims: 48

ECL Exemplary Claim: 1

DRWN 3 Drawing Page(s)

LN.CNT 3218

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to pyridylpyrimidine derivatives of the
general formula (I): ##STR1##

wherein R represents hydrogen or methyl and Z represents nitrogen
containing functional groups, the use of the pyridylpyrimidine
derivatives as pharmaceutically active agents, especially for the
prophylaxis and/or treatment of **prion** infections and
prion diseases, as well as compositions containing at least one
pyridylpyrimidine derivative and/or pharmaceutically acceptable salt
thereof. Furthermore, the present invention is directed to methods for
preventing and/or treating **prion** infections and **prion**
diseases using said pyridylpyrimidine derivatives. Human cellular
protein kinases, phosphatases and cellular signal transduction molecules
are disclosed as targets for detecting, preventing and/or treating
prion infections and diseases, especially BSE, vCJD, or CJD
which can be inhibited by the inventive pyridylpyrimidine derivatives.

L10 ANSWER 55 OF 111 USPATFULL on STN

AN 2003:244853 USPATFULL

TI Albumin fusion proteins

IN Rosen, Craig A., Laytonsville, MD, UNITED STATES
Sadeghi, Homayoun, Doylestown, PA, UNITED STATES
Prior, Christopher P., Rosemont, PA, UNITED STATES
Turner, Andrew J., Eagleville, PA, UNITED STATES

PI US 2003171267 A1 20030911
AI US 2001-833117 A1 20010412 (9)
PRAI US 2000-256931P 20001221 (60)
US 2000-199384P 20000425 (60)
US 2000-229358P 20000412 (60)
DT Utility
FS APPLICATION
LREP HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850
CLMN Number of Claims: 59
ECL Exemplary Claim: 1
DRWN 20 Drawing Page(s)
LN.CNT 13208

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.

L10 ANSWER 56 OF 111 USPATFULL on STN

AN 2003:238692 USPATFULL
TI Novel RGS9 protein binding interactions and methods of use thereof
IN Jones, Philip G., Cranbury, NJ, UNITED STATES
Young, Kathleen H., Newtown, PA, UNITED STATES
PA Wyeth, Madison, NJ (U.S. corporation)
PI US 2003166850 A1 20030904
AI US 2002-108210 A1 20020327 (10)
PRAI US 2001-279240P 20010328 (60)
DT Utility
FS APPLICATION
LREP WYETH, PATENT LAW GROUP, FIVE GIRALDA FARMS, MADISON, NJ, 07940
CLMN Number of Claims: 36
ECL Exemplary Claim: 1
DRWN 1 Drawing Page(s)
LN.CNT 4492

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to novel protein binding interactions, comprising a regulator of G-protein signalling protein (RGS) and a non G-protein binding partner. More particularly, the invention relates to a novel interaction between RGS9 and evecitin polypeptides, the use of such polypeptides, as well as the production of such polypeptides. The invention relates also to identifying compounds which may be agonists, antagonists and/or inhibitors of RGS9 and/or evecitin polypeptides, and therefore potentially useful in therapy. In particular embodiments, the RGS9 and evecitin polypeptides produced are used in methods for assaying the effects of test compounds on the activity of RGS9-evecitin dimers, methods for assaying the effects of test compounds on the activity of RGS9-evecitin dimers comprised in transgenic animals encoding RGS9 and evecitin, methods for diagnosis and treatment of diseases related to the activity of RGS9-evecitin dimers and methods for modulating G-protein activity.

L10 ANSWER 57 OF 111 USPATFULL on STN

AN 2003:231638 USPATFULL
TI Biological materials and methods useful in the diagnosis and treatment of diseases
IN Collinge, John, London, UNITED KINGDOM
Clarke, Anthony R., London, UNITED KINGDOM
Jackson, Graham S., London, UNITED KINGDOM
PA D-Gen Limited, London, UNITED KINGDOM (non-U.S. corporation)
PI US 2003161836 A1 20030828
AI US 2002-304630 A1 20021126 (10)
RLI Division of Ser. No. US 1999-431887, filed on 2 Nov 1999, GRANTED, Pat.

No. US 6534036
PRAI GB 1998-24091 19981104
GB 1999-6217 19990318
DT Utility
FS APPLICATION
LREP NIKOLAI & MERSEREAU, P.A., 900 SECOND AVENUE SOUTH, SUITE 820,
MINNEAPOLIS, MN, 55402
CLMN Number of Claims: 46
ECL Exemplary Claim: 1
DRWN 10 Drawing Page(s)
LN.CNT 2458
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to a method of making a β -form of a **prion** protein which preferably has more β -sheet than α -helix structure and is soluble in the absence of a denaturant and/or is non-aggregated and exhibits partial resistance to digestion with **proteinase K**. The invention also relates to use of the β -form in medicine, especially for raising antibodies useful in the treatment and/or diagnosis of **prion** diseases. The invention also relates to methods of screening for compounds which are capable of inhibiting and/or reversing the conversion of the native α -form of a **prion** protein to a β -form, and to uses of identified compounds in medicine.

L10 ANSWER 58 OF 111 USPATFULL on STN
AN 2003:220740 USPATFULL
TI Methods and compositions for diagnosing and treating rheumatoid arthritis
IN Pittman, Debra D., Windham, NH, UNITED STATES
Feldman, Jeffrey L., Arlington, MA, UNITED STATES
Shields, Kathleen M., Harvard, MA, UNITED STATES
Trepicchio, William L., Andover, MA, UNITED STATES
PI US 2003154032 A1 20030814
AI US 2001-23451 A1 20011217 (10)
PRAI US 2000-255861P 20001215 (60)
DT Utility
FS APPLICATION
LREP Patent Group, FOLEY, HOAG & ELIOT LLP, One Post Office Square, Boxton, MA, 02109
CLMN Number of Claims: 40
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 25385
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides methods and compositions for diagnostic assays for detecting R.A. and therapeutic methods and compositions for treating R.A. The invention also provides methods for designing, identifying, and optimizing therapeutics for R.A. Diagnostic compositions of the invention include compositions comprising detection agents for detecting one or more genes that have been shown to be up- or down-regulated in cells of R.A. relative to normal counterpart cells. Exemplary detection agents include nucleic acid probes, which can be in solution or attached to a solid surface, e.g., in the form of a microarray. The invention also provides computer-readable media comprising values of levels of expression of one or more genes that are up- or down-regulated in R.A.

L10 ANSWER 59 OF 111 USPATFULL on STN
AN 2003:219631 USPATFULL
TI Full-length human cDNAs encoding potentially secreted proteins
IN Dumas Milne Edwards, Jean-Baptiste, Paris, FRANCE
Bougueleret, Lydie, Petit Lancy, SWITZERLAND
Jobert, Severin, Paris, FRANCE
PI US 2003152921 A1 20030814
AI US 2001-876997 A1 20010608 (9)
RLI Continuation-in-part of Ser. No. US 2000-731872, filed on 7 Dec 2000, PENDING
PRAI US 1999-169629P 19991208 (60)
US 2000-187470P 20000306 (60)

DT Utility
FS APPLICATION
LREP Frank C. Eisenschenk, Ph.D., SALIWANCHIK, LLOYD & SALIWANCHIK, 2421 N.W.
41 STREET, SUITE A-1, GAINESVILLE, FL, 32606-6669
CLMN Number of Claims: 22
ECL Exemplary Claim: 1
DRWN 5 Drawing Page(s)
LN.CNT 27600

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention concerns GENSET polynucleotides and polypeptides. Such GENSET products may be used as reagents in forensic analyses, as chromosome markers, as tissue/cell/organelle-specific markers, in the production of expression vectors. In addition, they may be used in screening and diagnosis assays for abnormal GENSET expression and/or biological activity and for screening compounds that may be used in the treatment of GENSET-related disorders.

L10 ANSWER 60 OF 111 USPATFULL on STN

AN 2003:215353 USPATFULL
TI Genes encoding G-protein coupled receptors and methods of use therefor
IN Blatcher, Maria, Moorestown, NJ, UNITED STATES
Paulsen, Janet E., Londonderry, NH, UNITED STATES
Bates, Brian G., Chelmsford, MA, UNITED STATES
PA Wyeth, Madison, NJ (U.S. corporation)
PI US 2003149998 A1 20030807
AI US 2002-293983 A1 20021113 (10)
PRAI US 2001-332110P 20011116 (60)

DT Utility
FS APPLICATION
LREP Bill T. Brazil, Five Giralda Farms, Madison, NJ, 07940-0874
CLMN Number of Claims: 98
ECL Exemplary Claim: 1
DRWN 5 Drawing Page(s)
LN.CNT 6888

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates generally to the fields of neuroscience, bioinformatics and molecular biology. More particularly, the invention relates to newly identified polynucleotides that encode G-protein coupled receptors (GPCRs), the use of such polynucleotides and polypeptides, as well as the production of such polynucleotides and polypeptides. The invention relates also to identifying compounds which may be agonists, antagonists and/or inhibitors of GPCRs, and therefore potentially useful in therapy.

L10 ANSWER 61 OF 111 USPATFULL on STN

AN 2003:206867 USPATFULL
TI Antibodies specific for ungulate PrP.
IN Prusiner, Stanley B., San Francisco, CA, UNITED STATES
Safar, Jiri G., Walnut Creek, CA, UNITED STATES
Williamson, R. Anthony, San Diego, CA, UNITED STATES
Burton, Dennis R., La Jolla, CA, UNITED STATES
PI US 2003143224 A1 20030731
AI US 2003-355780 A1 20030130 (10)
RLI Continuation of Ser. No. US 2000-627218, filed on 27 Jul 2000, GRANTED,
Pat. No. US 6537548
DT Utility
FS APPLICATION
LREP BOZICEVIC, FIELD & FRANCIS LLP, 200 MIDDLEFIELD RD, SUITE 200, MENLO
PARK, CA, 94025
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN 9 Drawing Page(s)
LN.CNT 2123

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides antibodies that specifically bind with a high degree of binding affinity to a native ungulate PrP^{sup.C} and/or a denatured ungulate PrP^{sup.Sc}, but not to a native ungulate PrP^{sup.Sc}. Preferred antibodies find native bovine PrP^{sup.C} and treated PrP^{sup.Sc}.

but not native bovine PrP.sup.Sc and can be used in an assay to determine if a sample is infected with infectious **prions**, i.e. PrP.sup.Sc.

L10 ANSWER 62 OF 111 USPATFULL on STN

AN 2003:194529 USPATFULL

TI Method for detecting pathogenic **prion** proteins by means of mass spectroscopy

IN Lengsfeld, Thomas, Marburg, GERMANY, FEDERAL REPUBLIC OF

PI US 2003134340 A1 20030717

AI US 2003-345148 A1 20030116 (10)

PRAI DE 2002-10201777 20020117

DT Utility

FS APPLICATION

LREP Finnegan, Henderson, Farabow,, Garrett & Dunner, L.L.P., 1300 I Street, N.W., Washington, DC, 20005-3315

CLMN Number of Claims: 24

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 433

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method for detecting one or more pathogenic **prion** proteins in a sample, which can be of a body fluid of human or animal origin, and which contains a PrP protein that assumes a natural, nonpathogenic conformation, PrP.sup.C, and a pathogenic conformation, termed PrP.sup.Sc, is described. The method can comprise: providing a sample suspected of containing the pathogenic form of at least one **prion** protein; exposing the sample to a chemical agent under conditions where the chemical agent and the **prion** protein or proteins react to form at least one covalent bond involving the **prion** protein or proteins; and mass-spectroscopically analyzing the resulting **prion** protein or proteins to detect the presence of the pathogenic form of the **prion** protein or proteins; wherein at least one additional peak is observed in the mass spectrum when the pathogenic form of a **prion** protein is present.

L10 ANSWER 63 OF 111 USPATFULL on STN

AN 2003:181414 USPATFULL

TI Albumin fusion proteins

IN Rosen, Craig A., Laytonsville, MD, UNITED STATES

Haseltine, William A., Washington, DC, UNITED STATES

PI US 2003125247 A1 20030703

AI US 2001-833041 A1 20010412 (9)

PRAI US 2000-256931P 20001221 (60)

US 2000-199384P 20000425 (60)

US 2000-229358P 20000412 (60)

DT Utility

FS APPLICATION

LREP HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850

CLMN Number of Claims: 29

ECL Exemplary Claim: 1

DRWN 20 Drawing Page(s)

LN.CNT 15235

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.

L10 ANSWER 64 OF 111 USPATFULL on STN

AN 2003:159820 USPATFULL

TI Methods of inhibiting amyloid toxicity

IN Prenner, Irene Griswald, Brisbane, CA, UNITED STATES
Wright, Sarah, San Francisco, CA, UNITED STATES
Yednock, Theodore, Forest knolls, CA, UNITED STATES
Rydel, Russell, Belmont, CA, UNITED STATES

PI US 2003109435 A1 20030612
AI US 2002-190548 A1 20020709 (10)
PRAI US 2001-304315P 20010709 (60)
US 2001-341772P 20011217 (60)

DT Utility
FS APPLICATION
LREP Finnegan, Henderson, Farabow,, Garrett & Dunner, L.L.P., 1300 I Street,
N.W., Washington, DC, 20005-3315

CLMN Number of Claims: 98
ECL Exemplary Claim: 1
DRWN 17 Drawing Page(s)
LN.CNT 2361

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention features methods and compositions for inhibiting
amyloidogenic protein toxicity, inhibiting formation of an amyloidogenic
protein deposit and/or treating amyloidogenic diseases by administering
a pharmaceutically effective amount of one or more agents that bind an
integrin or an integrin subunit.

L10 ANSWER 65 OF 111 USPATFULL on STN
AN 2003:153616 USPATFULL
TI Small and intermediate conductance, calcium-activated potassium channels
and uses thereof

IN Adelman, John P., Portland, OR, UNITED STATES
Maylie, James, Portland, OR, UNITED STATES
Bond, Chris T., Portland, OR, UNITED STATES
Silvia, Christopher P., Durham, NC, UNITED STATES

PA Oregon Health Sciences University, Portland, OR, UNITED STATES (U.S.
corporation)

PI US 2003105284 A1 20030605
AI US 2002-115688 A1 20020403 (10)
RLI Division of Ser. No. US 1999-254590, filed on 24 May 1999, PENDING A 371
of International Ser. No. WO 1997-US16033, filed on 10 Sep 1997, UNKNOWN

PRAI US 1996-26451P 19960911 (60)
US 1997-40052P 19970307 (60)
US 1997-45233P 19970417 (60)

DT Utility
FS APPLICATION
LREP TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO CENTER, EIGHTH
FLOOR, SAN FRANCISCO, CA, 94111-3834

CLMN Number of Claims: 55
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 4918

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention relates to small and intermediate conductance,
calciumactivated potassium channel proteins. More specifically the
invention relates to compositions and methods for making and detecting
calciumactivated potassium channel proteins and the nucleic acids
encoding calciumactivated potassium channel proteins. The invention also
provides methods and compositions for assaying compounds which increase
or decrease potassium ion flux through a calciumactivated potassium
channel

L10 ANSWER 66 OF 111 USPATFULL on STN
AN 2003:140937 USPATFULL
TI NOVEL DERMATOPHAGOIDES PROTEINS AND USES THEREOF

IN McCall, Catherine A., Boulder, CO, UNITED STATES
Hunter, Shirley Wu, Fort Collins, CO, UNITED STATES
Weber, Eric R., Fort Collins, CO, UNITED STATES

PI US 2003096779 A1 20030522
AI US 2002-218743 A1 20020813 (10)
RLI Division of Ser. No. US 1999-292225, filed on 15 Apr 1999, GRANTED, Pat.
No. US 6455686

PRAI US 1998-98909P 19980902 (60)
 US 1998-85295P 19980513 (60)
 US 1998-98565P 19980417 (60)
 DT Utility
 FS APPLICATION
 LREP HESKA CORPORATION, INTELLECTUAL PROPERTY DEPT., 1613 PROSPECT PARKWAY,
 FORT COLLINS, CO, 80525
 CLMN Number of Claims: 31
 ECL Exemplary Claim: 1
 DRWN 2 Drawing Page(s)
 LN.CNT 5292
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB The present invention relates to high molecular weight Dermatophagoides
 proteins, nucleic acid molecules encoding such proteins, and therapeutic
 and diagnostic reagents derived from such proteins.
 L10 ANSWER 67 OF 111 USPATFULL on STN
 AN 2003:134536 USPATFULL
 TI Denaturat stable and/or protease resistant, chaperone-like oligomeric
 proteins, polynucleotides encoding same, their uses and methods of
 increasing a specific activity thereof
 IN Wang, Wangxia, Rehovot, ISRAEL
 Pelah, Dan, Rehovot, ISRAEL
 Alegrand, Tal, Gedera, ISRAEL
 Pouny, Yehonathan, Glvat Shmuel, ISRAEL
 Marton, Ira, Rehovot, ISRAEL
 Wolf, Amnon, Herzliah Pituach, ISRAEL
 Shoseyov, Oded, Karme Yosef, ISRAEL
 Altman, Arie, Rehovot, ISRAEL
 PA Yissum Research Development Company of the Hebrew University of
 Jerusalem (non-U.S. corporation)
 PI US 2003092624 A1 20030515
 AI US 2002-233409 A1 20020904 (10)
 RLI Continuation-in-part of Ser. No. WO 2002-IL174, filed on 5 Mar 2002,
 UNKNOWN
 PRAI US 2001-272771P 20010305 (60)
 DT Utility
 FS APPLICATION
 LREP G.E. EHRLICH LTD., c/o ANTHONY CASTORINA, SUITE 207, 2001 JEFFERSON
 DAVIS HIGHWAY, ARLINGTON, VA, 22202
 CLMN Number of Claims: 131
 ECL Exemplary Claim: 1
 DRWN 18 Drawing Page(s)
 LN.CNT 4107
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB Novel denaturant-stable, protease resistant, homo-oligomeric proteins,
 also referred to herein as stable proteins (SPs), having chaperone-like
 activity; methods of production and purification of SPs; nucleic acids
 encoding SPs; methods of isolating nucleic acids encoding SPs;
 antibodies recognizing SPs; the use of SPs for stabilizing, refolding,
 repairing, preventing aggregation and de-aggregating macromolecules such
 as proteins; fusion proteins including SPs; nucleic acid constructs
 encoding the fusion proteins; and their uses in a variety of methods and
 applications.
 L10 ANSWER 68 OF 111 USPATFULL on STN
 AN 2003:134009 USPATFULL
 TI Antibodies for specifically detecting pathogenic **prions** of
 human origin, and detection methods carried out using these antibodies
 IN Vey, Martin, Marburg, GERMANY, FEDERAL REPUBLIC OF
 Lang, Wiegand, Coelbe, GERMANY, FEDERAL REPUBLIC OF
 Groener, Albrecht, Marburg, GERMANY, FEDERAL REPUBLIC OF
 Bellon, Anne, Marburg, GERMANY, FEDERAL REPUBLIC OF
 PI US 2003092094 A1 20030515
 AI US 2002-273282 A1 20021018 (10)
 PRAI DE 2001-152677 20011019
 DT Utility
 FS APPLICATION

LREP Finnegan, Henderson, Farabow,, Garrett & Dunner, L.L.P., 1300 I Street,
N.W., Washington, DC, 20005-3315
CLMN Number of Claims: 22
ECL Exemplary Claim: 1
DRWN 3 Drawing Page(s)
LN.CNT 708

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Antibodies for specifically detecting pathogenic **prions** of human origin, and methods for detecting pathogenic **prions**, are described. In particular, a conformation-dependent **immunoassay** method for detecting pathogenic **prion** proteins in a sample of a body fluid, containing a PrP protein, which contains a first, natural, non-pathological conformation, i.e. PrP.sup.c, and a second, pathological conformation, i.e. PrP.sup.Sc, is described, in which method the **prion** proteins differ in their binding affinity for **monoclonal** antibodies which bind specifically to **prion** proteins of human origin, with the detection method comprising the following steps:

a) adding one of the abovementioned **monoclonal** antibodies, which is fixed to a solid support and which exhibits a higher affinity for the first **prion** protein conformation, to the first portion of the sample, and determining this first concentration;

b) treating the second portion of the sample in order to increase the binding affinity of the second conformation of the **prion** protein for the **monoclonal** antibody;

c) adding the **monoclonal** antibody to the treated second portion of the sample to be investigated, in order to determine the second concentration;

d) comparing the first **prion** protein concentration with the second **prion** protein concentration in order to ascertain the presence of the pathogenic **prion** protein conformation.

L10 ANSWER 69 OF 111 USPATFULL on STN

AN 2003:120203 USPATFULL

TI Small and intermediate conductance, calcium-activated potassium channels and uses thereof

IN Adelman, John P., Portland, OR, UNITED STATES

Maylie, James, Portland, OR, UNITED STATES

Bond, Chris T., Portland, OR, UNITED STATES

Silvia, Christopher P., Durham, NC, UNITED STATES

PA Oregon Health Sciences University, Portland, OR (U.S. corporation)

PI US 2003082684 A1 20030501

US 6828123 B2 20041207

AI US 2002-116260 A1 20020403 (10)

RLI Division of Ser. No. US 1999-254590, filed on 24 May 1999, PENDING A 371 of International Ser. No. WO 1997-US16033, filed on 10 Sep 1997, PENDING

PRAI US 1996-26451P 19960911 (60)

US 1997-40052P 19970307 (60)

US 1997-45233P 19970417 (60)

DT Utility

FS APPLICATION

LREP TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO CENTER, EIGHTH FLOOR, SAN FRANCISCO, CA, 94111-3834

CLMN Number of Claims: 55

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 4928

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention relates to small and intermediate conductance, calcium-activated potassium channel proteins. More specifically, the invention relates to compositions and methods for making and detecting calcium-activated potassium channel proteins and the nucleic acids encoding calcium-activated potassium channel proteins. The invention also provides methods and compositions for assaying compounds which

increase or decrease potassium ion flux through a calcium-activated potassium channel.

L10 ANSWER 70 OF 111 USPATFULL on STN
AN 2003:120202 USPATFULL
TI Small and intermediate conductance, calcium-activated potassium channels and uses thereof
IN Adelman, John P., Portland, OR, UNITED STATES
Maylie, James, Portland, OR, UNITED STATES
Bond, Chris T., Portland, OR, UNITED STATES
Silvia, Christopher P., Durham, NC, UNITED STATES
PA Oregon Health Sciences University, Portland, OR, UNITED STATES, 97201 (U.S. corporation)
PI US 2003082683 A1 20030501
US 6828122 B2 20041207
AI US 2002-115415 A1 20020402 (10)
RLI Division of Ser. No. US 1999-254590, filed on 24 May 1999, PENDING A 371 of International Ser. No. WO 1997-US16033, filed on 10 Sep 1997, PENDING
PRAI US 1996-26451P 19960911 (60)
US 1997-40052P 19970307 (60)
US 1997-45233P 19970417 (60)
DT Utility
FS APPLICATION
LREP TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO CENTER, EIGHTH FLOOR, SAN FRANCISCO, CA, 94111-3834
CLMN Number of Claims: 55
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 4896

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention relates to small and intermediate conductance, calcium-activated potassium channel proteins. More specifically, the invention relates to compositions and methods for making and detecting calcium-activated potassium channel proteins and the nucleic acids encoding calcium-activated potassium channel proteins. The invention also provides methods and compositions for assaying compounds which increase or decrease potassium ion flux through a calcium-activated potassium channel.

L10 ANSWER 71 OF 111 USPATFULL on STN
AN 2003:81453 USPATFULL
TI Antibodies specific for ungulate PrP
IN Prusiner, Stanley B., San Francisco, CA, United States
Safar, Jiri, Concord, CA, United States
Williamson, R. Anthony, San Diego, CA, United States
Burton, Dennis R., La Jolla, CA, United States
PA The Regents of the University of California, Oakland, CA, United States (U.S. corporation)
The Scripps Research Institute, La Jolla, CA, United States (U.S. corporation)
PI US 6537548 B1 20030325
AI US 2000-627218 20000727 (9)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Housel, James; Assistant Examiner: Winkler, Ulrike
LREP Bozicevic, Karl, Bozicevic, Field & Francis LLP
CLMN Number of Claims: 8
ECL Exemplary Claim: 1
DRWN 13 Drawing Figure(s); 9 Drawing Page(s)
LN.CNT 2073

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides antibodies that specifically bind with a high degree of binding affinity to a native ungulate PrP^{sup.C} and/or a denatured ungulate PrP^{sup.Sc}, but not to a native ungulate PrP^{sup.Sc}. Preferred antibodies find native bovine PrP^{sup.C} and treated PrP^{sup.Sc} but not native bovine PrP^{sup.Sc} and can be used in an assay to determine if a sample is infected with infectious prions, i.e. PrP^{sup.Sc}.

L10 ANSWER 72 OF 111 USPATFULL on STN
AN 2003:74128 USPATFULL
TI Biological materials and methods useful in the diagnosis and treatment
of diseases
IN Collinge, John, London, UNITED KINGDOM
Clarke, Anthony R., London, UNITED KINGDOM
Jackson, Graham S., London, UNITED KINGDOM
PA D. Gen Limited, London, UNITED KINGDOM (non-U.S. corporation)
PI US 6534036 B1 20030318
AI US 1999-431887 19991102 (9)
PRAI GB 1998-24091 19981104
GB 1999-6217 19990318
DT Utility
FS GRANTED
EXNAM Primary Examiner: Swartz, Rodney P
LREP Mersereau, C. G., Nikolai & Mersereau, P.A.
CLMN Number of Claims: 5
ECL Exemplary Claim: 1
DRWN 6 Drawing Figure(s); 10 Drawing Page(s)
LN.CNT 3459

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to a method of making a β -form of a **prion** protein which preferably has more β -sheet than α -helix structure and is soluble in the absence of a denaturant and/or is non-aggregated and exhibits partial resistance to digestion with **proteinase K**. The invention also relates to use of the β -form in medicine, especially for raising antibodies useful in the treatment and/or diagnosis of **prion** diseases. The invention also relates to methods of screening for compounds which are capable of inhibiting and/or reversing the conversion of the native α -form of a **prion** protein to a β -form, and to uses of identified compounds in medicine.

L10 ANSWER 73 OF 111 USPATFULL on STN
AN 2003:70964 USPATFULL
TI Agent
IN Weissmann, Charles, London, UNITED KINGDOM
Enari, Masato, Tokyo, JAPAN
PI US 2003049249 A1 20030313
AI US 2001-985164 A1 20011101 (9)
PRAI GB 2001-22162 20010913
DT Utility
FS APPLICATION
LREP Michele M. Simkin, FOLEY & LARDNER, Washington Harbour, 3000 K Street,
N.W., Suite 500, Washington, DC, 20007-5109
CLMN Number of Claims: 8
ECL Exemplary Claim: 1
DRWN 4 Drawing Page(s)
LN.CNT 1557

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to a method of treating or preventing **prion** infection in a subject comprising administering to said subject a therapeutically effective amount of an agent wherein said agent cleaves PrPC.

L10 ANSWER 74 OF 111 USPATFULL on STN
AN 2003:64789 USPATFULL
TI Small and intermediate conductance, calcium-activated potassium channels
and uses thereof
IN Adelman, John P., Portland, OR, UNITED STATES
Maylie, James, Portland, OR, UNITED STATES
Bond, Chris T., Portland, OR, UNITED STATES
Silvia, Christopher P., Durham, NC, UNITED STATES
PA Oregon Health Sciences University, Portland, OR (U.S. corporation)
PI US 2003044910 A1 20030306
US 6828420 B2 20041207
AI US 2002-115671 A1 20020403 (10)

RLI Division of Ser. No. US 1999-254590, filed on 24 May 1999, PENDING A 371
of International Ser. No. WO 1997-US16033, filed on 10 Sep 1997, PENDING
PRAI US 1996-26451P 19960911 (60)
US 1997-40052P 19970307 (60)
US 1997-45233P 19970417 (60)
DT Utility
FS APPLICATION
LREP TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO CENTER, EIGHTH
FLOOR, SAN FRANCISCO, CA, 94111-3834
CLMN Number of Claims: 50
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 4796

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention relates to small and intermediate conductance,
calcium-activated potassium channel proteins. More specifically, the
invention relates to compositions and methods for making and detecting
calcium-activated potassium channel proteins and the nucleic acids
encoding calcium-activated potassium channel proteins. The invention
also provides methods and compositions for assaying compounds which
increase or decrease potassium ion flux through a calcium-activated
potassium channel.

L10 ANSWER 75 OF 111 USPATFULL on STN

AN 2003:64747 USPATFULL
TI Method for detecting **prion** proteins in tissue samples
IN Aslamkhan, Abubakr, Durham, NC, UNITED STATES
Higgins, Donald, Franklinton, NC, UNITED STATES
PI US 2003044868 A1 20030306
AI US 2001-924812 A1 20010808 (9)
DT Utility
FS APPLICATION
LREP PARADIGM GENETICS, INC, 108 ALEXANDER DRIVE, P O BOX 14528, RTP, NC,
27709-4528
CLMN Number of Claims: 13
ECL Exemplary Claim: 1
DRWN 4 Drawing Page(s)
LN.CNT 778

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Surprisingly, the present inventors have discovered that thermal
denaturation of **prion** protein facilitates its detection by
immunological methods. Accordingly, the present invention provides
methods for the preparation and thermal denaturation of samples for
prion detection, comprising: homogenizing a candidate sample and
heating said sample in a buffer, preferably one with properties that aid
stabilization of the denatured form of the protein. The methods
described in this disclosure can be used in the detection of PrP.sup.Sc.
Such detection is useful for the diagnosis of transmissible spongiform
encephalopathies. This method can be used with **immunoassays** of
various formats, including, but not limited to, dot blot and
western blot assays, which utilize polyclonal
antibodies, **monoclonal** antibodies, antibody fragments,
receptors, natural and synthetic ligands and other entities.

L10 ANSWER 76 OF 111 USPATFULL on STN

AN 2003:57484 USPATFULL
TI Small and intermediate conductance, calcium-activated potassium channels
and uses thereof
IN Adelman, John P., Portland, OR, UNITED STATES
Maylie, James, Portland, OR, UNITED STATES
Bond, Chris T., Portland, OR, UNITED STATES
Silvia, Christopher W., Durham, NC, UNITED STATES
PA Oregon Health Sciences University, Portland, OR, UNITED STATES, 97201
(U.S. corporation)
PI US 2003040048 A1 20030227
AI US 2002-116561 A1 20020403 (10)
RLI Division of Ser. No. US 1999-254590, filed on 24 May 1999, PENDING A 371
of International Ser. No. WO 1997-US16033, filed on 10 Sep 1997, UNKNOWN

PRAI US 1996-26451P 19960911 (60)
 US 1997-40052P 19970307 (60)
 US 1997-45233P 19970417 (60)
 DT Utility
 FS APPLICATION
 LREP TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO CENTER, EIGHTH
 FLOOR, SAN FRANCISCO, CA, 94111-3834
 CLMN Number of Claims: 55
 ECL Exemplary Claim: 1
 DRWN No Drawings
 LN.CNT 4870
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB This invention relates to small and intermediate conductance,
 calcium-activated potassium channel proteins. More specifically, the
 invention relates to compositions and methods for making and detecting
 calcium-activated potassium channel proteins and the nucleic acids
 encoding calcium-activated potassium channel proteins. The invention
 also provides methods and compositions for assaying compounds which
 increase or decrease potassium ion flux through a calcium-activated
 potassium channel.

L10 ANSWER 77 OF 111 USPATFULL on STN
 AN 2003:33306 USPATFULL
 TI Methods for detection of **prion** protein as an indication of
 transmissible spongiform encephalopathies
 IN O'Rourke, Katherine I., Pullman, WA, United States
 Knowles, Donald P., Pullman, WA, United States
 Baszler, Timothy V., Moscow, ID, United States
 Parish, Steven M., Pullman, WA, United States
 PA The United States of America as represented by the Secretary of
 Agriculture, Washington, DC, United States (U.S. government)
 Washington State University Research Foundation, Pullman, WA, United
 States (U.S. corporation)
 PI US 6514707 B1 20030204
 AI US 2000-687672 20001012 (9)
 RLI Division of Ser. No. US 1997-950271, filed on 14 Oct 1997, now patented,
 Pat. No. US 6165784
 DT Utility
 FS GRANTED
 EXNAM Primary Examiner: Navarro, Mark
 LREP Connor, Margaret A., Silverstein, M. Howard, Fado, John D.
 CLMN Number of Claims: 12
 ECL Exemplary Claim: 1
 DRWN 0 Drawing Figure(s); 0 Drawing Page(s)
 LN.CNT 883
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB Methods to detect **prion** or PrP-Sc protein as an indication of
 transmissible spongiform encephalopathies (**TSEs**), including
 preclinical detection of infected live animals, and postmortem detection
 methods, are described. In one aspect, the invention is directed to a
 non-invasive diagnostic assay using third eyelid-associated lymphoid
 tissue. In another aspect, the invention is directed to
monoclonal antibodies that specifically bind a conserved epitope
 of PrP-Sc protein in fixed or frozen treated tissue.

L10 ANSWER 78 OF 111 USPATFULL on STN
 AN 2003:30264 USPATFULL
 TI G-protein coupled receptor and uses therefor
 IN Blatcher, Maria, Moorestown, NJ, UNITED STATES
 Bates, Brian Gaither, Chelmsford, MA, UNITED STATES
 Paulsen, Janet Elizabeth, Londonderry, NH, UNITED STATES
 PA Wyeth, Madison, NJ (U.S. corporation)
 PI US 2003022211 A1 20030130
 AI US 2002-166221 A1 20020607 (10)
 PRAI US 2001-297131P 20010607 (60)
 DT Utility
 FS APPLICATION
 LREP WYETH, PATENT LAW GROUP, FIVE GIRALDA FARMS, MADISON, NJ, 07940

CLMN Number of Claims: 41

ECL Exemplary Claim: 1

DRWN 16 Drawing Page(s)

LN.CNT 4491

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention is based on the identification of a G-protein coupled receptor (GPCR) that is expressed predominantly in the brain and placenta and nucleic acid molecules that encoded the GPCR, which is referred to herein as the hCAR protein and hCAR gene respectively (for human Constitutively Active Receptor). Based on this identification, the present invention provides: (1) isolated hCAR protein; (2) isolated nucleic acid molecules that encode an hCAR protein; (3) antibodies that selectively bind to the hCAR protein; (4) methods of isolating allelic variants of the hCAR protein and gene; (5) methods of identifying cells and tissues that express the hCAR protein/gene; (6) methods of identifying agents and cellular compounds that bind to the hCAR protein; (7) methods of identifying agents that modulate the expression of the hCAR gene; and (8) methods of modulating the activity of the hCAR protein in a cell or organism.

L10 ANSWER 79 OF 111 USPATFULL on STN

AN 2003:24323 USPATFULL

TI Mammalian chemokine reagents

IN Wang, Wei, Palo Alto, CA, UNITED STATES

Gish, Kurt C., Sunnyvale, CA, UNITED STATES

Schall, Thomas J., Menlo Park, CA, UNITED STATES

Vicari, Alain, Mountain View, CA, UNITED STATES

Zlotnik, Albert, Palo Alto, CA, UNITED STATES

PA Schering Corporation, a New Jersey corporation (U.S. corporation)

PI US 2003018167 A1 20030123

US 6723520 B2 20040420

AI US 2002-39659 A1 20020103 (10)

RLI Division of Ser. No. US 1997-887977, filed on 3 Jul 1997, ABANDONED

PRAI US 1996-21664P 19960705 (60)

US 1996-28329P 19961011 (60)

US 1997-48593P 19970604 (60)

DT Utility

FS APPLICATION

LREP DNAX Research, Inc., 901 California Avenue, Palo Alto, CA, 94304-1104

CLMN Number of Claims: 22

ECL Exemplary Claim: 1

DRWN 1 Drawing Page(s)

LN.CNT 4211

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Novel chemokines from mammals, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding said chemokines. Chemokine receptors are also provided. Methods of using said reagents and diagnostic kits are also provided.

L10 ANSWER 80 OF 111 USPATFULL on STN

AN 2002:339249 USPATFULL

TI Transgenic animals expressing heparanase and its uses

IN Zcharia, Eyal, Kiryat Hayovel, ISRAEL

Vlodavsky, Israel, Mevaseret Zion, ISRAEL

Metzger, Shula, Beit Hakerem, ISRAEL

Chajek-Shaul, Tova, Ramat Sharett, ISRAEL

Goldshmidt, Orit, Kiryat Yovel, ISRAEL

Pecker, Iris, Rishon LeZion, ISRAEL

Ilan, Neta, Rehovot, ISRAEL

PA Insight Strategy & Marketing Ltd. (non-U.S. corporation)

PI US 2002194625 A1 20021219

AI US 2001-864321 A1 20010525 (9)

DT Utility

FS APPLICATION

LREP G.E. EHRLICH (1995) LTD., c/o ANTHONY CASTORINA, SUITE 207, 2001

JEFFERSON DAVIS HIGHWAY, ARLINGTON, VA, 22202

CLMN Number of Claims: 24

ECL Exemplary Claim: 1

DRWN 3 Drawing Page(s)

LN.CNT 1264

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A transgenic animal expressing heparanase from a transgene, methods for its preparation, compositions-of-matter derived therefrom and its uses.

L10 ANSWER 81 OF 111 USPATFULL on STN

AN 2002:337398 USPATFULL

TI Small and intermediate conductance, calcium-activated potassium channels and uses thereof

IN Adelman, John P., Portland, OR, UNITED STATES

Maylie, James, Portland, OR, UNITED STATES

Bond, Chris T., Portland, OR, UNITED STATES

Silvia, Christopher P., Durham, NC, UNITED STATES

PA Oregon Health Sciences University, Portland, OR, UNITED STATES, 97201 (U.S. corporation)

PI US 2002192757 A1 20021219

US 6894147 B2 20050517

AI US 2002-115695 A1 20020403 (10)

RLI Division of Ser. No. US 1999-254590, filed on 24 May 1999, PENDING A 371 of International Ser. No. WO 1997-US16033, filed on 10 Sep 1997, UNKNOWN

PRAI US 1996-26451P 19960911 (60)

US 1997-40052P 19970307 (60)

US 1997-45233P 19970417 (60)

DT Utility

FS APPLICATION

LREP TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO CENTER, EIGHTH FLOOR, SAN FRANCISCO, CA, 94111-3834

CLMN Number of Claims: 55

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 4892

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention relates to small and intermediate conductance, calcium-activated potassium channel proteins. More specifically, the invention relates to compositions and methods for making and detecting calcium-activated potassium channel proteins and the nucleic acids encoding calcium-activated proteins. The invention also provides methods for assaying compounds which increase or decrease potassium ion flux through a calcium-activated potassium channel.

L10 ANSWER 82 OF 111 USPATFULL on STN

AN 2002:295329 USPATFULL

TI SMALL AND INTERMEDIATE CONDUCTANCE, CALCIUM-ACTIVATED POTASSIUM CHANNELS AND USES THEREOF

IN ADELMAN, JOHN P., PORTLAND, OR, UNITED STATES

MAYLIE, JAMES, PORTLAND, OR, UNITED STATES

BOND, CHRIS T., PORTLAND, OR, UNITED STATES

SILVIA, CHRISTOPHER P., DURHAM, NC, UNITED STATES

PI US 2002165379 A1 20021107

US 6797486 B2 20040928

AI US 1999-254590 A1 19990524 (9)

WO 1997-US16033 19970910

DT Utility

FS APPLICATION

LREP TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO CENTER, EIGHTH FLOOR, SAN FRANCISCO, CA, 94111-3834

CLMN Number of Claims: 55

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 4892

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention relates to small and intermediate conductance, calciumactivated potassium channel proteins. More specifically, the invention relates to compositions and methods for making and detecting calciumactivated potassium channel proteins and the nucleic acids encoding calciumactivated potassium channel proteins. The invention also provides methods and compositions for assaying compounds which increase

or decrease potassium ion flux through a calciumactivated potassium channel.

L10 ANSWER 83 OF 111 USPATFULL on STN

AN 2002:295102 USPATFULL

TI Brain-associated inhibitor of tissue-type plasminogen activator

IN Yepes, Manuel, Alexandria, VA, UNITED STATES

Lawrence, Daniel A., Derwood, MD, UNITED STATES

Coleman, Timothy A., Gaithersburg, MD, UNITED STATES

PI US 2002165147 A1 20021107

AI US 2001-987021 A1 20011113 (9)

RLI Continuation-in-part of Ser. No. US 2001-957485, filed on 21 Sep 2001,
PENDING Continuation of Ser. No. US 2000-521664, filed on 8 Mar 2000,
ABANDONED Continuation of Ser. No. US 2000-722292, filed on 28 Nov 2000,
PENDING Division of Ser. No. US 1999-348817, filed on 8 Jul 1999,
GRANTED, Pat. No. US 6191260 Division of Ser. No. US 1997-948997, filed
on 10 Oct 1997, GRANTED, Pat. No. US 6008020

PRAI US 2000-247971P 20001114 (60)

US 1999-123704P 19990310 (60)

US 1996-28117P 19961011 (60)

DT Utility

FS APPLICATION

LREP HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850

CLMN Number of Claims: 24

ECL Exemplary Claim: 1

DRWN 27 Drawing Page(s)

LN.CNT 9975

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to a novel BAIT protein which is a member
of serpin superfamily which is expressed primarily in brain tissue. In
particular, isolated nucleic acid molecules are provided encoding the
human and recombinant methods for producing the same. The invention
further relates to screening methods for identifying agonists and
antagonists of BAIT activity. Also provided are diagnostic methods for
detecting nervous system-related disorders and therapeutic methods for
treating nervous system-related disorders. Additionally, the present
invention is related to methods of treating patients with BAIT
polynucleotides or polypeptides, wherein said patients have had seizures
or epilepsy.

L10 ANSWER 84 OF 111 USPATFULL on STN

AN 2002:294618 USPATFULL

TI Diagnostic method for a transmissible spongiform encephalopathy or a
prion disease

IN Clinton, Michael, Roslin, UNITED KINGDOM

Miele, Gino, Roslin, UNITED KINGDOM

Manson, Jean Catherine, Newbury, UNITED KINGDOM

PI US 2002164661 A1 20021107

AI US 2001-999305 A1 20011031 (9)

PRAI GB 2000-26604 20001031

DT Utility

FS APPLICATION

LREP HALE AND DORR, LLP, 60 STATE STREET, BOSTON, MA, 02109

CLMN Number of Claims: 14

ECL Exemplary Claim: 1

DRWN 13 Drawing Page(s)

LN.CNT 1175

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method is provided for the diagnosis of a transmissible spongiform
encephalopathy (**TSE**) or **prion** disease in an animal
which comprises assaying a sample obtained from said animal to determine
the number of hematopoietic cells of the erythroid, megakaryocyte or
platelet cell lineages in the sample or an expression product thereof.

L10 ANSWER 85 OF 111 USPATFULL on STN

AN 2002:280095 USPATFULL

TI Small and intermediate conductance, calcium-activated potassium channels
and uses thereof

IN Adelman, John P., Portland, OR, UNITED STATES
Maylie, James, Portland, OR, UNITED STATES
Bond, Chris T., Portland, OR, UNITED STATES
Silvia, Christopher P., Durham, NC, UNITED STATES
PI US 2002155531 A1 20021024
US 6692937 B2 20040217
AI US 2001-922364 A1 20010803 (9)
RLI Division of Ser. No. US 1999-254590, filed on 24 May 1999, PENDING A 371
of International Ser. No. WO 1997-US16033, filed on 10 Sep 1997, UNKNOWN
PRAI US 1996-26451P 19960911 (60)
US 1997-40052P 19970307 (60)
US 1997-45233P 19970417 (60)
DT Utility
FS APPLICATION
LREP TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO CENTER, EIGHTH
FLOOR, SAN FRANCISCO, CA, 94111-3834
CLMN Number of Claims: 28
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 4728

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention relates to small and intermediate conductance, calcium
activated potassium channel proteins. More specifically, the invention
relates to compositions and methods for making and detecting calcium
activated potassium channel proteins and the nucleic acids encoding
calcium activated potassium channel proteins. The invention also
provides methods and compositions for assaying compounds which increase
or decrease potassium ion flux through a calcium activated potassium
channel.

L10 ANSWER 86 OF 111 USPATFULL on STN

AN 2002:265546 USPATFULL
TI Human V2 vomeronasal receptor
IN Lok, Si, Seattle, WA, UNITED STATES
Holloway, James L., Seattle, WA, UNITED STATES
PI US 2002146418 A1 20021010
AI US 2001-3356 A1 20011115 (10)
PRAI US 2000-252373P 20001121 (60)
DT Utility
FS APPLICATION
LREP Phillip B.C. Jones, J.D., Ph.D., ZymoGenetics, Inc., 1201 Eastlake
Avenue East, Seattle, WA, 98102
CLMN Number of Claims: 18
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 4076

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB In mammals, the vomeronasal organ, which detects pheromones, resides in a
blind-ended pouch within the septum of the nose. Vomeronasal
organ-derived signals bypass higher cognitive centers and are processed
directly in regions of the amygdala and hypothalamus, which have been
implicated in the regulation of innate behavior, reproductive
physiology, and other neuroendocrine responses. Zvn2R1 encodes a human
vomeronasal receptor.

L10 ANSWER 87 OF 111 USPATFULL on STN

AN 2002:246898 USPATFULL
TI Transgenic mice expressing human APP and TGF- β demonstrate
cerebrovascular amyloid deposits
IN Mucke, Lennart, Foster City, CA, United States
Wyss-Coray, Tony, Berkeley, CA, United States
Masliah, Eliezer, Chula Vista, CA, United States
PA The Regents of the University of California, Oakland, CA, United States
(U.S. corporation)
PI US 6455757 B1 20020924
AI US 1999-262519 19990304 (9)
RLI Continuation-in-part of Ser. No. US 1997-947295, filed on 8 Oct 1997
DT Utility

FS GRANTED
EXNAM Primary Examiner: Crouch, Deborah
LREP Francis, Carol L., Borden, Paula A., Bozicevic, Field & Francis, LLP
CLMN Number of Claims: 14
ECL Exemplary Claim: 1
DRWN 9 Drawing Figure(s); 6 Drawing Page(s)
LN.CNT 1966

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention features non-human transgenic animal models for Alzheimer's disease (AD) and CAA, wherein the transgenic animal is characterized by 1) expression of bioactive transforming growth factor- β 1 (TGF- β 1) or 2) both expression of bioactive TGF- β 1 and expression of a human amyloid β precursor protein (APP) gene product. The transgenic animals may be either homozygous or heterozygous for these alterations. Bigenic animals are further characterized by development of AD-associated and/or CAA-associated pathology within about two to three months of age, and at about twelve months of age are characterized by a reduced number of neuritic plaques relative to singly transgenic animals. The invention also features methods of screening for biologically active agents that facilitate reduction of β -amyloid deposits in vivo and methods for facilitating reduction of formation of neuritic plaques in a subject susceptible to AD.

L10 ANSWER 88 OF 111 USPATFULL on STN

AN 2002:246848 USPATFULL
TI Dermatophagoides nucleic acid molecules, proteins and uses thereof
IN McCall, Catherine A., Boulder, CO, United States
Hunter, Shirley Wu, Fort Collins, CO, United States
Weber, Eric R., Fort Collins, CO, United States
PA Heska Corporation, Fort Collins, CO, United States (U.S. corporation)
PI US 6455686 B1 20020924
AI US 1999-292225 19990415 (9)
PRAI US 1998-98909P 19980902 (60)
US 1998-85295P 19980513 (60)
US 1998-98565P 19980417 (60)

DT Utility

FS GRANTED

EXNAM Primary Examiner: Crouch, Deborah; Assistant Examiner: Woitach, Joseph
LREP Heska Corporation
CLMN Number of Claims: 22
ECL Exemplary Claim: 1
DRWN 2 Drawing Figure(s); 2 Drawing Page(s)
LN.CNT 5011

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to high molecular weight Dermatophagoides proteins, nucleic acid molecules encoding such proteins, and therapeutic and diagnostic reagents derived from such proteins.

L10 ANSWER 89 OF 111 USPATFULL on STN

AN 2002:235431 USPATFULL
TI Intraflagellar transport
IN Witman, George B., Grafton, MA, UNITED STATES
Pazour, Gregory J., Framingham, MA, UNITED STATES
Rosenbaum, Joel L., Branford, CT, UNITED STATES
Cole, Douglas G., Pullman, WA, UNITED STATES
PI US 2002127620 A1 20020912
AI US 2001-866582 A1 20010524 (9)
PRAI US 2000-206923P 20000524 (60)
DT Utility
FS APPLICATION
LREP J. PETER FASSE, FISH & RICHARDSON P.C., 225 Franklin Street, Boston, MA, 02110-2804
CLMN Number of Claims: 36
ECL Exemplary Claim: 1
DRWN 28 Drawing Page(s)
LN.CNT 4367

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to various intraflagellar transport (IFT) polypeptides and the nucleic acids that encode them. The new IFT particle polypeptides and nucleic acids can be used in a variety of diagnostic, screening, and therapeutic methods.

L10 ANSWER 90 OF 111 USPATFULL on STN

AN 2002:227919 USPATFULL

TI Assay for disease related conformation of a protein and isolating same

IN Prusiner, Stanley B., San Francisco, CA, UNITED STATES

Safar, Jiri G., Walnut Creek, CA, UNITED STATES

PI US 2002123072 A1 20020905

US 6677125 B2 20040113

AI US 2002-47431 A1 20020114 (10)

RLI Continuation of Ser. No. US 2001-754443, filed on 3 Jan 2001, PENDING
Continuation of Ser. No. US 1998-169574, filed on 9 Oct 1998, GRANTED,
Pat. No. US 6214565 Continuation of Ser. No. US 1998-26967, filed on 20
Feb 1998, GRANTED, Pat. No. US 5977324

DT Utility

FS APPLICATION

LREP BOZICEVIC, FIELD & FRANCIS LLP, 200 MIDDLEFIELD RD, SUITE 200, MENLO
PARK, CA, 94025

CLMN Number of Claims: 27

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 1643

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB An assay method is disclosed which isolates and detects the presence of a disease related conformation of a protein (e.g., PrP.sup.Sc) present in a sample also containing the non-disease related conformation of the protein (e.g., PrP.sup.C). The sample is treated (e.g., contacted with protease) in a manner which hydrolyzes the disease related conformation and not the non-disease related conformation. The treated sample is contacted with a binding partner (e.g., a **labeled** antibody which binds PrP.sup.Sc) and the occurrence of binding provides and indication that PrP.sup.Sc is present. Alternatively the PrP.sup.Sc of the treated sample is denatured (e.g., contacted with guanadine) or unfolded. The unfolded PrP.sup.Sc is contacted with a binding partner and the occurrence of binding indicates the presence of PrP.sup.Sc in the sample. In another embodiment, PrP.sup.Sc and PrP.sup.C are reacted with a **labeled** antibody that binds both conformations and a conformation that binds only the disease related conformation, and the presence of the disease related conformation is determined by comparing the two.

L10 ANSWER 91 OF 111 USPATFULL on STN

AN 2002:199102 USPATFULL

TI Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof

IN Friedman, Jeffrey M., New York, NY, UNITED STATES

Halaas, Jeffrey L., New York, NY, UNITED STATES

Gajiwala, Ketan, New York, NY, UNITED STATES

Burley, Stephen K., New York, NY, UNITED STATES

Zhang, Yiying, New York, NY, UNITED STATES

Proenca, Ricardo, Astoria, NY, UNITED STATES

Maffei, Margherita, New York, NY, UNITED STATES

PA The Rockefeller University (U.S. corporation)

PI US 2002107211 A1 20020808

AI US 2000-736084 A1 20001213 (9)

RLI Continuation of Ser. No. US 1995-485943, filed on 7 Jun 1995, PENDING

DT Utility

FS APPLICATION

LREP David A. Jackson, Esq., KLAUBER & JACKSON, 411 Hackensack Avenue,
Hackensack, NJ, 07601

CLMN Number of Claims: 53

ECL Exemplary Claim: 1

DRWN 52 Drawing Page(s)

LN.CNT 6895

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates generally to the control of body weight of animals including mammals and humans, and more particularly to materials identified herein as modulators of weight, and to the diagnostic and therapeutic uses to which such modulators may be put. In its broadest aspect, the present invention relates to the elucidation and discovery of nucleotide sequences, and proteins putatively expressed by such nucleotides or degenerate variations thereof, that demonstrate the ability to participate in the control of mammalian body weight. The nucleotide sequences in object represent the genes corresponding to the murine and human ob gene, that have been postulated to play a critical role in the regulation of body weight and adiposity. Preliminary data, presented herein, suggests that the polypeptide product of the gene in question functions as a hormone. The present invention further provides nucleic acid molecules for use as molecular probes, or as primers for polymerase chain reaction (PCR) amplification, i.e., synthetic or natural oligonucleotides. In further aspects, the present invention provides a cloning vector, which comprises the nucleic acids of the invention; and a bacterial, insect, or a mammalian expression vector, which comprises the nucleic acid molecules of the invention, operatively associated with an expression control sequence. Accordingly, the invention further relates to a bacterial or a mammalian cell transfected or transformed with an appropriate expression vector, and correspondingly, to the use of the above mentioned constructs in the preparation of the modulators of the invention. Also provided are antibodies to the ob polypeptide. Moreover, a method for modulating body weight of a mammal is provided. In specific examples, genes encoding two isoforms of both the murine and human ob polypeptides are provided.

L10 ANSWER 92 OF 111 USPATFULL on STN

AN 2002:191539 USPATFULL

TI Full-length human cDNAs encoding potentially secreted proteins

IN Milne Edwards, Jean-Baptiste Dumas, Paris, FRANCE

Bougueleret, Lydie, Petit Lancy, SWITZERLAND

Jobert, Severin, Paris, FRANCE

PI US 2002102604 A1 20020801

AI US 2000-731872 A1 20001207 (9)

PRAI US 1999-169629P 19991208 (60)

US 2000-187470P 20000306 (60)

DT Utility

FS APPLICATION

LREP John Lucas, Ph.D., J.D., Genset Corporation, 10665 Sorento Valley Road, San Diego, CA, 92121-1609

CLMN Number of Claims: 29

ECL Exemplary Claim: 1

DRWN 5 Drawing Page(s)

LN.CNT 28061

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention concerns GENSET polynucleotides and polypeptides. Such GENSET products may be used as reagents in forensic analyses, as chromosome markers, as tissue/cell/organelle-specific markers, in the production of expression vectors. In addition, they may be used in screening and diagnosis assays for abnormal GENSET expression and/or biological activity and for screening compounds that may be used in the treatment of GENSET-related disorders.

L10 ANSWER 93 OF 111 USPATFULL on STN

AN 2002:126308 USPATFULL

TI Apo-A-I regulation of T-cell signaling

IN Dayer, Jean-Michel, Geneva, SWITZERLAND

Burger, Danielle, Carouge, SWITZERLAND

Kohno, Tadahiko, Thousand Oaks, CA, UNITED STATES

Edwards, Carl K., III, Thousand Oaks, CA, UNITED STATES

PI US 2002064820 A1 20020530

AI US 2001-803918 A1 20010313 (9)

PRAI US 2000-189008P 20000313 (60)

US 2000-193551P 20000331 (60)

DT Utility

FS APPLICATION

LREP Finnegan, Henderson, Farabow, Garrett & Dunner, L.L.P., 1300 I Street,
N.W., Washington, DC, 20005-3315
CLMN Number of Claims: 61
ECL Exemplary Claim: 1
DRWN 14 Drawing Page(s)
LN.CNT 4242

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides AFTI polypeptides and nucleic acid molecules encoding the same. The invention also provides vectors, host cells, selective binding agents, and methods for producing AFTI polypeptides. Also provided are methods for the treatment, diagnosis, amelioration, or prevention of diseases with AFTI polypeptides, particularly IL-1 mediated diseases, TNF- α mediated diseases, and diseases involving monocyte activation.

L10 ANSWER 94 OF 111 USPATFULL on STN

AN 2002:95551 USPATFULL

TI Fragments of **prion** proteins

IN Fishleigh, Robert Vincent, Cheshire, UNITED KINGDOM

Robson, Barry, Cheshire, UNITED KINGDOM

Mee, Roger Paul, Manchester, UNITED KINGDOM

PA Proteus Molecular Design Limited, Macclesfield, UNITED KINGDOM (non-U.S. corporation)

PI US 6379905 B1 20020430

AI US 1998-76721 19980513 (9)

RLI Division of Ser. No. US 244701, now patented, Pat. No. US 5773572, issued on 30 Jun 1998

PRAI GB 1991-25747 19911203

GB 1992-14663 19920710

DT Utility

FS GRANTED

EXNAM Primary Examiner: Wortman, Donna C.

LREP Pennie & Edmonds LLP

CLMN Number of Claims: 18

ECL Exemplary Claim: 1

DRWN 0 Drawing Figure(s); 0 Drawing Page(s)

LN.CNT 2176

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Synthetic polypeptides having at least one antigenic site of a **prion** protein, methods for their use and manufacture, antibodies raised against such polypeptides and diagnostic kits containing these polypeptides or antibodies.

L10 ANSWER 95 OF 111 USPATFULL on STN

AN 2002:66639 USPATFULL

TI Compositions comprising heat shock proteins or alpha(2) macroglobulin, antigenic molecules and saponins, and methods of use thereof

IN Armen, Garo H., Manhasset, NY, UNITED STATES

PI US 2002037290 A1 20020328

AI US 2001-909778 A1 20010720 (9)

PRAI US 2000-223133P 20000807 (60)

DT Utility

FS APPLICATION

LREP Pennie & Edmonds LLP, 1155 Avenue of the Americas, New York, NY, 10036-2711

CLMN Number of Claims: 119

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 4136

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to pharmaceutical compositions and methods for the prevention and treatment of autoimmune diseases, infectious diseases, neurodegenerative diseases, and primary and metastatic neoplastic diseases. In the practice of the invention, the compositions are employed comprising: (a) a heat shock protein (hsp) or an alpha(2)macroglobulin (α 2M); (b) a saponin; and, optionally, (c) an antigenic molecule. The antigenic molecule displays the antigenicity of an antigen of: (a) a cell that elicits an autoimmune response; (b) an

agent of an infectious disease; (c) a cancerous cell; or (d) a cell or structure associated with a neurodegenerative or amyloid disease. The hsps that can be used in the practice of the invention include but are not limited to hsp70, hsp90, gp96, calreticulin, hsp 110, grp 170, and PDI, alone or in combination with each other. The antigenic molecule can be covalently or noncovalently bound to the hsp or α 2M, free in solution, and/or covalently bound to the saponin. The compositions of the invention can be administered alone or in combination with the administration of antigen presenting cells sensitized with an hsp- or α 2M-antigenic molecule complex.

L10 ANSWER 96 OF 111 USPATFULL on STN

AN 2002:32174 USPATFULL

TI Methods and compositions for diagnosing tauopathies

IN Ghetti, Bernardino, Indianapolis, IN, UNITED STATES

Spillantini, Maria Grazia, Cambridge, UNITED KINGDOM

Murrell, Jill R., Avon, IN, UNITED STATES

Goedert, Michel, Cambridge, UNITED KINGDOM

Farlow, Martin, Indianapolis, IN, UNITED STATES

Klug, Aaron, Cambridge, UNITED KINGDOM

PA Advanced Research and Technology (non-U.S. corporation)

PI US 2002018995 A1 20020214

AI US 2000-726771 A1 20001129 (9)

RLI Continuation of Ser. No. WO 1999-US12036, filed on 28 May 1999, UNKNOWN

PRAI US 1998-87557P 19980601 (60)

DT Utility

FS APPLICATION

LREP Steven L. Highlander, FULBRIGHT & JAWORSKI L.L.P., Suite 2400, 600

Congress Avenue, Austin, TX, 78701

CLMN Number of Claims: 46

ECL Exemplary Claim: 1

DRWN 4 Drawing Page(s)

LN.CNT 2728

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates generally to methods and compositions for the diagnosis, modeling and treatment of tau-related pathologies. In particular, the present invention shows that mutations in the tau gene lead to neurofibrillary tangle formation. More specifically gene mutations are described that lead to alterations in ratios of tau isoforms are shown to lead to the formation of abnormal tau filaments.

L10 ANSWER 97 OF 111 USPATFULL on STN

AN 2002:8938 USPATFULL

TI Models of prion disease

IN Prusiner, Stanley B., San Francisco, CA, UNITED STATES

Korth, Carsten, San Francisco, CA, UNITED STATES

PI US 2002004938 A1 20020110

US 6767712 B2 20040727

AI US 2001-895963 A1 20010628 (9)

RLI Continuation of Ser. No. US 1999-318888, filed on 26 May 1999, PENDING

DT Utility

FS APPLICATION

LREP Karl Bozicevic, BOZICEVIC, FIELD & FRANCIS, LLP, Suite 200, 200

Middlefield Road, Menlo Park, CA, 94025

CLMN Number of Claims: 22

ECL Exemplary Claim: 1

DRWN No Drawings.

LN.CNT 1413

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides a novel PrP protein, and nucleic acids encoding this protein, where the PrP protein is characterized in vivo by 1) incomplete glycosylation relative to glycosylation of wild-type PrP^{sup.C} and 2) proper cellular localization, i.e. an ability to be transported to the cell surface. This novel, under-glycosylated PrP, unlike its normal cellular counterpart, can easily be converted into a protease-resistant isoform by incubation with infectious prions. The invention further provides systems for the study of prion disorders and methods of using these systems, e.g. the study of the

mechanical processes in progression of **prion**-mediated disease or the identification of new therapeutic agents for treatment of **prion**-mediated disorders. In such systems, protease-resistant under-glycosylated PrP is generated de novo and can be detected by standard immunoblot techniques.

L10 ANSWER 98 OF 111 USPATFULL on STN

AN 2002:3842 USPATFULL

TI Assay for specific strains of multiple disease related conformations of a protein

IN Prusiner, Stanley B., San Francisco, CA, UNITED STATES

Safar, Jiri G., Concord, CA, UNITED STATES

Cohen, Fred E., San Francisco, CA, UNITED STATES

PI US 2002001817 A1 20020103

US 6617119 B2 20030909

AI US 2001-901865 A1 20010709 (9)

RLI Continuation of Ser. No. US 1998-151057, filed on 10 Sep 1998, PENDING

Continuation-in-part of Ser. No. US 1998-26957, filed on 20 Feb 1998,

ABANDONED Continuation-in-part of Ser. No. US 1997-804536, filed on 21

Feb 1997, GRANTED, Pat. No. US 5891641

DT Utility

FS APPLICATION

LREP Karl Bozicevic, Bozicevic, Field and Francis LLP, Suite 200, 200

Middlefield Road, Menlo Park, CA, 94025

CLMN Number of Claims: 20

ECL Exemplary Claim: 1

DRWN 19 Drawing Page(s)

LN.CNT 2676

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Assay methodology of the invention allows for: (1) determining if a sample contains a conformation of a protein which is associated with disease and the concentration and amount of such if present; (2) determining the amount of protease resistant disease related protein in a sample and by subtracting that amount from the total amount of disease related protein present determining the amount of protease sensitive disease protein in the sample; and (3) determining the strain and incubation time of a disease related protein by (i) relating the relative amounts of protease resistant and protease sensitive protein to known strains to thereby determine the strain; and (ii) plotting the concentration of protease sensitive protein on a graph of incubation time versus concentration of protease sensitive protein for known strains to predict the incubation time of an unknown strain of pathogenic protein in a sample.

L10 ANSWER 99 OF 111 USPATFULL on STN

AN 2001:152492 USPATFULL

TI **Proteinase K** resistant surface protein of neisseria meningitidis

IN Brodeur, Bernard R., Sillery, Canada

Martin, Denis, St-Augustin-de-Des Maures, Canada

Hamel, Josee, Sillery, Canada

Rioux, Clement, Ville-de-Cap-Rouge, Canada

PA BioChem Pharma Inc., Quebec, Canada (non-U.S. corporation)

PI US 6287574 B1 20010911

AI US 1997-913362 19971113 (8)

RLI Continuation of Ser. No. US 1995-406362, filed on 17 Mar 1995, now abandoned

PRAI US 1995-1983P 19950804 (60)

DT Utility

FS GRANTED

EXNAM Primary Examiner: Graser, Jennifer

LREP Foley & Lardner

CLMN Number of Claims: 9

ECL Exemplary Claim: 1

DRWN 27 Drawing Figure(s); 23 Drawing Page(s)

LN.CNT 2034

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A highly conserved, immunologically accessible antigen at the surface of

Neisseria meningitidis organisms. Immunotherapeutic, prophylactic and diagnostic compositions and methods useful in the treatment, prevention and diagnosis of Neisseria meningitidis diseases. A **proteinase K** resistant Neisseria meningitidis surface protein having an apparent molecular weight of 22 kDa, the corresponding nucleotide and derived amino acid sequences (SEQ ID NO: 1, NO:3, NO:5 and NO:7: SEQ ID NO: 2, NO:4, NO:6, and NO:8), recombinant DNA methods for the production of the Neisseria meningitidis 22 kDa surface protein, and antibodies that bind to the Neisseria meningitidis 22 kDa surface protein.

L10 ANSWER 100 OF 111 USPATFULL on STN

AN 2001:134006 USPATFULL

TI Assay for disease related conformation of a protein and isolating same
IN Prusiner, Stanley B., San Francisco, CA, United States
Safar, Jiri G., Concord, CA, United States

PI US 2001014455 A1 20010816

US 6406864 B2 20020618

AI US 2001-754443 A1 20010103 (9)

RLI Continuation of Ser. No. US 1998-169574, filed on 9 Oct 1998, GRANTED,
Pat. No. US 6214565

DT Utility

FS APPLICATION

LREP Karl Bozicevic, BOZICEVIC, FIELD & FRANCIS LLP, Suite 200, 200
Middlefield Road, Menlo Park, CA, 94025

CLMN Number of Claims: 27

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 1618

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB An assay method is disclosed which isolates and detects the presence of a disease related conformation of a protein (e.g., PrP.sup.Sc) present in a sample also containing the non-disease related conformation of the protein (e.g., PrP.sup.C). The sample is treated (e.g., contacted with protease) in a manner which hydrolyzes the disease related conformation and not the non-disease related conformation. The treated sample is contacted with a binding partner (e.g., a **labeled** antibody which binds PrP.sup.Sc) and the occurrence of binding provides and indication that PrP.sup.Sc is present. Alternatively the PrP.sup.Sc of the treated sample is denatured (e.g., contacted with guanadine) or unfolded. The unfolded PrP.sup.Sc is contacted with a binding partner and the occurrence of binding indicates the presence of PrP.sup.Sc in the sample. In another embodiment, PrP.sup.Sc and PrP.sup.C are reacted with a **labeled** antibody that binds both conformations and a conformation that binds only the disease related conformation, and the presence of the disease related conformation is determined by comparing the two.

L10 ANSWER 101 OF 111 USPATFULL on STN

AN 2001:112058 USPATFULL

TI **Monoclonal** antibodies and antibody cocktail for detection of
prion protein as an indication of transmissible spongiform
encephalopathies

IN O'Rourke, Katherine I., Albion, WA, United States

PA The United States of America as represented by the Secretary of
Agriculture, Washington, DC, United States (U.S. corporation)

PI US 6261790 B1 20010717

AI US 1999-353348 19990715 (9)

DT Utility

FS GRANTED

EXNAM Primary Examiner: Swartz, Rodney P

LREP Connor, Margaret A., Silverstein, M. Howard, Fado, John D.

CLMN Number of Claims: 20

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 954

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods to detect **prion** or PrP-Sc protein as an indication of
transmissible spongiform encephalopathies (**TSEs**) are

described. In one aspect, the invention is directed to **monoclonal** antibodies that specifically bind a conserved epitope of **prion** proteins and use of the antibodies in **immunoassays** to detect PrP-Sc, in fixed or unfixed tissue, as an indication of the presence of **TSE** infection. In another aspect, the invention is directed to a **monoclonal** antibody cocktail having the **monoclonal** antibody in combination with a second **monoclonal** antibody which specifically binds to a second conserved epitope of **prion** proteins. One or both **monoclonal** antibodies of the cocktail can recognize epitopes found in all mammalian species in which a natural **TSE** has been reported and in a number of closely related species. Thus, the antibody cocktail provides high sensitivity, defined specificity, and broad reactivity to PrP proteins in spite of interspecies and intraspecies variation of species such as ruminant livestock, cats, mink, humans, and non-human primates.

L10 ANSWER 102 OF 111 USPATFULL on STN

AN 2001:88925 USPATFULL

TI Assay for disease related conformation of a protein

IN Prusiner, Stanley B., San Francisco, CA, United States

Safar, Jiri G., Concord, CA, United States

PI US 2001001061 A1 20010510

AI US 2000-731419 A1 20001205 (9)

RLI Continuation of Ser. No. US 1998-26957, filed on 20 Feb 1998, PENDING
Continuation-in-part of Ser. No. US 1997-804536, filed on 21 Feb 1997,
GRANTED, Pat. No. US 5891641

DT Utility

FS APPLICATION

LREP Karl Bozicevic, BOZICEVIC, FIELD & FRANCIS LLP, Suite 200, 200
Middlefield Road, Menlo Park, CA, 94025

CLMN Number of Claims: 20

ECL Exemplary Claim: 1

DRWN 14 Drawing Page(s)

LN.CNT 2288

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB An assay method is disclosed which makes it possible to determine the presence of a diseased related conformation of a protein (e.g., PrP.sup.Sc or the β -sheet form of β A4) in a sample. A sample is divided into two portions and the first portion is cross-linked to a first solid support and then contacted with a **labeled** antibody which binds to a non-disease form of the protein with a higher degree of affinity (e.g., 4 to 30 fold higher) than to the disease form of the protein. The second portion is treated in a manner which causes any disease form of the protein to change conformation to a form with a higher binding affinity for the **labeled** antibody. The treated second portion is then bound to a second solid support and contacted with **labeled** antibody. The level of **labeled** antibody binding to a protein in the first and second portions is determined and the amounts measured in each are compared. The difference between the two measurements is an indication of whether the disease related conformation of the protein was present in the sample. The method can also determine the concentration of the disease related conformation and the particular strain present.

L10 ANSWER 103 OF 111 USPATFULL on STN

AN 2001:51789 USPATFULL

TI Assay for disease related conformation of a protein and isolating same

IN Prusiner, Stanley B., San Francisco, CA, United States

Safar, Jiri G., Concord, CA, United States

PA The Regents of the University of California, Oakland, CA, United States
(U.S. corporation)

PI US 6214565 B1 20010410

AI US 1998-169574 19981009 (9)

DT Utility

FS Granted

EXNAM Primary Examiner: Swartz, Rodney P.

LREP Bozicevic, Karl, DeVore, Dianna L.Bozicevic, Field & Francis LLP

CLMN Number of Claims: 25

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 1675

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB An assay method is disclosed which isolates and detects the presence of a disease related conformation of a protein (e.g., PrP.sup.Sc) present in a sample also containing the non-disease related conformation of the protein (e.g., PrP.sup.C). The sample is treated (e.g., contacted with protease) in a manner which hydrolyzes the disease related conformation and not the non-disease related conformation. The treated sample is contacted with a binding partner (e.g., a **labeled** antibody which binds PrP.sup.Sc) and the occurrence of binding provides and indication that PrP.sup.Sc is present. Alternatively the PrP.sup.Sc of the treated sample is denatured (e.g., contacted with guanadine) or unfolded. The unfolded PrP.sup.Sc is contacted with a binding partner and the occurrence of binding indicates the presence of PrP.sup.Sc in the sample. In another embodiment, PrP.sup.Sc and PrP.sup.C are reacted with a **labeled** antibody that binds both conformations and a conformation that binds only the disease related conformation, and the presence of the disease related conformation is determined by comparing the two.

L10 ANSWER 104 OF 111 USPATFULL on STN

AN 2001:8223 USPATFULL

TI Transgenic mouse model of alzheimer's disease and cerebral amyloid angiopathy

IN Mucke, Lennart, Foster City, CA, United States

Wyss-Coray, Tony, Berkeley, CA, United States

Masliah, Eliezer, Chula Vista, CA, United States

PA The Regents of the University of California, Oakland, CA, United States (U.S. corporation)

PI US 6175057 B1 20010116

AI US 1997-947295 19971008 (8)

DT Utility

FS Granted

EXNAM Primary Examiner: Crouch, Deborah

LREP Francis, Carol L., Borden, Paula A.Bozicevic, Field & Francis LLP

CLMN Number of Claims: 23

ECL Exemplary Claim: 1

DRWN 6 Drawing Figure(s); 5 Drawing Page(s)

LN.CNT 1697

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention features non-human transgenic animal models for Alzheimer's disease (AD) and CAA, wherein the transgenic animal is characterized by 1) overexpression of bioactive transforming growth factor- β 1 (TGF- β 1) or 2) both overexpression of bioactive TGF- β 1 and expression of a human amyloid β precursor protein (APP) gene product. The transgenic animals may be either homozygous or heterozygous for these alterations. Bigenic animals are further characterized by development of AD-associated and/or CAA-associated pathology within about two to three months of age.

L10 ANSWER 105 OF 111 USPATFULL on STN

AN 2000:174412 USPATFULL

TI Antibodies for the detection of **prion** protein as an indication of transmissible spongiform encephalopathies

IN O'Rourke, Katherine I., Albion, WA, United States

Knowles, Donald P., Pullman, WA, United States

Baszler, Timothy V., Moscow, ID, United States

Parish, Steven M., Pullman, WA, United States

PA The United States of America as represented by the Secretary of Agriculture, Washington, DC, United States (U.S. government)
Washington State University Research Foundation, Pullman, WA, United States (U.S. corporation)

PI US 6165784 20001226

AI US 1997-950271 19971014 (8)

DT Utility

FS Granted
EXNAM Primary Examiner: Navarro, Albert
LREP Silverstein, M. Howard, Fado, John D., Connor, Margaret A.
CLMN Number of Claims: 3
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 843

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods to detect **prion** or PrP-Sc protein as an indication of transmissible spongiform encephalopathies (**TSEs**), including preclinical detection of infected live animals, and postmortem detection methods, are described. In one aspect, the invention is directed to a non-invasive diagnostic assay using third eyelid-associated lymphoid tissue. In another aspect, the invention is directed to **monoclonal** antibodies that specifically bind a conserved epitope of PrP-Sc protein in fixed or frozen treated tissue.

L10 ANSWER 106 OF 111 USPATFULL on STN

AN 2000:98001 USPATFULL
TI Heterofunctional cellular immunological reagents, vaccines containing same and methods for the use of same
IN Zimmerman, Daniel H., Bethesda, MD, United States
Elliott, Donald A., Bethesda, MD, United States
PA Cel Sci Corporation, Alexandria, VA, United States (U.S. corporation)
PI US 6096315 20000801
AI US 1995-469923 19950606 (8)
RLI Division of Ser. No. US 1994-354751, filed on 8 Dec 1994, now patented, Pat. No. US 5652342 which is a continuation of Ser. No. US 1992-985750, filed on 4 Dec 1992, now abandoned which is a continuation of Ser. No. US 1991-731394, filed on 17 Jul 1991, now abandoned which is a continuation of Ser. No. US 1988-206381, filed on 14 Jun 1988, now abandoned

DT Utility
FS Granted
EXNAM Primary Examiner: Stucker, Jeffrey
CLMN Number of Claims: 18
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2023

AB The present invention relates to a heterofunctional cellular immunological reagent comprising at least two T cell specific binding ligands covalently linked together, wherein one of the T cell specific binding ligands binds to a specific class or subclass of T cells and another of the T cell specific binding ligands is an antigen associated with disease or a causative agent of disease, or epitope thereof. The present invention also relates to vaccines containing the heterofunctional cellular immunological reagents and methods for the use of the same.

L10 ANSWER 107 OF 111 USPATFULL on STN

AN 2000:13000 USPATFULL
TI **Prion** protein standard and method of making same
IN Prusiner, Stanley B., San Francisco, CA, United States
PA The Regents of the University of California, Oakland, CA, United States (U.S. corporation)
PI US 6020537 20000201
AI US 1998-199523 19981125 (9)
RLI Continuation-in-part of Ser. No. US 1997-935363, filed on 22 Sep 1997 which is a continuation-in-part of Ser. No. US 1996-692892, filed on 30 Jul 1996, now patented, Pat. No. US 5792901 which is a continuation-in-part of Ser. No. US 1995-521992, filed on 31 Aug 1995, now patented, Pat. No. US 5908969 which is a continuation-in-part of Ser. No. US 1995-509261, filed on 31 Jul 1995, now patented, Pat. No. US 5763740 which is a continuation-in-part of Ser. No. US 1994-242188, filed on 13 May 1994, now patented, Pat. No. US 5565186

DT Utility
FS Granted
EXNAM Primary Examiner: Campell, Bruce R.; Assistant Examiner: Baker,

Anne-Marie
LREP DeVore, Dianna L.Bozicevic, Field & Francis LLP
CLMN Number of Claims: 31
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1796

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides **prion** protein standards for use as reference materials for **prion** detection. The standard may be species specific, i.e. the standard is comprised of a preparation for detection of a single strain **prion** or it may be prepared to allow detection of multiple **prion** strains simultaneously. The invention also provides methods of preparing the **prion** protein standards using a group of non-human host mammals which have their genome manipulated with respect to genetic material related to a PrP gene such that the mammals are susceptible to infection with a **prion** which generally only infects an animal which is genetically diverse from the host.

L10 ANSWER 108 OF 111 USPATFULL on STN

AN 1999:141625 USPATFULL

TI Isolated nucleic acid molecules useful as leukemia markers and in breast cancer prognosis and encoded polypeptides

IN Rio, Marie-Christine, Illkirch, France
Tomasetto, Catherine, Strasbourg, France
Basset, Paul, Strasbourg, France
Byrne, Jennifer, Ashfield, Australia

PA Bristol-Myers Squibb Company, Princeton, NJ, United States (U.S. corporation)
Institut National de la Sante et de la Recherche Medicale, Paris Cedex, France (non-U.S. corporation)
Centre National de la Recherche Scientifique, Paris Cedex, France (non-U.S. corporation)
Universite Louis Pasteur, Strasbourg Cedex, France (non-U.S. corporation)

PI US 5981218 19991109
AI US 1996-691814 19960731 (8)
PRAI US 1995-2183P 19950809 (60)

DT Utility
FS Granted

EXNAM Primary Examiner: Feisee, Lila; Assistant Examiner: Kaufman, Claire M.

LREP Sterne, Kessler, Goldstein & Fox P.L.L.C.

CLMN Number of Claims: 48

ECL Exemplary Claim: 1

DRWN 53 Drawing Figure(s); 45 Drawing Page(s)

LN.CNT 7347

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to four novel human genes amplified and overexpressed in breast carcinoma and located on the q11-q21.3 region of chromosome 17. The four novel genes are useful in breast cancer prognosis. The present invention also relates to a fifth novel human gene expressed in breast carcinoma and located on chromosome 6q22-q23. A sixth novel gene is also described that is the murine homolog of the human D52 gene. The genes and gene fragments of the present invention are themselves useful as DNA and RNA probes for gene mapping by in situ hybridization with chromosomes and for detecting gene expression in human tissues (including breast and lymph node tissues) by Northern blot analysis.

L10 ANSWER 109 OF 111 USPATFULL on STN

AN 1999:43389 USPATFULL

TI Assay for disease related conformation of a protein

IN Prusiner, Stanley B., San Francisco, CA, United States
Safar, Jiri G., Concord, CA, United States

PA The Regents of the University of California, Oakland, CA, United States (U.S. corporation)

PI US 5891641 19990406
AI US 1997-804536 19970221 (8)

DT Utility
FS Granted
EXNAM Primary Examiner: Woodward, Michael P.; Assistant Examiner: Zeman, Mary K.
LREP Bozicevic, KarlBozicevic & Reed LLP
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN 11 Drawing Figure(s); 6 Drawing Page(s)
LN.CNT 1990

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB An assay method is disclosed which makes it possible to determine the presence of a diseased related conformation of a protein (e.g., PrP.sup.Sc) in a sample. A sample is divided into two portions and the first portion is cross-linked to a first solid support and then contacted with a **labelled** antibody which binds to a non-disease form of the protein with a higher degree of affinity (e.g, 4 to 30 fold higher) than to the disease form of the protein. The second portion is treated in a manner which causes any disease form of the protein to change conformation to a form with a higher binding affinity for the **labelled** antibody. The treated second portion is then bound to a second solid support and contacted with **labelled** antibody. The level of **labelled** antibody binding to a protein in the first and second portions is determined and the amounts measured in each are compared. The difference between the two measurements is an indication of whether the diseased related conformation of the protein was present in the sample.

L10 ANSWER 110 OF 111 USPATFULL on STN

AN 1998:75717 USPATFULL
TI Fragments of **prion** proteins
IN Fishleigh, Robert Vincent, Cheshire, England
Robson, Barry, Cheshire, England
Mee, Roger Paul; Manchester, England
PA Proteus Molecular Design Limited, Macclesfield, England (non-U.S. corporation)
PI US 5773572 19980630
WO 9311155 19930610
AI US 1994-244701 19940602 (8)
WO 1992-GB2246 19921203
19940602 PCT 371 date
19940602 PCT 102(e) date
PRAI GB 1991-25747 19911203
GB 1992-14663 19920710

DT Utility
FS Granted
EXNAM Primary Examiner: Knode, Marian C.; Assistant Examiner: Wortman, Donna C.
LREP Pennie & Edmonds LLP
CLMN Number of Claims: 13
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1647

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Synthetic polypeptides having at least one antigenic site of a **prion** protein are disclosed together methods for their use and manufacture and antibodies raised against such polypeptides. Diagnostic kits using the polypeptides and/or antibodies are also disclosed.

L10 ANSWER 111 OF 111 USPATFULL on STN

AN 97:66227 USPATFULL
TI Heterofunctional cellular immunological reagents, vaccines containing same and methods for the use of same
IN Zimmerman, Daniel H., Bethesda, MD, United States
Elliott, Donald A., Bethesda, MD, United States
PA Cel-Sci Corporation, Alexandria, VA, United States (U.S. corporation)
PI US 5652342 19970729
AI US 1994-354751 19941208 (8)
RLI Continuation of Ser. No. US 1992-985750, filed on 4 Dec 1992, now

abandoned which is a continuation of Ser. No. US 1991-731394, filed on 17 Jul 1991, now abandoned which is a continuation of Ser. No. US 1988-206381, filed on 14 Jun 1988, now abandoned

DT Utility

FS Granted

EXNAM Primary Examiner: Cunningham, Thomas M.

LREP Sherman and Shalloway

CLMN Number of Claims: 5

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 1854

AB The present invention relates to a heterofunctional cellular immunological reagent comprising at least two T cell specific binding ligands covalently linked together, wherein one of the T cell specific binding ligands binds to a specific class or subclass of T cells and another of the T cell specific binding ligands is an antigen associated with disease or a causative agent of disease, or epitope thereof. The present invention also relates to vaccines containing the heterofunctional cellular immunological reagents and methods for the use of the same.